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ABSTRACT
Scientific research investigating the generation and regulation of circadian rhythms has 
become more popular over the last few years. Chronopharmaceutics and identifying that 
the timing of drug delivery is important are valuable steps toward the global recognition 
of this topic. Clinical depression is one example of what is considered a ‘disorder of 
time keeping’ i.e. a disruption in the internal body clock. Although the intricate 
mechanisms behind both depression and the workings of the body clock are, at best, 
moderately understood, the pivotal involvement of serotonin (5-HT) in both depression 
and in the regulation of circadian rhythms justifies further investigation. The aims of 
this thesis were to further the knowledge of the normally functioning circadian 
pacemaker (the suprachiasmatic nuclei; SCN) with the view that studies of 
abnormalities in clock function such as depressive illness and jet-lag, might be better 
understood.
The in vivo sampling technique of microdialysis was utilised in the rat to examine the 
function of the 5-HTib auto- and hetero- receptors in the SCN, the 5-HTiA autoreceptor 
in the midbrain raphe nuclei regulating 5-HT release in the SCN , and the relationship 
between the serotonergic and glutmatergic systems in the SCN and midbrain raphe was 
also examined.
The 5 -H T ib autoreceptor in the SCN was shown to exhibit a marked diurnal variation in 
function, as examined at six time points across the light:dark cycle, whereas the function 
of the 5 -H T ib heteroreceptor was not significantly different at the two time points 
examined. Reverse-transcriptase polymerase chain reaction (RT-PCR) was used to 
examine 5 -H T iB auto-, hetero- and postsynaptic receptor mRNA, and to identify 
potential diurnal rhythms in message levels. Postsynaptic 5 -H T iB receptor and 5 -H T ib 
heteroceptor mRNA levels varied significantly over eight equally spaced time points. 
The 5 -H T jb autoreceptor mRNA levels on the other hand, did not display a circadian 
variation. It is therefore unlikely that the functional variation in the 5 -H T ib autoreceptor 
is a result of an underlying rhythm in mRNA expression. Thus, the amount of 5 -H T ib 
receptor protein present in the SCN was examined. Immunocytochemical detection of 
the 5 -H T ib receptor in brain tissue proved unsuccessful, and Western blotting was 
chosen to detect possible changes in protein levels over eight time points across the
lightrdark cycle. Using this method the 5 -H T ib receptor levels did not appear to display 
a diurnal variation. Therefore, the mechanism(s) behind the functional variation in 5- 
HTib autoreceptor function has yet to be elucidated. The somatodendritic 5 -H T ia 
autoreceptor did not display a diumal variation in function as measured at two time 
points utilising a dual probe paradigm.
5-HT release in the SCN was shown to be regulated by both ionotropic and 
metabotropic glutamate receptors. The effect of NMD A was concentration-dependent 
and displayed a circadian variation, which was in part due to stimulation of (X2- 
adrenoceptors by endogenously released agonist. The effect of metabotropic glutamate 
receptor stimulation also displayed a diumal variation, whereas the effect of kainate did 
not exhibit variation, and AMP A receptor stimulation was without effect on 5-HT 
release.
NMDA receptor stimulation in the midbrain raphe nuclei also regulated SCN 5-HT 
release as measured by the dual probe paradigm, which was in part mediated by a 
stimulation of somatodendritic 5-HTjA autoreceptors. This provides functional evidence 
for the presence of a retino-raphe-hypothalamic tract in the rat, although it probably 
involves stimulation of intemeurones in the raphe nuclei.
Together, the data collected in this thesis provide a better understanding of the 
regulation of 5-HT release in the circadian pacemaker by autoreceptor and glutamatergic 
receptor stimulation. The data might be useful to further the understanding of 
abnormalities in clock function.
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The mammalian circadian timing system (CTS) is a set of neural structures that have 
evolved uniquely to synchronise an organism’s biochemical, physiological and 
behavioural processes to its environment. The factors that bring about synchronisation, 
or entrainment, are called zeitgebers (‘zeit’ time, ‘geber’ to give) and the principle 
zeitgeber is the lightidark cycle. Circadian rhythms are those rhythms that can persist in 
the absence of environmental cues and ‘free run’ with a periodicity of approximately 
twenty four hours, hence ‘circa’, about; ‘diem’, one day. This persistence of circadian 
rhythms provides powerful evidence for the existence of an internal, self sustaining 
clock.
The components of the mammalian CTS are thus:
(1) Photoreceptors and projections of retinal ganglion cells that form entrainment 
pathways
(2) A circadian pacemaker or pacemakers
(3) Efferent pathways that couple the pacemaker to effector systems displaying 
circadian function.
1.1 THE SUPRACHIASMATIC NUCLEI (SCN)
Experimental evidence has shown the suprachiasmatic nuclei (SCN) of the 
hypothalamus to generate, control and express circadian rhythmicity in vertebrates. 
Stephan and Zucker (1972) demonstrated that nocturnal and free running circadian 
rhythms of drinking and locomotor activity were severely disrupted by relatively 
discrete lesions in the area of the SCN. Since this time, many fascinating and well 
performed experiments have been carried out implanting donor SCN tissue into a host 
animal that has become arrhythmic after its pacemaker has been destroyed by selective 
lesions (for review see Ralph and Lehman, 1991). In general, animals are maintained 
under constant environmental lighting conditions, and the rhythm in either locomotor 
activity or drinking activity, or another parameter of circadian rhythmicity monitored. 
After a period of time when the animal exhibits free running rhythms, a surgical 
destruction of the SCN is undertaken. The animal is again monitored for a period of 
time, and successful lesions are those that destroy rhythmicity. Foetal SCN tissue is 
then prepared and implanted into the third ventricle near to the site of the destroyed host 
SCN. A period of approximately four weeks is needed before circadian rhythmicity is
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restored. Subsequent experiments using tau mutant hamsters that present with a free 
running period shorter than that of wild type animals, identified that the restoration of 
circadian rhythmicity was attributable to that of the donor animal (Ralph et al., 1991). 
Successful transplants were those situated close to the site of the original SCN, and were 
thought to involve neuronal contacts containing vasopressin and vasointestinal 
polypeptide from the donor SCN with the host brain into the periventricular and 
subparaventricular zones (DeCoursey and Buggy, 1989; Griffioen et al., 1993; Lehman 
et al., 1987). However, a humoral agent is also considered important in the restoration 
of circadian rhythmicity. Experiments in which donor tissue was encapsulated in a 
semipermeable polymeric membrane prior to implantation into the host brain, prevented 
neural outgrowth of foetal SCN whilst maintaining diffusion of humoral signals. 
Hamsters that had been made arrhythmic by SCN lesions and implanted with the 
encapsulated donor tissue, had their locomotor activity rhythm restored after 
approximately 21 days (Silver etal., 1996).
The SCN are small paired nuclei situated in the midline on the ventral surface of the 
brain above (‘supra’) the optic chiasm (‘chiasmatic’). In all mammalian species looked 
at to date, the SCN are readily compartmentalised into a ventrolateral (VL) and 
dorsomedial (DM) segment with respect to immunostaining of perykarya, cell size, 
neuropil extent, neurotransmitter content and afferent projections to the nucleus. 
Comprehensive early studies, utilising immunological staining techniques, attempted to 
locate neurotransmitters to the nucleus (Card and Moore, 1984; van den Pol and 
Tsujimoto, 1985). Many immunoreactive fibres for arginine vasopressin (AVP), 
bombesin, y-amino butyrate (GABA), glutamate decarboxylase (GAD), gastrin-releasing 
peptide (GRP), neurophysin, serotonin (5-hydroxytryptamine, 5-HT), somatostatin 
(SOM) and vasointestinal peptide (VIP) were found in the nuclei with VIP, GRP and 
bombesin concentrated in the VL-SCN and A VP, SOM concentrated in the DM-SCN. 
In addition to these early studies, glutamate, aspartate (van den Pol, 1991; van den Pol 
and Tsujimoto, 1985) and substance-P (Takatsuji et al., 1991) have been located in the 
VL-SCN and neuropeptide-Y (NPY) to the DM-SCN (Shinohara et al., 1993).
A great number of fibres cross the midline between the left and right SCN suggesting 
that the two nuclei do not function as separate entities, but rather as a single body (van 
den Pol and Tsujimoto, 1985). An interesting aspect of the hamster SCN, unique to this
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rodent species, is that the DM-SCN join in the midline and present as a single nucleus 
(Card and Moore, 1984). An important aspect of pacemaker function is the co­
ordinated relay of messages to the nuclei and the efficient output of signals to the 
effector regions.
A number of factors can shift (advance or delay) or reset the phase of the circadian 
clock, as measured by in vitro preparations of SCN slices, or in vivo behavioural 
rhythms. Presumably these phase shifting responses are the result of an altered balance 
between transmitter substances of input pathways to the central pacemaker. Often the 
ability of a chemical agent or physical manipulation of an animal to produce a phase 
shift is presented as a phase response curve (PRC). The PRC is a record of the relative 
phase change versus the zeitgeber time at which the manipulation was carried out. The 
zeitgeber time (ZT) is a measurement of circadian time relative to either the lightrdark 
cycle or, in animals allowed to free run, the ZT is related to the onset of locomotor 
activity: ZT 12 is designated as the time of lights off in an entrained animal or as the 
onset of activity in a free running animal.
1.2 SCN AFFERENTS
The afferent fibres collectively entrain the circadian pacemaker to environmental cues. 
The principle afferent fibres originate from the retina (retinohypothalamic tract and 
geniculohypothalamic tract) and from the midbrain raphe nuclei (raphe-hypothalamic 
tract) although the SCN do receive fibres from the infralimbic cortex, septal nuclei, 
substantia innominata and the ventral subiculum (Pickard, 1982; Moore, 1996).
1.2.1 THE RETINOHYPOTHALAMIC TRACT (RHT)
The first convincing evidence demonstrating a mammalian retinal projection to the SCN 
was in 1972 when tritiated amino acids were injected into the posterior chamber of the 
eye, anterogradely transported and detected by autoradiography of hypothalamic brain 
slices (Moore and Lenn, 1972). These authors demonstrated that the retinal projection 
terminated solely in the SCN of the hypothalamus. However, subsequent studies have 
demonstrated RHT terminals to be more widespread; in the anterior hypothalamic area, 
the retrochiasmatic area and the lateral hypothalamic area (Johnson et al., 1988a; Moore 
et a l, 1995). The pathway originates from a small population of small to medium sized
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retinal ganglion cells that are randomly scattered throughout the retina (Pickard et al, 
1982; Moore et al, 1995), and conveys information via the optic nerve fibres to the 
retinorecipient areas. Sectioning of the RHT in hamsters eliminates the normal retinal 
innervation of the SCN whilst sparing projections to other visual centres, and even when 
exposed to a light:dark cycle these animals present with a free running rhythm, 
characteristic of constant environmental lighting conditions, indicating the RHT is 
necessary for entrainment (Johnson et a l, 1988a). Optic nerve stimulation in in vitro 
preparations of hypothalamic slices evokes excitatory post synaptic potentials (EPSPs) 
in the neurons of the SCN (Cahill and Menaker, 1989; Kim and Dudek, 1991), and 
electrical stimulation of the optic nerves in vivo mimics the phase dependent shifts of 
hamster wheel running induced by light pulses in constant dark (de Vries et al., 1994).
The transmitter of the RHT has been the focus of much speculation since the 
demonstration of the pathway. There is mounting evidence implicating the excitatory 
amino acid glutamate as the putative neurotransmitter of the RHT, exerting its actions 
through a combination of NMD A (V-methyl-D-aspartate), non-NMDA (kainate and a- 
amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid [AMPA]) and metabotropic 
glutamate receptors. Glutamate has been detected immunocytochemically in the rat 
hypothalamus in presynaptic neurones of the retinohypothalamic tract (van den Pol, 
1991; de Vries et a l, 1993), providing ultrastructural evidence that glutamate is the 
transmitter of the RHT. Additionally, NMDA, AMPA, Kainate and metebotropic 
glutamate receptor mRNA have all been detected in the retinorecipient region of the 
SCN of rodents by means of in situ hybridization or Northern analysis (van den Pol, 
1994; Mick et a l, 1995; O’Hara et a l, 1995; van den Pol et a l, 1995; Ghosh et a l, 
1997), and many in vitro (Cahill and Menaker, 1989; Kim and Dudek, 1991; Shibata et 
a l, 1994) and in vivo (Amir, 1992; Ohi et a l, 1991; de Vries et a l,  1994) experiments 
have demonstrated their importance in the regulation of circadian rhythms.
In slices of rat hypothalamus preloaded with tritiated glutamate and aspartate, optic 
nerve stimulation increases the release of both amino acids (Liou et a l, 1986) strongly 
suggesting excitatory amino acid involvement in RHT transmission. Excitatory 
responses of SCN neurons in vitro to applied glutamate do not show day-night variation 
(Shirakawa and Moore, 1994a). Topically applied glutamate in similar preparations can 
phase shift neuronal firing when applied during the early (delay) or late (advance)
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subjective night but not when applied during the subjective day (Shirakawa and Moore, 
1994b). This phenomenon of phase delay in the early subjective night versus phase 
advance in the late subjective night is in keeping with glutamate mimicking light pulse 
stimulation in experiments monitoring activity records of animals allowed to free run in 
constant darkness. However, N-acetylaspartylglutamate (Moffett et a l , 1990), aspartate 
(van den Pol, 1991) and substance-P (Takatsuji et a l, 1991) have also all been detected 
immunocytochemically in presynaptic neurones of the SCN, suggesting there may be 
additional transmitters of the RHT. Indeed, substance-P has been shown to potentiate 
glutamate-evoked excitatory responses in an in vitro rat SCN slice preparation 
(Shirakawa and Moore, 1994a) and to increase the uptake of 2-deoxyglucose in the SCN 
during the subjective night when light is known to affect the clock. Substance-P also 
exhibits a PRC in rat SCN slices similar to that of light (Shibata et a l, 1992a). This 
data strengthens the hypothesis that substance-P is involved in entrainment of circadian 
rhythms, although the degree of interaction between this system and the glutaminergic 
system is unknown.
NMDA can mimic the suppressive effects of light pulse on pineal melatonin production. 
In addition, a specific NMDA receptor antagonist can inhibit light-suppressed melatonin 
production (Ohi et a l,  1991). Light-induced increases in rat heart rate are also blocked 
by prior infusion into the SCN with a competitive NMDA antagonist (Amir, 1992). In 
vitro SCN brain slice preparations can be a very useful tool for identifying potential 
phase shifting agents. Topical application of NMDA to SCN slice induces phase shifts 
very similar to those seen with glutamate (Ding et a l, 1994; Shibata et a l, 1994; 
Watanabe et a l, 1994), and the non-competitive NMDA antagonist MK-801 can 
attenuate phase delays in hamster wheel running induced by electrical stimulation of the 
optic nerves in the early subjective night (de Vries et a l, 1994). AMPA receptor 
stimulation when applied topically to SCN brain slices can also phase delay neuronal 
firing when applied during the early subjective night (Watanabe et a l, 1994). EPSPs 
evoked in the SCN by electrical stimulation of the optic nerve are blocked by 
application of a non-selective antagonist of amino acid receptors and kainate also 
reduces the amplitude of the postsynaptic response (Cahill and Menaker, 1989). 
Somewhat surprisingly, a competitive NMDA receptor antagonist was without effect 
both under the same conditions (Cahill and Menaker, 1989), and in another slice 
preparation (Kim and Dudek, 1991). 1S,3R-ACPD, an agonist at metabotropic
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glutamate receptors, can also activate SCN cells as shown in an in vitro slice preparation 
(Scott and Rusak, 1996).
Nitric oxide, a highly reactive messenger molecule produced from the conversion of L- 
arginine to L-citrulline by the enzyme nitric oxide synthase (NOS), is released upon 
stimulation of NMDA receptors (Knowles et a l , 1989) and has been implicated in the 
regulation of circadian rhythms (Amir, 1992; Ding et al., 1994; Watanabe et al., 1994, 
1995; Weber et al., 1995a). Light-induced phase shifts of circadian rhythm wheel 
running activity are attenuated by systemic (Watanabe et al., 1995) or 
intracerebroventricular (Weber et al., 1995a) injection of the NOS inhibitor L-NAME, 
and in in vitro slice preparations of the SCN, L-NAME can block the phase delay 
produced by NMDA receptor stimulation during the early subjective night (Watanabe et 
a l, 1994). These data suggest that the NMDA- or light- induced phase shifts are 
mediated by nitric oxide.
Light induced phase shifts also involve the induction of a number of immediate early 
genes (c-fos, egr-1, NGF1-A, NGF1-B) (Ebling et al., 1991; Sutin and Kilduff, 1992) in 
the subjective night, the most commonly studied being c-fos and its protein product Fos. 
Light induced Fos protein is induced in the retinorecipient region of the VL-SCN only 
during periods in which light can phase shift the circadian pacemaker (Rea, 1989). A 
greater amount of Fos has been detected after a light pulse that will phase advance the 
clock (late subjective night) than will delay the clock (early subjective night) (Romijn et 
a l, 1996). Light induced Fos protein in the rat is blocked by prior administration of the 
NDMA receptor channel blocker MK801 (Ebling et al., 1991; Park et al., 1993) and 
NMDA infusion intracerebroventricularly can induce c-fos (Ebling et al., 1991), 
implicating NMDA receptor stimulation in the production of the immediate early gene. 
Phosporylation of the cyclic AMP response element binding protein (CREB) produces 
pCREB which can activate a number of immediate early genes (Sheng and Greenberg, 
1990). Light can induce the production of pCREB in the rat in vivo during the 
subjective night and in an in vitro preparation of rat SCN slices glutamate can also 
induce pCREB production in the SCN (Ding et al., 1997). This induction of pCREB 
involves the stimulation of NMDA receptors and the production of nitric oxide, as both 
an NMDA receptor competitive antagonist and an inhibitor of NOS can attenuate the 
photic/glutamate induction of pCREB. In addition, a NO-generator can induce a similar
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induction of pCREB. The cascade of events leading to photic phase shifting therefore 
appears to involve release of glutamate from the RHT, stimulation of NMDA receptors, 
release of nitric oxide, stimulation of phosphorylation of CREB and induction of 
immediate early genes. However, an inhibitor of NOS injected intracerebroventricularly 
in free running hamsters fails to block the induction of light induced Fos expression 
during either the early or late subjective night (Weber et a l, 1995a) which would 
suggest that the involvement of nitric oxide was after induction of Fos. The difference 
between these experiments may reflect differences in species (rat versus hamster) or 
photoperiod. The production of pCREB was inducable in animals maintained on a 
12:12 LD cycle, whereas in the experiments where inhibition of NOS failed to prevent 
light induced Fos expression the hamsters were maintained in constant darkness.
It therefore appears that the retinal hypothalamic tract releases glutamate at its terminals 
to act upon postsynaptic NMDA and non-NMDA glutamate receptors to phase shift the 
circadian clock during the subjective night. The phase shift produced by the stimulation 
of NMDA receptors is mediated by nitric oxide and involves the induction of immediate 
early genes.
1.2.2 THE RAPHE-HYPOTHALAMIC TRACT (RaHT)
The serotonergic innervation of the SCN originates in the midbrain raphe nuclei (Moore 
et a l,  1978; Azmitia and Segal, 1978). This serotonergic projection from the raphe 
nuclei also innervates the intergeniculate leaflet (IGL) of the thalamus (Moore and 
Card, 1994). Many attempts have been made to establish a role for 5-HT in the 
circadian timing system, and the general consensus is that 5-HT serves to modulate 
photic inputs rather than to have a direct effect upon the clock itself.
A large majority of the studies performed to elucidate the role of serotonin in the 
regulation of circadian rhythms have been carried out in hamsters. Depleting the 
serotonergic input to the hamster SCN by administration of the selective neurotoxin 5,7- 
dihydroxytryptamine (DHT) throws up some confusing data regarding phase changes in 
either constant light (LL) or constant dark (DD). Under light:dark (LD) conditions DHT 
treatment induces the rapid appearance of advanced activity onset (Smale et a l, 1990; 
Morin and Blanchard, 1991; Penev et a l, 1993), delayed offset and longer duration of
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the nocturnal activity phase, whereas in LL normal circadian rhythmicity was rapidly 
lost in DHT-treated animals. Although in DD there was no effect on circadian period, 
there was an overall change in the temporal properties of the phase response curve to 
light (Morin and Blanchard, 1991). 5-HT depletion potentiates light induced phase 
delays in the mid subjective night and potentiates Fos induction in mice (Bradbury et 
a l, 1997) indicating that 5-HT modulates the magnitude of the photic response. This 
action of 5-HT may be via stimulation of 5-HTiA receptors as in hamsters maintained 
under constant dark conditions (DD), systemic administration of the 5-HTiA antagonist 
NAN-190 potentiated light-induced phase shifts in wheel running activity (Rea et a l,
1995).
Metamphetamine (MA) when infused into the SCN increases extracellular 5-HT 
concentration (Ozaki et a l, 1991). In rat SCN slices, application of MA significantly 
attenuated optic nerve stimulated-evoked field potentials (Moriya et a l, 1996), which is 
abolished by pre-treatment with the 5-HTjA receptor antagonist NAN-190, suggesting 
that the inhibition is mediated via the action of a 5-HTiA-like receptor. Indeed, 5-HTiA 
agonists reportedly attenuate optic nerve stimulation-evoked field potentials in the SCN 
(Liou et a l,  1986) and cause a dose dependent inhibition of both spontaneous activity 
and photic responses in SCN cells (Ying and Rusak, 1994). Light-induced Fos 
expression in hamsters is reduced by the serotonergic agonist, quipazine (Selim et a l, 
1993) or the systemic administration of MA. The effect is selectively attenuated by 
NAN-190 applied in addition to MA, thus indicating the actions of MA to be via a 5- 
HTiA-like receptor (Moriya et a l, 1996). In the rat, however, blockade of the 5-HTjA 
receptor with NAN-190 partially blocks the photic induction of Fos in the SCN, 
although the 5-HTjA agonist 8-OH-DPAT also reduces Fos induction (Recio et a l,
1996) and quipazine can induce c-fos in the VL-SCN in a manner similar to that of a 
light pulse in the rat (Moyer et a l, 1997). The serotonergic regulation of photically 
induced Fos in rats therefore appears to be opposite to the serotonergic regulation in the 
hamster. Thus, species differences must be taken into account when interpreting drug 
actions.
This modulation of photic responses by 5-HT might be due to a direct retinal projection 
to the raphe nuclei thereby acting upon the serotonergic neurones projecting to the SCN. 
In the cat (Foote et a l,  1978) and rat (Villar et a l, 1987; Shen and Semba, 1994;
Kawano et al., 1996) a retinal projection to the raphe nuclei has been identified. This 
opens up the possibilty that the RaHT constitutes an indirect retinal pathway from the 
retina to the SCN.
In addition to modulating photic inputs to the SCN, stimulation of the serotonergic 
system can also induce phase shifts in vitro an in vivo. In preparations of rat brain 
slices, the serotonergic agonist quipazine or 5-HT itself, produces phase shifts in the 
electrical activity rhythm (Prosser et al., 1990; Medanic and Gillette, 1992). Quipazine 
can also induce c-fos in the SCN during the subjective day in rat SCN slices maintained 
in vitro (Prosser et al., 1994a) and during the light phase of rats maintained on a 12:12 
LD cycle (Moyer et al., 1997). This pattern of Fos protein induction incorporates both 
the VL-SCN and the DM-SCN, whereas light-induced Fos expression is present only in 
the VL-SCN. The presence of Fos in the DM-SCN is similar to that induced after in 
vivo electrical stimulation of the IGL (Abe and Rusak, 1992). Thus, the action of 
quipazine in these circumstances might incorporate the IGL, which itself receives 
innervation from the serotonergic midbrain raphe. The effects on electrical activity 
rhythm in SCN slices by quipazine is mimicked by application of the 5-HTiA agonist 8- 
OH-DPAT (Starkey, 1996; Prosser et a l, 1994a; Shibata et al., 1992b), and phase 
shifting of wheel running activity in hamsters after 8-OH-DPAT administration has also 
been reported (Cutera et al., 1994, 1997; Tominger et al., 1992). The phase advancing 
ability of 8-OH-DPAT when applied during the mid subjective day involves nitric oxide 
production, activation of cAMP dependent protein kinase A (PKA) and the opening of 
potassium channels: an inhibitor of NOS can block the 8-OH-DPAT induced phase 
advance in firing, whilst an NO donor can mimic the effect of the agonist (Starkey,
1996), and inhibitors of PKA and a variety of potassium channel blockers can block 8- 
OH-DPAT induced phase advances in rat SCN slices (Prosser et a l, 1994b).
The actions of 5-HT agonists during the subjective day are thought to mediate non- 
photic phase shift of the circadian clock. Animal handling, cage change and general 
arousal of the animal during the light phase has the ability to phase shift the circadian 
pacemaker. The firing rate of the midbrain raphe serotonergic neurones, releasing 5-HT 
at their terminals, is correlated to the activity state of the animal. The more aroused the 
animal is the more the serotonergic neurones fire, and the greater the terminal release of 
5-HT. It is reasonable to predict that the actions of exogenously applied 5-HT agonists
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are mimicking the actions of an increase in raphe neuron firing. In 5-HT depleted 
animals a 3 hour bout of activity induced by exposure to a new running wheel fails to 
evoke a phase advance of the clock rhythm during the light period (Bobrzynska et al., 
1996a). This in itself is evidence for 5-HT involvement in the ability of a non-photic 
cue (novelty wheel running) to phase shift the rhythm. However, this mediation of non- 
photic phase shifting by 5-HT is thought to be via an action through the IGL.
1.2.3 THE GENICULOHYPOTHALAMIC TRACT (GHT)
A second retinal pathway to the SCN is an indirect pathway via the 
geniculohypothalamic tract (GHT). Retinal fibres project afferent fibres to the IGL 
before relaying axons to the SCN (Moore and Card, 1990). The IGL contain a 
population of neuropeptide-Y (NPY) neurones (Harrington et a l, 1987) that project 
bilaterally to the VL-SCN (Morin et al., 1992) and these neurones also colocalise with 
GABA. Each IGL also sends met-enkephalin and GABA fibres to the contralateral IGL. 
Since the IGL receive photic information, it was the general consensus that these nuclei 
must relay photic information to the SCN. However, evidence is accumulating that this 
structure may also convey non-photic information. A non-photic stimulus that can 
phase shift the circadian clock in hamsters, dependent upon the time of application, is 
the systemic administration of the benzodiazepine triazolam. Destruction of the lateral 
geniculate nuclei with a selective neurotoxin prevented the triazolam-induced phase 
advances in hamster wheel running activity, suggesting that an intact IGL was required 
for the phase shifting ability of the benzodiazepine (Johnson et a l, 1988c; Janik and 
Mrosovsky,1994). The effect of triazolam on the pacemaker has a very similar effect on 
activity as that of dark pulses presented during a period of constant light (Bobrzynska et 
a l,  1996b). Both of these non-photic manipulations are thought to mediate their effects 
by an increase in activity of the animals. Indeed, the phase advancing or delaying 
effects of trialozam or dark pulses can be completely suppressed by immobilisation of 
the animals during treatment (Van Reeth and Turek, 1989). Another non-photic 
stimulus capable of phase shifting circadian rhythms is that of novel wheel running. 
Lesions of the IGL completely block the activity-induced phase shift (Janik and 
Mrosovsky, 1994; Wickland and Turek, 1994) suggesting the common pathway of all 
non-photic phase shifting is via the IGL and involves an increase in animal activity for 
the phase shift to result. As stated in the preceding section (1.2.2) the mediator of the
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non-photic phase shifts is considered to be 5-HT released at afferent terminals 
originating from the midbrain raphe nuclei. The serotonergic involvement in the control 
and regulation of circadian rhythms is thus complicated and can both modulate photic 
input to the pacemaker directly to the SCN and convey non-photic information 
indirectly via the IGL.
1.3 SCN EFFERENTS
The most dense projection of neurones from the SCN ends in an area with a relatively 
low density of cells dorsal to the SCN, in a region known as the subparaventricular 
zone, centred between the anterior hypothalamic area and the periventricular nucleus. A 
small number of fibres continue through the paraventricular nucleus of the 
hypothalamus to end in the midline thalamic nucleus, and a number of fibres continue 
caudally to end in the dorsomedial nucleus and the dorsal part of the ventromedial shell 
and the posterior hypothalamic area. A small number of neurones end in the region 
ventral and lateral to the ventromedial nucleus. A modest terminal field is in the 
paratenial nucleus and rostral part of the paraventricular thalamic nucleus, and only a 
few fibres can be found in the ventromedial parts of the pre-optic region, the 
intermediate lateral septal nucleus and the ventral lateral geniculate nucleus (Watts and 
Swanson, 1987; Watts et al, 1987).
These efferent projections of the SCN shed precious little light on the functioning of the 
nuclei and how they can influence all manner of circadian responses. It may be that 
circadian patterns of neuronal activity generated in the SCN are relayed to effector 
circuitry in the subparaventricular zone, which serves as an amplification stage thereby 
increasing the influence of the SCN.
1.4 AIMS OF THESIS
The aims of this thesis as a whole were to further the understanding of the mechanisms 
controlling SCN function in the rat. In particular, the regulation of 5-HT release by 
autoreceptor and glutamatergic agonists in the SCN was investigated in the freely 
moving conscious animal using microdialysis. Specific aims of the thesis are outlined 
in each of the following Chapters.
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CHAPTER 2
GENERAL MICRODIALYSIS AND HPLC-ED
PARAMETERS
2.1 MICRODIALYSIS
There is a need for more accurate and detailed information concerning the complex and 
biochemical reactions in the normal and abnormal brain. An ideal method must provide 
an instantaneous and reliable concentration measurement of a wide variety of interstitial 
substances in discrete brain areas, and be as non-invasive as possible. The microdialysis 
technique is an important breakthrough in the neurobiological sciences as it has 
provided much needed information on the in vivo neurochemistry of the intact brain.
2.1.1 Principles of microdialysis
In vivo brain microdialysis involves the stereotaxic implantation of a dialysis probe into 
a given area of the brain. The membrane at the tip of the probe allows free diffusion of 
water and solutes between the brain interstitial space and a solution of artificial 
cerebrospinal fluid (aCSF) which is continually being renewed and sampled for dialysis. 
Due to the ‘macro’ size of the probes (outer diameter 290 J i m )  in relation to the size of 
the nerve terminals, brain dialysis cannot be expected to measure neurotransmitter 
release at synaptic sites, but rather neurotransmitter diffused into the extracellular space 
after its release. The brain is well suited for microdialysis because of the presence of the 
blood brain barrier which rapidly closes over the implantation site about 30 min after 
implantation (Dykstra et al., 1992), thus avoiding contamination from the systemic 
circulation (Beneviste, 1989).
Microdialysis has advantages over other methods of sampling from neuronal tissues. 
What was once a solitary sample from a whole post mortem brain can now be several 
samples from a freely moving conscious animal. The procedure of microdialysis is 
continually being improved, and is streets ahead of the method of push-pull cannula 
which preceded it. Push-pull cannula (Gaddum, 1961) involved the implantation of two 
stainless steel tubes into the brain, and the extracellular fluid perfused with aCSF. 
Neurotransmitters and metabolites would thus diffuse into the perfusion fluid, but the 
‘open’ design of the system created many problems including excessive tissue damage, 
relatively low recoveries from the extracellular medium and the necessity to ‘clean up’ 
the perfusate before analysis by high performance liquid chromatography (HPLC). 
Being a ‘closed’ system, microdialysis can avoid these problems. It does not pump fluid 
into the brain tissue (a study by Dykstra et a l , 1992 confirmed this by measuring flow
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rate of the dialysate leaving the probe compared to that entering the probe, and found no 
loss of fluid due to bulk flow across the membrane), thereby limiting tissue damage, and 
there is no need for ‘clean up’ of dialysate samples due to the molecular weight cut-off 
of the membrane. Although the implantation of a dialysis probe produces inevitable 
damage to surrounding brain tissue, tissue levels of neurotransmitters elevated by nerve 
damage equilibrate within 90 minutes and sampling can begin. Long term sampling 
from microdialysis probes reduces the efficiency of the membrane and its ability to 
recover solutes from the interstitial space. This is due to hypertrophy of astrocytes 
encompassing the probe, and layers of cell products surrounding the dialysis membrane 
(Benveniste and Diemer, 1987). Thus, guide cannulae are often employed during long 
term sampling through which microdialysis probes can be inserted and removed at 
various times over the experimental period, avoiding clogging of the membrane.
In addition to monitoring neurotransmitters in different brain areas and in different 
behavioural states, drugs can be administered locally into a brain region via the probe 
(dissolved in aCSF), and immediate effects upon transmitters detected. However, it is 
important to recognise that the concentration of drug infused via the probe will not 
reflect the concentration profile of the drug diffused into the interstitial space. Many 
factors will determine the amount of drug passing through the dialysis membrane into 
the interstitial space (see Beneviste, 1989) including: diffusion coefficients of the drug, 
drug concentration and drug interaction with the membrane. Once present in the 
interstitial space, the availability of the drug is dependent upon the uptake of the drug in 
intracellular and vascular compartments and binding of the receptor to other membrane 
proteins i.e. the in vivo performance of a microdialysis probe depends primarily on the 
behaviour of the solute in the tissue. The concentration of drug outside the membrane 
therefore, cannot be expected to reach that in the aCSF, and it is important to bear in 
mind this fact when interpreting results of drug infusions down the probe.
The distance a drug will diffuse through the tissue from the probe is only very limited 
and is dependent upon the duration the drug is present in the perfusing aCSF. Dykstra et 
a l (1992) perfused radiolabelled sucrose via the probe for 14 and 61.5 min, and 
examined autoradiograms of histological sections cut perpendicular to the site of 
implantation. After 14 min radiolabelled probe was visible surrounding the probe tract 
in a radius of 1 mm, whereas after 61.5 min, the label had diffused to approximately 2
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mm radially. This demonstrates the importance of stereotaxis during probe implantation 
for accurate implantation, and also the need for histological examination of brain tissue 
following microdialysis experiments to ensure correct probe positioning.
The most important characteristic of a dialysis probe is its ability to recover compounds 
of interest from the extracellular space, since this is a major factor determining the limit 
of detection of the system. Therefore, prior to each experiment the in vitro probe 
recovery must be tested to ensure that the recovery of 5HT across the dialysis membrane 
is high enough to detect the low interstitial concentrations. The probe is continuously 
perfused at a constant flow rate and inserted into an aqueous solution of the substance to 
be detected, at a known concentration. Other than the substance to be measured, the 
perfusion fluid and the medium outside the probe should be identical. The probe is 
perfused for 30 minutes and the dialysate collected. Recovery is expressed as a 
percentage of the 5HT in the recovered dialysate as compared to that in the medium 
outside.
Factors affecting the recovery of compounds via the probes include the molecular 
weight cut-off of the membrane, dialysis membrane area and the perfusion flow rate. 
Each membrane has a different molecular weight cut-off value for different molecules, 
and recovery depends on the size of the pores in relation to the size of the molecule. 
The appropriate membrane is therefore chosen with regard to the size of the molecule of 
interest. Obviously, the greater the surface area of the membrane, the larger the surface 
for free diffusion (Sandberg and Lindstrom, 1983) and hence a higher rate of recovery. 
Conversely, recovery of solutes are inversely proportional to perfusion flow rate. The 
slower the perfusion flow rate, the higher the rate of recovery across the membrane (see 
Result and Discussion section this Chapter). An obvious consideration is whether a 
given probe can detect what are effectively minute changes in concentration of 
substances in the interstitial fluid. Fortunately, recovery is independent of changes in 
the concentration outside the membrane (Johnson and Justice, 1983). Therefore, when 
the outer substance concentration is suddenly increased or decreased, the gradient across 
the dialysis membrane changes accordingly, thus keeping recovery constant.
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2.2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY WITH ELECTRO­
CHEMICAL DETECTION (HPLC-ED)
The successful application of high performance liquid chromatography (HPLC) to 
biomedical analysis often depends upon good sample preparation. Fortunately, due to 
the nature of the ‘closed’ microdialysis sampling system, there is no need for ‘clean up’ 
of the samples. The microdialysis samples can therefore be injected directly into the 
HPLC system.
2.2.1 Principles of chromatography
Reversed-phase chromatography is the most versatile and widely used HPLC method. 
Injected analytes are partitioned between a hydrophobic stationary phase (the HPLC 
column) and an aqueous (polar) mobile phase. The HPLC column is packed with a very 
uniform micro-particulate silica (3-10 Jim), chemically bonded with an octadecylsilyl 
(ODS) group to give a non-polar surface. The mobile phase used for elution is usually 
water mixed with methanol, or another water-miscible organic solvent. Separation of 
substances is dependent on their molecular charge, and elution is in order of increasing 
hydrophobicty (or decreased polarity). Although HPLC is a very efficient system for 
sample identification it can be further improved by using additives, such as ion-pairing 
agents added to the mobile phase to aid separation of amines (5-HT; see section 2.3.5), 
or by pre-column derivatisation for example for the detection and quantification of 
amino acids (glutamate; see section 2.3.6).
2.2.2 Basic HPLC-ED apparatus set up
Analysis by HPLC requires five basic components: (1) a pump, (2) an injection system,
(3) a column, (4) a detector, in this case an electrochemical detector (ED), and (5) a 
recording system to measure the output from the detector. The basic set up of the 
HPLC-ED is shown in figure 2.1. EC detection involves the oxidation and/or the 
reduction of compounds passing over an electrode, across which a given potential is 
maintained with respect to a reference electrode. The resultant flow of electrons is then 
measured by the working electrode, and subsequently amplified and measured on a 
suitable recording device.
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2.2.3 Detection of 5-HT by ‘ion-pairing’ HPLC
Catacholamines are readily broken down by oxidation at the ring hydroxyl groups 
producing an orthoquinone derivative and two electrons. Whilst a problem to scientists 
involved in the amine field, the electrochemist has used this to their advantage. 
Carrying out the oxidation at the surface of an electrode by applying a positive potential, 
results in a current produced directly proportional to the number of molecules oxidised.
It is worth considering the reasons for the inclusion of certain components of the mobile 
phase. Amines are known to become unstable in alkaline conditions and therefore an 
acidic pH is required, achieved by the inclusion of citric acid. Methanol is included to 
providing a less polar environment for the passing elutes, and at the same time 
shortening retention times of all compounds. However, under acidic conditions, the 
amino groups of monoamines tend to be more protonated and are therefore even less 
hydrophobic than if they were uncharged. For that reason, passing through a 
hydrophobic column, their separation, at best, would be poor. It is thus advisable to use 
‘ion-pairing’. This introduces a polar element to the otherwise hydrophobic surface 
chemistry of the column that can interact with the positively charged species and hence 
retard elution of molecules from the column. The fine balance between methanol 
concentration and octane sulphonic acid (OSA) concentration determine the elution time 
of the compounds and the separation of the compounds within the dialysate.
2.2.4 Detection of glutamate by pre-column derivatisation HPLC
Amino acid side chains rarely have physical characteristics which would permit direct 
estimation in solution. Therefore, to aid detection, derivatisation of the amino acids at 
the N-terminus is carried out with agents such as o-phthalaldehyde (OPA). The reaction 
of the OPA reagent with an amino acid produces a new heterocyclic species, responsible 
for the electrochemical activity of the OPA-amino acid derivatisation. In general, 
phosphate buffers are utilised with methanol present as an organic modifier. An 
important factor for adequate separation of amino acids present in biological samples is 
the pH of the mobile phase. Gentle manipulation of the pH will differentially modulate 
the retention time of different amino acids, thereby ensuring sufficient separation. 
Again, not unlike the system for separating 5-HT, it is a fine balance between methanol 
concentration and the pH of the mobile phase that determines retention time and 
adequate separation.
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Ethylenediaminetetraacetic acid (EDTA), present in the mobile phase of both systems, 
has the ability to chelate divalent cations. This is beneficial because divalent cations 
promote auto-oxidation of catechol-containing moieties, and stripping of divalent 



















Figure 2.1. Diagrammatic representation of the HPLC-ED system employed for the 
separation of both 5-HT and glutamate in microdialysate samples. The mobile phase is 
driven through the entire system by the pump and, in the case of 5-HT separation, 
recirculated. Pump ‘noise’ is eliminated by the presence of a pulse dampener. Samples 
are injected into the system with a Hamilton syringe, via a Rheodyne injection port, and 
expelled onto the column. The use of a guard column is employed when separating 
amino acids. Samples are detected electrochemically, and a record of the chromatogram 




Construction of concentric microdialysis probes was achieved using the following raw 
materials: 20 mm and 10 mm lengths of 24 gauge stainless steel cannulae (inner 
diameter (ID) 0.3 mm; Coopers Needle Works, Birmingham), 25 mm lengths of silica 
glass tubing (outer diameter (OD) 0.17 mm / ID 0.12 mM, Scientific Glass 
Engineering), 10 mm lengths of vinyl tubing (OD 0.8 mm / ID 0.5 mm; Elkay 
Laboratory products), lengths of Gambro membrane (OD 290 pm / ID 240 pm; 6000 
Kda cut-off; Gambro), and super glue (Cyanoacrylic, Loctite 454 gel, RS Components).
One end of a 20 mm length cannula was inserted into the end of the vinyl tubing. Into 
the other end of the vinyl tubing was inserted a 10 mm cannula, leaving approximately a 
4 mm gap in the centre of vinyl tubing between the 20 and 10 mm tubes. A small hole 
was then made in the centre of the vinyl tubing through which a length of silica glass 
tubing was threaded to emerge at the free end of the 20 mm cannula such that it 
extended approximately 1.5 mm out the end of the cannula. At this free end a short 
length of membrane (approx. 10 mm) was threaded over the silica tubing, and inserted a 
short way up the cannula, and affixed in position with a small quantity of super glue. 
Using a binocular dissection microscope the membrane was cut to a length of 2 mm 
(‘SCN-probes’) or 4 mm (‘hippocampal- and raphe-probes’) plus 0.5 mm to allow for 
plugging the end with glue. All join sites were sealed with glue, and a second 10 mm 
cannula positioned over the exposed end of silica tubing. Figure 2.2 shows a diagram of 
the completed concentric probe assembly.
2.3.2 In vitro probe recovery
In vitro recoveries of all probes were tested prior to implantation. The dialysis probes 
were suspended into an artificial CSF solution (see ‘dialysis set-up’ section 2.3.4) 
containing a known concentration of 5-HT (1 jiM) or glutamate (1 nM), and 
continuously perfused with the artificial CSF solution minus the 5-HT/glutamate, at a 
flow rate to be used in the experiment (1.2 jil/min). The probes were perfused for thirty 
minutes and the dialysates collected into an Eppendorf (containing 5 |il of 0.5 M 
perchloric acid for probes being tested for recovery of 5-HT). Recovery was expressed
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as a percentage of the 5-HT/glutamate in the recovered dialysate as compared to that in 
the recovery medium. Individual probe recovery was between 10-20 %. Probes with 
recoveries below 10 % were discarded. In situ, the recovery of solutes from the 
interstitial space through the probe is dependent upon many factors and the relationship 
between in vitro and in vivo recovery is complex (Benveniste and Huttemeier, 1990). 
Therefore, the in vitro recovery of the probe is mearly an indication of how the probe 
will function in vivo and the interstitial concentratin of solute cannot simply be 
extrapolated from the in vitro recovery. It was therefore decided not to correct each 
dialysate sample for the in vitro recovery and to express the data simply as a percentage 
value.
2.3.3 Probe implantation
Eighteen hours prior to the start of an experiment, rats were anaesthatised with 
equithesin (0.3 ml / 100 g body weight, i.p.), and placed in a stereotaxic frame with the 
incisor bar set at -3.3 mm, to maintain the head in a level position. Animals maintained 
under reverse light:dark cycle conditions had their eyes covered with black tape (PVC 
electrical insulation tape) during surgery to exclude light. The top of the head was 
shaved and a 1.5 cm incision made along the midline. The fascia was removed from the 
surface of the skull and the incision site kept open by use of artery clips. Once the skull 
surface was allowed to dry thoroughly, Bregma was clearly visible. The probe 
implantation site was calculated using Bregma as a reference. Three (for single probe 
implantation) or four (double probe implantation) burr holes were created in the skull 
using a dental drill (Claudius Ash Steel Burr; model number GLC0183); one (or two) 
hole(s) directly above the site of implantation, and two further holes. The dura mater 
was punctured using a sharp needle, and the probe(s) lowered slowly into the brain, to 
establish a final position on the lateral border of the SCN (co-ordinates, according to 
Paxinos and Watson, 1982; 6° angle, 1.5 mm medio-lateral (ML), -1.3 mm anterio­
posterior (AP), 9.7 mm dorso-ventral (DV)), the hippocampus (4.6 mm ML, -6.0 mm 
AP, 8.5 mm DV) or the midbrain raphe nuclei (14° angle, 1.5 mm ML, -7.8 mm AP, 9.5 
mm DV). The probes were anchored to the skull using two stainless steel screws (2 mm 
diameter, Semat Technology UK Ltd.) inserted into the two additional burr holes, and 
cemented into place with dental cement (Dentsply Ltd.).
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2.3.4 Dialysis set up
Animals were placed individually into experimental cages which consisted of a round 
plastic cage (diameter 30 cm; depth 30 cm) and a liquid swivel switch (Biotech 
Instruments Ltd.) suspended by a retort stand above the centre of the cage (see figure 
2.3). The dialysis solution (aCSF; composition in mM: NaCl 147; KCL 4; CaCL 4), 
containing 1|±M of the selective serotonin reuptake inhibitor (SSRI), citalopram, except 
where indicated, was continuously perfused through the probes with a Harvard 
Apparatus compact infusion pump (Model 22, Harvard Apparatus), set at a flow rate of
1.2 jil/min. Sample collection did not involve contact with the experimental animal 
and, therefore, any changes in collected 5HT were not due to excessive handling of the 
animal. The total volume of the inlet and outlet tubing was 45 jxl and thus the time 
taken for the aCSF to pass through the entire dialysis system was 37.5 minutes. Dialysis 
collection was every ten (glutamate) or fifteen minutes (5-HT), into 500 j l l I  eppendorf 
tubes. The collection vials for analysis of dialysate 5-HT contained 5 |il 0.5 M 
perchloric acid to prevent amine oxidation.
2.3.5 Separation and detection of 5-HT in dialysate
The analysis of 5-HT was accomplished via a reverse phase HPLC-ED using an 
amperometric detector (Antec Electrochemical detector, Antec Leyden B.V., The 
Netherlands). 5-HT content was analysed by injecting a 22 jllI volume of dialysate via a 
Hamilton syringe into a Rheodyne Syringe Loading Sample Injector port (model 7125; 
Rheodyne Incorporated, California, USA) holding a 100 p.1 loop. This off-loads the 
sample directly into the HPLC equipped with a 10 cm long, 4.6 mm bore, 3 |il 30DS2 
reverse phase column (Spherisorb, Jones Chromatography). The 5-HT was 
subsequently oxidised on the working electrode at +0.75 volts relative to a Ag/AgCl 
reference electrode. The current resultant from this oxidation of solute reaching the 
working electrode was amplified and converted to a voltage (I/E converter). The 
detector signal was detected on a programmable integrator (Hewlett Packard). 
Separation at 5.4 mins was achieved with a mobile phase consisting of 82.7 mM citric 
acid monohydrate, 43.4 mM anhydrous di-sodium hydrogen phosphate, 1.02 mM di­
sodium EDTA, 214 |LM OSA and 20 % methanol, pumped around the system using a 
Gynotek duel piston pump (model M300, Severn Analytical, Cheshire, UK; flow rate 
0.7 ml/min). The mobile phase was filtered prior to use through 0.2 J i m  filters
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(Millipore) and continually purged with helium to degas the solution. Concentration of 
5-HT was determined by the ratio of sample to standard peak height stored in the 
memory of the programmed integrator, and the results expressed as femtomols.
2.3.6 Separation and detection of glutamate in dialysate
Detection of glutamate in the dialysate samples was achieved using pre-column 
derivatisation of amino acids with an amperometric detector (Antec E-C detector). The 
derivitising agent consisted of 11 mg of OPA dissolved in 0.25 ml ethanol (HPLC 
grade), 0.25 ml 1 M sodium sulphite and 4.5 ml 0.1 M sodium tetraborate (pH 9.5). 
This OPA-reagent was stored in a brown bottle to protect it from light and maintained at 
room temperature for a period of up to 5 days. Derivitisation of amino acids was 
accomplished by diluting 10 pi of dialysate to a total volume of 50 pi with Milli-Q 
water and adding 1 pi of OPA-reagent. The reaction proceeded for 15 min at room 
temperature before samples were injected (50 pi) into the HPLC system.
The mobile phase, filtered through 0.2 pm filters and continually degassed with helium, 
consisted of 0.1 M sodium phosphate, 5 mM EDTA and 10 % methanol (pH 5.2) 
pumped around the system at a flow rate of 1.0 ml/min using a Jasco (PU-980) pump. 
During sample analysis the system was operated as an open loop circuit, but when not in 
use, the mobile phase was recycled. Fifty microlitres of derivitised sample was injected 
into a Rheodyne Syringe Loading Sample Injector port (model 7125) holding a 100 pi 
loop. The HPLC system consisted of a Cig, 25 cm, 5 pm reverse phase column (Rainin 
Dynamax) protected by a guard column (Rainin Dynamax). The working electrode was 
set at +0.85 volts relative to a Ag/AgCl reference electrode. The chromatogram was 
printed onto a chart recorder (JJ Instruments) and glutamate was identified from the 
retention time of an injected standard solution and quantified by comparison of the 









■  glue seals
Gambro membrane
Figure 2.2. Complete concentric probe assembly as constructed in the laboratory. For 
details of assembly, see text.
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Figure 2.3. Microdialysis experimental set up. The animals were placed in a round 
experimental cage (diameter 30 cm; depth 30 cm) equipped with a liquid swivel 
suspended above the cage with a retort stand. The aCSF supplied via a 1 ml syringe, 
was continuously perfused through the system. Dialysate collection involved no contact 
with the animal.
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2.4 RESULTS and DISCUSSION
2.4.1 General HPLC parameters
During the experimental period a number of HPLC columns and mobile phases of 
differing compositions were tested for their ability to separate 5-HT or glutamate in 
dialysate samples. Optimal conditions were those described in the preceding section. 
HPLC columns when used continuously had a shelf life of about 4-6 months. After this 
time separation of substances was incomplete, the pressure on the HPLC column 
increased or a double peak was produced on the chromatogram. When this occurs, the 
programmed integrator could not recognise the peak of interest and produces false 
readings. In these situations, the column was first reversed and generally pressure levels 
dropped to suitable levels and the double peak often disappeared. Alternatively, the 
column was washed through with a series of graded methanol concentrations (25, 50, 
75, 100, 75, 50, 25 %) for a period of 15-30 min each. Often a new column was needed 
to obtain optimal separation. However, each column had slight differences from the 
preceding one, and the mobile phase has to be slightly modified to achieve adequate 
separation. Representative HPLC traces are shown for 5-HT and glutamate in figures
2.4 and 2.5 respectively.
2.4.2 General microdialysis parameters
Although the in vitro recovery of each individual probe is not a true reflection of its 
ability to recover transmitters in vivo (Benveniste and Huttemeier, 1990), it is a valuable 
estimate of how the membrane is likely to function under different conditions. For 
example, although an increase in perfusion flow rate will increase the flux across the 
membrane (the amount of fluid passing over the membrane per unit of time), and 
increase the volume of the dialysate over the collection period, the amount of transmitter 
recovered is lowered with a higher perfusion rate. Figure 2.6 shows the effect of flow 
rate on in vitro probe recovery. Three dialysis probes were perfused in a solution of 
lpM 5-HT at different rates of flow between 1 and 4 fil/min, for a fixed period of 30 
min. The data were grouped together, and a linear regression value calculated. There 
was a very strong inverse correlation between flow rate and amount recovered (R = - 
0.917). From this preliminary experiment, a flow rate of 1.2 jul/min was chosen and 
used in all subsequent dialysis experiments.
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It was my aim to measure 5-HT and glutamate released from the circadian pacemaker, 
the SCN. However, due to its size and positioning within the mammalian brain, the 
SCN poses many problems for the neuroscientist. The SCN lie on the ventral surface of 
the brain in the midline. The probe is implanted from the dorsal surface of the brain and 
lowered into position using stereotaxis. Unfortunately due to excessive bleeding from 
the superior sagital sinus running throughout the midline, the probe could not be 
lowered vertically into the brain. Many preliminary experiments were performed to 
verify the best coordinates for implantation, and an angle of 6° yielded the best results. 
Approximately 70% of all implantated probes were accurately implanted as verified post 
mortem. The SCN are paired nuclei (see Introduction) and each nucleus is 950 (im long, 
420 J i m  wide and 400 J i m  in depth in the rodent. Lowering the probe (outer diameter 
290 J i m )  directly into the nucleus would therefore ablate the nucleus on the side of 
implantation. Thus, the probe is implanted so that its medial side lies adjacent to the 
lateral border of the nucleus. In this position it is expected that most of the 5-HT 
measured in the dialysate is of SCN origin, as the serotonergic innervation of the 
hypothalamus from the midbrain raphe culminates in the SCN (Moore et al., 1978). 
Additionally, a study (S. Barassin, personal communication) verified that the majority of 
5-HT collected from the dialysate of rats implanted with dialysis probes in similar 
positions (lying next to, rather than in, the SCN) did indeed originate from the SCN. 
The lateral border of the probes were blocked using glue, exposing only the medial side 
of the probe tip, lying adjacent to the SCN. The amount of 5-HT collected from such 
probes and intact probes with the whole membrane surface exposed, did not differ 
significantly. Regarding the collection of dialysate glutamate, one cannot be as positive 
that the glutamate has originated from the SCN. Although retinal afferents to the SCN 
release glutamate at their terminals (see Introduction), glutamate immunoreactivity in 
the whole hypothalamus is high (van den Pol, 1991). However, microdialysis has been 
successfully employed to measure glutamate from the SCN, and drugs acting thereupon 
(Selim et al., 1993; Srkalovic et a l, 1994).
Regarding the implantation of probes into the midbrain raphe nuclei, the same problem 
of bleeding from the superior sagital sinus was evident, because of their midline 
positioning. The probes were therefore implanted at an angle of 14°.
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It was deemed necessary to include the SSRI citalopram (1 pM) in the aCSF of all 
dialysis experiments involving perfusion of the SCN with subsequent 5-HT collection. 
Preliminary experiments carried out during the light phase measured basal levels of 5- 
HT collected from dialysate samples not containing citalopram, of between 0 and 5 
femtomols (fmol). Upon addition of citalopram the basal 5-HT level increased four-fold 
(figure 2.7A). The limit of detection of the HPLC was between 0 and 5 fmol and 
therefore, with addition of drugs postulated to decrease neuronal 5-HT (e.g. RU24969), 
it was necessary to have higher basal levels of 5-HT in order to observe the expected 
decrease.
Citalopram was excluded from the aCSF perfusing the midbrain raphe nuclei during the 
double probe experiments. During these experiments drugs were infused via probes 
implanted into the midbrain raphe, and the effects on raphe and SCN 5-HT 
concentration measured. Citalopram in the aCSF perfusing the raphe would increase 
synaptic 5-HT, thereby increasing the stimulation of 5-HTiA somatodendritic 
autoreceptors, decreasing serotonergic neuronal firing (Sprouse and Aghajanian, 1987) 
and decreasing terminal 5-HT release (Davidson and Stamford, 1995). The levels of 5- 
HT in the SCN dialysate would therefore be decreased, and any further decrease 
expected after infusion of drugs into the raphe nuclei during these experiments would be 
more difficult to detect (Romero et al., 1994).
The experimental setup using the round cages equipped with a liquid swivel was such 
that it avoided excess contact with the animal, thereby ensuring that any fluctuations in 
5-HT overflow were not due to excessive handling of the animal. Figure 2.7B shows 
the effect of handling an animal (n=2) for a short period on 5-HT in the collected 
dialysate from the midbrain raphe at mid light. A three-fold increase in 5-HT was 
observed.
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Figure 2.4. Typical HPLC traces for the separation of 5-HT in dialysate samples as 
recorded by the programmed integrator. (A) 20 p.1 aCSF; (B) 20 i^l 10'9 M 5-HT(20 
fmol); (C) 22 jil dialysate sample. Note the separation of the 5-HT peak from the 





Figure 2.5. Typical HPLC traces for the separation of glutamate in dialysate samples as 
displayed by the chart recorder. (A) 1 pmol glutamate no derivatising agent (10 pi); (B) 
1 pmol glutamate with derivatising agent (10 pi); (C) dialysate sample with derivatising 
agent (50 pi). Note the separation of the glutamate peak from the remaining 
components in the dialysate sample indicated by the arrow. Glutamate elution time 7.0 
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Figure 2.6. Effect of flow rate of perfusing aCSF on the amount of 5-HT collected from 
a typical dialysis probe, measured by in vitro recovery in a solution of 1 pM 5-HT. 
Flow rate (pl/min) is plotted versus the percent of recovered 5-HT relative to the 
amount recovered at 1 pl/min i.e. amount of 5-HT recovered at a flow rate of 1 pl/min is 
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Figure 2.7. Parameters affecting 5-HT overflow as measured from the dialysate. A: 
Effect of addition of the SSRI citalopram (1 pM) to the perfusing aCSF, on 5-HT 
overflow from the SCN. An immediate increase in measurable 5-HT is observed during 
the period of citalopram inclusion, denoted by the hatched bar. B: Effect of handling 
the animal during the dialysate collection period (n=2). The animals were handled 
gently for a period of 5 min, denoted by the hatched bar. An immediate increase in 
dialysate 5-HT concentration in the raphe was observed.
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CHAPTER 3
THE FUNCTION OF THE TERMINAL 5-HT1B AUTO- AND 
HETERO- RECEPTORS IN THE SCN
3.1 INTRODUCTION
Diumal variation in brain serotonin concentration first became evident after mouse 
brains were removed at various time points during the day and night, crushed, and the 
extract analysed spectrophotometrically for 5-HT. At four hourly intervals 
measurements of total brain 5-HT levels were obtained, with a peak demonstrated 
during the light phase at ZT 6, and a nadir at the end of the light phase at ZT 11 
(Albrecht et al., 1956). This study was unsophisticated compared to what is possible 
today, and examined whole brain 5-HT content rather than individual brain regions; 
nonetheless, the authors did recognise that “drastic changes in certain parts of the brain, 
like the hypothalamus, may be obscured if other parts of the brain do not vary at the 
same time and in the same direction”. It was not until 1968 that rhythms in 5-HT 
content were identified in hypothalamic tissue in rats over 24 hours (Quay, 1968). 5-HT 
levels peaked in hypothalamic tissue during the mid- to end-light period, and were low 
during the hours of darkness.
Since this time, many investigators have identified rhythms in 5-HT concentration in 
hypothalamic tissue with higher tissue levels being associated with the light phase 
(Ferraro and Steger, 1990; Cagampang and Inouye, 1994). The amplitude of the rhythm 
has been shown to be greatest in the SCN (Martin and Marsden, 1985). This rhythm in 
5-HT levels is thought to be generated by an endogenous pacemaker, but influenced by 
the photic cycle (Cagampang and Inouye, 1994).
Many factors may contribute to the circadian rhythm in serotonergic neuronal level 
including the activity of the rate limiting enzyme tryptophan-5-hydroxylase or the 5-HT 
breakdown enzyme monoamine oxidase, the availability of the 5-HT precursor 
tryptophan and the neuronal uptake of tryptophan. A review of each of these processes 
is beyond the scope of this thesis but the interested reader is directed to a recent review 
by Martin and Redfem (1997).
It is now well established that the synthesis and release of 5-HT is influenced by 
inhibitory autoreceptors. Somatodendritic autoreceptors have been identified as 5-HTia 
autoreceptors, stimulation of which reduces firing of serotonergic neurones (Sprouse 
and Aghajanian, 1987) and predictably results in a reduction of terminal 5-HT release.
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Terminal autoreceptors in the rat are classed as 5 -H T jb receptors (Engel et a l, 1986; 
Limberger et a l, 1991; Trillat et a l, 1997) and are negatively coupled to adenylate 
cyclase (Bouhelal et a l,  1988). Stimulation of these receptors reduces terminal 5-HT 
release, and 5 -H T iB receptor binding sites have been identified in high densities in 
rodent SCN (Pickard et a l, 1996). It is possible that a variation in the function of the 5- 
HTib autoreceptor contributes to variation in 5-HT synthesis and release, thereby 
indirectly influencing clock mechanisms within the SCN. In addition to regulating 5- 
HT release, 5 -H T ib receptors can act as presynaptic heteroceptors regulating the release 
of transmitters other than 5-HT for example acetylcholine (Bolanos-Jimenez et a l, 
1995; Maura and Raiteri, 1986) and dopamine (Hallbus et a l, 1997). Included in the 
high density of 5 -H T ib binding sites recorded in the SCN are 5 -H T ib heteroceptors on 
retinal afferents (Pickard et a l,  1996). Bilateral orbital enucleation decreases the 
density of 5 -H T ib binding sites, indicative of a retinal terminal location. These 
heteroceptors are thought to play a key role in modulating retinal transmission to the 
SCN as systemic or local administration of a 5 -H T ib agonist can inhibit light induced 
phase shifts and decrease light induced Fos expression in the mouse SCN (Pickard et 
a l, 1996; Pickard and Rea, 1997).
The aim of this Chapter was to firstly perform pharmacological controls to establish that 
the measured 5-HT/Glutamate in the dialysate was of neuronal origin and secondly to 
examine the function of the terminal 5 -H T ib auto- and hetero- receptors in the SCN and 
compare the function of the 5 -H T ib autoreceptor in the SCN with that present in the 
hippocampus. I therefore investigated the function of the terminal 5 -H T ib autoreceptor 
using the 5 -H T ia/ ib agonist RU24969 which has high affinity for the 5 -H T ib receptor. 
Experiments were performed at six time points over the 12:12 hour lightidark cycle in 
the SCN region of the conscious rat using in vivo microdialysis in order to determine 
whether there was any diumal variation in the function of the receptor. In a comparative 
study, the function of the 5 -H T ib autoreceptor was examined at mid-light versus mid­
dark in another serotonergic rich area, the hippocampus (Moore and Halaris, 1975). The 
function of the 5 -H T ib heteroreceptor in the SCN was also investigated using RU24969 




Male Wistar rats (University of Bath strain; 260-320 g) were maintained under a 12:12 
light:dark cycle regime (lights on 07:00 “normal” light:dark cycle; lights on 19:00 
“reverse” light:dark cycle; temperature 22 ± 2°C). The animals were housed in groups 
of six prior to experimentation, with food and water available ad libitum.
3.2.2 Microdialysis
1) The 5-HTib autoreceptor
Each animal was implanted with a microdialysis probe as described in the preceding 
chapter section 2.3.3, directed at either the SCN or the hippocampus, and introduced to 
the experimental cage. The probe was continuously perfused with aCSF (1.2 jil/min) 
containing 1 jiM of the SSRI citalopram. Six 15 min control samples were collected, 
and the three samples immediately before drug infusion served as pre-intervention 
controls. Drugs were infused via the probe and dialysate samples were collected every 
15 min over a period of 3 hours post-drug infusion. Dialysate 5-HT content was 
analysed by HPLC-ED as described in Chapter 2 section 2.3.5.
2 ) The 5 -H T ib heteroceptor
The animals were implanted with a microdialysis probe directed at the SCN. The probe 
was continuously perfused with aCSF (1.2 jil/min) containing no citalopram. Two to 
four 10 min control samples were collected which served as pre-intervention control 
samples. Drugs were infused via the probe and dialysate samples collected over a 60 
min experimental period. Dialysate glutamate concentration was analysed by HPLC-ED 
as described in Chapter 2 section 2.3.6.
*
Samples not analysed immediately were snap frozen and maintained on dry ice until 
analysis. At the end of the experiment the animal was killed by CO2 asphyxiation and 
the brain removed and frozen onto dry ice. Slicing freehand with a sharp razor blade, 
the probe tract was clearly visible as a fine line through the brain tissue. With the aid of 
a stereotaxic atlas (Paxinos and Watson, 1982) the position of the probe tract within the 
hypothalamus and hippocampus was established. The animals whose probe tracts were 
not in the target area were discarded for analysis.
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3.2.3 Drugs
RU24969 [5-Methoxy-3(l,2,3,6-tetrahydro-4-pyridinyl)-lH-indole] was provided by 
Roussel-Uclaf and citalopram hydrobromide by Lundbeck (Copenhagen-Valby). 
WAY100635 (N-[2-[4-(2-methoxyphenyl)-l-piperazinyl]ethyl]-N-(2-pyridinyl)
cyclohexanecarboxamide trihydrochloride) was donated by P.J.Mitchell from the 
University of Bath.
3.2.4 Statistics
5-HT or glutamate concentration in the dialysate samples (uncorrected for probe 
recovery) were expressed as a percentage of the mean of the pre-intervention controls 
samples. The sampes collected immediately prior to drug infusion were averaged and 
each value and subsequent value was expressed as a percentage of this mean value. 
Values post-drug treatment were analysed by one-way analysis of variance (ANOVA) 
with repeated measures with Student Newman Keuls post hoc test to detect differences 
between pre-intervention controls samples. Basal 5-HT and glutamate concentration 
were expressed as fmol or pmol, respectively, and analysed by one way ANOVA with 




3.3.1 The 5-HTib autoreceptor
Basal 5-HT levels varied significantly across the light dark cycle. 5-HT concentration in 
SCN dialysate samples were 28.7 ± 2.89, 32.7 ± 7.05, 41.7 ± 5.18, 17.6 ± 3.90, 20.4 ±
4.03 and 15.7 ± 1.56 mean ± s.e.m. fmol for zeitgeber times 3, 6, 9, 15, 18 and 21 
respectively (figure 3.1). As a general trend, the 5-HT in the SCN dialysate during the 
light phase was higher than that collected during the dark phase. Highest levels were 
measured at ZT 9, and the levels at ZT 15, 18 and 21 were significantly lower than those 
at ZT 9 (p < 0.05). In the absence of drug infusion the 5-HT overflow from the SCN did 
not vary significantly over the three hour collection period at any of the six time points.
3.3.1.1 Pharmacological controls
Perfusion for 60 min with calcium free aCSF resulted in an immediate and significant 
decrease in 5-HT overflow, with a maximal decrease of 93.0 ± 3.67 % (p < 0.001). 
Upon reperfusion with aCSF containing calcium ions, 5-HT overflow began to increase, 
but remained significantly lower than pre-intervention controls 45 min after reperfusion 
(figure 3.2A). Modified aCSF containing 100 mM KC1 was perfused for 60 min, 
causing an immediate and significant increase in 5-HT overflow. Maximal increase was 
349 ± 80.8 % (p < 0.01). After reperfusion with normal aCSF, 5-HT levels returned to 
basal (figure 3.2B).
3.3.1.2 Effect of local infusion of RU24969 into the SCN
The effect of stimulation of the 5-HTiB autoreceptor with RU24969 (5-HTia/ib agonist; 
ljiM; 15 min infusion) was dependant upon the zeitgeber time at which the drug was 
infused.
During the light phase, infusion of RU24969 at ZT 3 and 6 produced a significant and 
prolonged decrease in 5-HT overflow, reaching a maximal decrease of 30.6 ± 11.9 and 
41.0 ± 11.7 % mean ± s.e.m. of baseline, respectively (p < 0.01; figure 3.3A and 3.3B). 
At ZT 9 infusion of RU24969 failed to produce any significant change in dialysate 5-HT 
concentration (figure 3.3C).
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During the dark phase, infusion of RU24969 at ZT 15 produced a significant and 
prolonged decrease in SCN 5-HT, reaching a nadir of 56.1 ± 17.2 % of baseline (p < 
0.05; figure 3.3D). At ZT 18, RU24969 infusion failed to significantly change dialysate 
5-HT concentration (figure 3.3E). At ZT 21, RU24969 infusion produced a significant, 
but short lived, decrease in SCN 5-HT overflow, reaching a low of 54.3 ± 17.0 % of 
baseline (p < 0.05; figure 3.3F).
These findings are summarised in figure 3.4 which plots the maximal percentage 
decrease in dialysate 5-HT post-RU24969 infusion, against the zeitgeber time, and 
demonstrates the functional ability of the 5-HTjb autoreceptor across the light dark 
cycle.
3.3.1.3 Effect of WAY100635 on the RU24969 infusion at ZT 6
In addition to stimulation at the 5-HTib receptor site, RU24969 also demonstrates 
affinity for the 5-HTiA receptor. Therefore, to exclude the involvement of the 5-HTiA 
receptor in the observed response, the tissue was pretreated with WAY100635, an 
antagonist specific for the 5-HTiA receptor site at ZT 6. WAY100635 (1 fiM) was 
infused for 15 min prior to and 15 min during RU24969 infusion. The ability of 
RU24969 to decrease dialysate 5-HT levels was not affected by the presence of 
WAY100635 (figure 3.5A). Therefore, it can be assumed that RU24969 is acting solely 
by stimulation of the 5-HTib receptor under these given circumstances. WAY100635 
infusion alone did not significantly affect SCN 5-HT levels at ZT 6 (figure 3.5B).
3.3.1.4 Effect of a local infusion of RU24969 into the hippocampus at ZT 6 and 18 
There was such a contrast between the ability of RU24969 to decrease dialysate 5-HT at 
ZT 6 (mid-light) versus ZT 18 (mid-dark) in the SCN, that it was decided to test another 
serotonin-rich brain area with RU24969 to establish whether this effect was SCN- 
specific. Hippocampal 5-HT levels pre-drug infusion were 54.4 ± 20.1 and 40.9 ± 15.3 
fmol for ZT 6 and 18, respectively (mean ± s.e.m.). A 15 min infusion of RU24969 (1 
jiM) in the hippocampus at ZT 6 produced a significant decline in dialysate 5-HT, 
evident 60 min after the start of the infusion (maximal decrease 32.3 ± 15.0 % of 
baseline; p < 0.01; figure 3.6). At ZT 18 the reduction in dialysate 5-HT post-RU24969
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infusion was less pronounced but reached statistical significance 60 min after the start of 
the infusion (maximal decrease 58.4 ± 9.63 % of baseline; p < 0.01).
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Figure 3.1. Basal 5-HT concentration as measured in SCN dialysate at six zeitgeber 
times across the 12:12 light:dark cycle. Data are expressed as mean ± s.e.m. (n = 4 - 8). 
Basal 5-HT levels at ZT 15, 18 and 21 are significantly different from basal levels 
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Figure 3.2. Effect of removal of calcium ions from (A) and increasing potassium ion 
concentration (100 mM) in (B) the perfusing aCSF on the 5-HT overflow from SCN 
dialysate. Calcium ions were removed from, or potassium ions were added to, the aCSF 
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Figure 3.3 (A-F). Effect of RU24969 infusion (1 pM) on 5-HT overflow in the SCN at 
ZT 3 (A), 6 (B), 9 (C), 15 (D), 18 (E) and 21 (F). Values are mean ± s.e.m. expressed 
as a percentage of three pre-intervention control samples. RU24969 was infused for 15 
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Figure 3.4. Percentage maximal decrease in 5-HT overflow following infusion of 
RU24969 (1 jiM; 15 min) at zeitgeber times 3, 6, 9, 15, 18 and 21. * p < 0.05; ** p < 
0.01. Maximal decrease in dialysate 5-HT concentration post-RU24969 infusion is 
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Figure 3.5. A: Effect of WAY100635 (1 (J,M) on the response to RU24969 (1 jliM) on 
5-HT overflow in the SCN at ZT 6. WAY100635 was infused 15 min prior to, and 15 
min concurrently with RU24969. The solid bar denotes WAY100635 infusion, and the 
hatched bar the RU24969 infusion. Values are mean ± s.e.m. expressed as a percentage 
of three pre-intervention controls. B: Effect of WAY100635 (1 \iM) alone on 5-HT 
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Figure 3.6. Effect of RU24969 infusion (1 pM) on hippocampal 5-HT overflow at ZT 6 
and 18. Values are mean ± s.e.m. expressed as a percentage of three pre-intervention 
control samples. RU24969 was infused for 15 min denoted by the hatched bar. * p < 
0.05; **p<0.01.
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3.3.2 The 5 - H T jb  heteroceptor
Basal glutamate overflow from the SCN differed at the two zeitgeber times tested. 
Higher levels were measured at ZT 18 versus ZT 6, being 1.82 ± 0.51 and 0.463 ± 0.21 
picomols respectively (p<0.05).
3.3.2.1 Pharmacological controls
Modified aCSF containing 100 mM KC1 was perfused via the probe for 30 min, 
producing a significant increase in glutamate overflow. Maximal increase was 338 ± 
116 % of baseline (p < 0.05) occurring 30 min after the start of the infusion (figure 
3.7A). Perfusion for 30 min with the voltage-dependant calcium channel blocker nickel 
chloride (NiCl; 2 mM), significantly decreased glutamate overflow from the SCN. 
Thirty min after the start of the infusion dialysate glutamate concentration dropped to
15.2 ± 5.39 % of baseline (p < 0.05; figure 3.7B).
3 . 3 . 2 . 2  Effect of local infusion of RU24969 into the SCN
A 15 min infusion of RU24969 (1 pM) into the SCN significantly decreased glutamate 
overflow in the dialysate samples at ZT 6 and ZT 18. The effect was more pronounced 
at ZT 6, reaching a nadir of 40.8 ± 12.5 % of baseline within 20 min of the start of the 
infusion (p < 0.05; figure 3.8A). At ZT 18, RU24969 infusion did result in a significant 
decrease in SCN glutamate to a level 37.9 ± 18.3 % of baseline, but not until 50 min 
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Figure 3.7. Effect of increasing potassium ion concentration (100 mM KC1; A) and 
including the voltage dependant calcium channel blocker, nickel chloride (NiCl; 2 mM; 
B) in the perfusing aCSF on the glutamate overflow from SCN dialysate. Potassium 
ions or NiCl was added to the aCSF for a period of 30 min, denoted by the hatched bar. 
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Figure 3.8. Effect of RU24969 (1 p,M) on glutamate overflow in the SCN at ZT 6 (A) 
and ZT 18 (B). Results are mean ± s.e.m. values expressed as a percentage of pre- 
intervention controls. RU24969 was infused into the SCN via the dialysis probe for 15 




Basal 5-HT levels from the SCN region showed a very distinct diurnal variation, with 
maximal levels being recorded at ZT 9, towards the end of the light period, and the 
lowest levels recorded through the dark period. This diurnal variation is very similar to 
results presented in a review by Martin and Marsden (1984) as unpublished data from 
their laboratories. They also obtained peak 5-HT levels from the microdialysate 
samples of the SCN after mid-light, with the levels declining toward the dark phase, and 
during the dark phase. A few laboratories have measured the output of the 5-HT 
metabolite 5-hydroxyindole acetic acid (5-HIAA) by in vivo voltametry or microdialysis 
across the light dark cycle. 5-HIAA is elevated during the hours of darkness and 
reaches a nadir during the light phase (Faradji et al., 1983; ; Ramirez et al., 1987; Glass 
et al., 1992), and is closely correlated with an increase in locomotor activity. This 
rhythm in 5-HIAA exactly mirrors the rhythm for 5-HT I observed here. Glass and his 
coworkers (1992) account for the nocturnal rise in 5-HIAA by an increased metabolism 
and release of 5-HT, because local application to the SCN of the sodium channel 
blocker tetrodotoxin significantly reduced microdialysate concentrations of 5-HIAA 
during the dark phase whilst having no effect during the light phase. Also, addition of 
5-HT to the perfusate significantly enhanced 5-HIAA levels, indicating that increased 
extracellular serotonin may be reflected by increased 5-HIAA concentrations, 
presumably due to additional metabolic breakdown of the 5-HT. From these 
experiments one might asssume that the higher rate of conversion of 5-HT to 5-HIAA 
during the dark phase indicates that the clearance of 5-HT is enhanced at night. If 
clearance is enhanced at night one might expect extracellular 5-HT measured in 
dialysate samples to be low, which is what I observed.
The firing of raphe serotonergic neurones correlates with the state of arousal of the 
animal. Raphe firing is low during sleep and periods of inactivity, and high during 
periods of activity. Therefore, terminal 5-HT release would be expected to be low 
during the light phase and high during the dark phase of a nocturnal animal. This 
however does not match the extracellular concentrations measured by microdialysis. As 
already suggested, however, clearance rates of 5-HT are higher during the dark, and it 
may be that during this phase greater release of 5-HT from serotonergic neurones is
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more than compensated by greater neuronal reuptake and/or more rapid breakdown. 
Indeed the uptake of tritiated 5-HT into SCN slices shows a diurnal variation with the 
highest levels recorded at the start of the dark phase (Meyer and Quay, 1976) and 
imipramine labelling of the 5-HT presynaptic reuptake site is highest at end dark (Wirz- 
Justice et a l , 1983). It must be borne in mind, however, that the perfusion media 
contained the reuptake blocker citalopram, and so variation in dialysate 5-HT observed 
here cannot easily be attributable to alterations in the capacity of the neurones to take up 
5-HT. The diumal variation in measured 5-HT from the dialysate samples of the SCN is 
therefore most likely to be due to increased breakdown of 5-HT during the dark phase 
(supported by findings of high nocturnal 5-HIAA levels).
It was important to establish the origin of the 5-HT in the dialysate. Exocytotic release 
of neurotransmitter is considered to be a calcium dependent process and removal of 
calcium ions from the perfusion fluid resulted in an immediate and significant decrease 
in dialysate 5-HT. Conversely, increasing the concentration of potassium ions in the 
perfusing aCSF will lead to depolarisation of the nerve membrane and concomitant 
release of neurotransmitter similar to that seen when an action potential travels down the 
nerve. Indeed, infusion of 100 mM KC1 led to an immediate and significant increase in 
5-HT overflow. Two essential criteria for establishing a neuronal origin of the 5-HT 
present in the dialysate have thus been fulfilled. This is in agreement with other authors 
who have dialysed the hypothalamus and measured 5-HT levels (Auerbach et a l , 1989).
RU24969 has been shown previously to be an agonist at 5 -H T ib autoreceptors 
regulating 5-HT release in the hippocampus (Sharp et al., 1989; Martin et a l , 1992), the 
frontal cortex (Middlemiss, 1985) and the amygdala (Bosker et al., 1997). 
Unfortunately RU24969 has been shown to act as a 5-HT reuptake blocker in the 
absence of a reuptake blocker in the perfusing aCSF (Auerbach et a l, 1991; Hjorth and 
Tao, 1991). However, in the presence of citalopram, RU24969 was shown to act as an 
agonist at the 5 -H T jb autoreceptor. Thus, in the given experimental conditions, 
RU24969 is expected to act soley as an agonist. Although RU24969 is an agonist at 5- 
HTib receptors (Sills et al, 1984) it does have an affinity for the 5-HT]A receptor. It was 
thus important to establish whether the RU24969 was acting via its actions on the 5- 
HTja or 5 -H T ib receptor. Simultaneous infusion of RU24969 and the 5 -H T iA receptor 
antagonist WAY100635 at ZT 6 did not alter the profile of inhibition by RU24969 alone
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(figure 3.4), and we may assume that under the given experimental conditions, 
RU24969 was acting by activation of 5-HTib receptors. There was no apparent tonic 
influence of 5-HTia receptors in the SCN, demonstrated by the absence of response to 
infusion of WAY 100635 alone. A previous report by Sayer (1994) failed to 
demonstrate any significant effects on 5-HT overflow in the SCN following infusion of 
the 5-HTia receptor agonist 8-OH-DPAT into the SCN at mid-light, thereby confirming 
that local stimulation of the 5-HTiA receptor does not alter local 5-HToverflow.
The effect of 5 - H T ib  receptor stimulation by RU24969 on 5-HT overflow from the SCN 
was strikingly dependent upon the zeitgeber time at which the drug was applied. During 
the early- and mid-light phase (ZTs 3 and 6) and the early-dark phase (ZT 15) RU24969 
produced a significant and prolonged decrease in dialysate 5-HT levels. Towards the 
end of the dark period (ZT 21) the response to RU24969 was to produce a significant, 
but short acting reduction in dialysate 5-HT levels. Surprising RU24969 produced no 
effect on dialyate 5-HT levels towards the end of the light period (ZT 9) or at the mid­
dark phase (ZT 18). During the dark phase, when RU24969 elicited a decrease in 5-HT 
overflow, it did so to a lesser degree than when RU24969 decreased 5-HT overflow 
during the light phase (figure 3.3). Previous in vivo studies that have investigated the 
function of the terminal 5-HT1B autoreceptor have done so only at a single time point 
during either the light or dark phase. Rollema and coworkers (1996) investigated 
guinea pig hypothalamic 5-HT release with the 5-HTm agonist CP-135807 (the guinea 
pig terminal autoreceptor is of the 5-HTid subtype; Limberger et al., 1991). CP-135807 
dose-dependently reduced 5-HT overflow, and at a concentration of 1 j i M  decreased 5- 
HT levels to 30 % of basal, which is comparable to the results presented here for ZT 3 
and ZT 6.
Acute stress has been shown to affect 5 - H T ib  autoreceptor function (Bolanos-Jimenez et 
al., 1995). During the light phase a 40 min restraint stress significantly reduced the 
efficacy of the 5 - H T i b  receptor agonist CP93129 in decreasing potassium evoked 
tritiated 5-HT release in a synaptosome preparation. However, in my experiments all 
animals were prepared in the same manner and all experiments were performed under 
the same conditions. Additionally, the use of the round experimental cages equipped 
with a liquid swivvel ensured no contact with the animal (see Chapter 2 section 2.3.4). 
The variation in receptor function is not likely to be explained by stress of the animals.
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This diumal variation in 5-HTjb autoreceptor function in the rat in response to RU24969 
stimulation has not been reported before. However, a study by Martin and coworkers 
(1987) did suggest that the behavioural response to RU24969 in the mouse exhibited a 
circadian variation. The effects of RU24969 on locomotor activity was examined at 
different time points during the light dark cycle. The ability of the drug to induce 
locomotor activity did not vary across the light dark cycle, but the ability of the 
antagonist metergoline to antagonise the response varied at ZT 8 versus ZT 17. The 
antagonist was 3-5 fold more effective at blocking the response to RU24969 at ZT 8 
than at ZT 18 (i.e. just after mid-light versus mid -dark). Although the authors were 
incorrect in stating that the behavioural response to 5-HTjb receptor stimulation 
exhibited a circadian variation, it did appear to exhibit a diumal variation; the degree of 
pre- and postsynaptic receptor contribution is unknown. Another behavioural study 
performed by Moser and Redfem (1984) set out to examine the activity of 5-HT 
receptors over 24 hours by administration of a mixed 5-HT receptor agonist, 5-methoxy- 
N,N-dimethyltryptamine, with a slightly higher affinity for the 5 -HT2 class of receptor. 
There was a clear diumal variation in head twitch responses with peak activity occurring 
at mid-light. Although they postulated the effect to be attributable to pasrsynaptic 
receptor stimulation it does reflect a diumal rhythm in central 5-HT receptor function. 
Because the agonist used in their studies had affinity for receptor subtypes other than the 
5 -HT2 receptor, it is possible that the observed affect on rat behaviour was due to the 
stimulation of the 5-HT 1 receptor class. This effect is unlikely to be attributable to 5- 
HTja receptors as extensive behavioural studies carried out by Lu and Nagayama (1996; 
Nagayama and Lu, 1997) administering the 5-HTia agonist 8-OH-DPAT, measured 
peak responses at mid-dark with a nadir at mid-light. These experiments by Moser and 
Redfem (1984) may thus be attributable to 5-HTiB receptor stimulation considering the 
peak locomotor response was during the mid-light phase.
Subsequent in vitro studies have failed to identify variation in the function of the 
terminal 5 - H T ib  receptor. Singh and Redfem (1994a) failed to demonstrate a circadian 
variation in the function of rat terminal 5 - H T ib  autoreceptors even though they sampled 
at four equally spaced time points across the light dark cycle. However, these authors
(1) sampled from hippocampus and cortex and not the hypothalamus where the SCN is 
situated (2) used an in vitro superfusion preparation, which whilst giving an indication
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as to the mechanisms of neuronal release, cannot get as full a picture as those 
experiments performed in vivo and (3) they based their assumptions on the ability of 
methiothepin (a putative autoreceptor antagonist) to antagonise the inhibition by 5-HT, 
rather than seeing the effect of 5-HTiB agonist stimulation. The results reported from 
these in vivo microdialysis experiments in the freely moving animal can be assumed to 
provide a more accurate reflection of autoreceptor function. In another in vitro study the 
ability of RU24969 to decrease stimulation-induced release of tritiated 5-HT from 
preloaded rat hypothalamic slices was similar in slices obtained from the light phase and 
the dark phase (Blier et a l ., 1989). These experiments were carried out only at two time 
points over the light dark cycle, and not at a fixed zeitgeber time, as in our experiments. 
It is thus possible that Blier and collaborators (1989) have sampled tissues in the dark 
phase either side of the mid-dark period, in which case they would indeed observe 
decreases in 5-HT overflow. The results from the data presented in this chapter 
therefore highlight the importance of stating the zeitgeber time in reports and sampling 
(in vivo) or collecting samples (in vitro) at equally spaced time points.
Many possibilities exist as to why there is a variation in 5 - H T ib  receptor function 
including differential expression of receptor message over the light:dark cycle, 5 - H T ib  
receptor occupation by endogenous agonists, changes in the density of the 5 - H T ib  
autoreceptors in the nuclei, differential second messenger systems and receptor 
phosphorylation or internalisation. Messenger RNA (mRNA) for the 5 - H T ib  receptors 
has been shown not to vary at two equally spaced time points across the light:dark cycle 
(Roca et al., 1993). However these experiments examined SCN tissue from rats held in 
constant darkness, and so although there was no circadian variation, there may be a 
diumal variation. Even so, one must bear in mind that mRNA expression within the 
SCN will measure receptor expression in the cell body relating to postsynaptic 
receptors, and will not measure the presynaptic autoreceptor as examined in these 
microdialysis experiments.
If the function of the 5 - H T ib  autoreceptor varied in accordance with basal 5-HT levels 
then the reduced efficacy of the 5 - H T ib  agonist to inhibit the release of 5-HT might 
result from the competition at 5 - H T ib  receptors with the endogenous 5-HT released. 
During the dark phase when the basal 5-HT levels are low the autoreceptor function 
appears to be reduced because at ZT 18 there is no effect of 5 - H T jb  autoreceptor
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stimulation and at ZTs 15 and 18 the maximal decrease in 5-HT overflow following 
RU24969 infusion is only approximately 50 %, whereas at ZTs 3 and 6 maximal 
reduction is between 60 and 70 % of basal. This unfortunately does not account for why 
there is an apparent absence of 5 -H T ib autoreceptor function at ZT 9 when the basal 5- 
HT levels are at their peak. It may be that high extracellular 5-HT levels down regulate 
the receptor in response to being continually activated, although it is an anomaly why 
this would happen specifically at this time point.
5 -H T jb receptor binding has been shown in one study to be significantly higher during 
the dark phase than during the light phase (Prosser et a l, 1993). Unfortunately this does 
not correlate with our findings in which the response is absent at mid-dark. It may be 
that at mid-dark the receptor occupation by endogenous ligand is at its highest and 
therefore exogenously applied agonist cannot displace the natural ligand to exert its 
effect. If occupation of the 5 -H T ib receptor by endogenous 5-HT is higher during the 
dark phase, this may explain why extracellular 5-HT levels are lower during the dark. It 
is importanat to remember that the 5-HT concentration detected in the microdialysate is 
only a reflection of extracellular 5-HT and not synaptic 5-HT concentration.
5 -H T ib receptors are negatively coupled to adenylate cyclase (Bouhelal et al., 1988), 
stimulatation of which will lead to changes in intracellular levels of cAMP. The 
functional activity of the 5 -H T ib autoreceptors is related to availability of the second 
messengers and the substrate cAMP. Circadian variation in the levels of endogenous 
cAMP have been detected in rat SCN micropunches (Prosser and Gillette, 1991; 
Yamazaki et a l, 1994) with peak levels during the late day and late night, but low 
during early night. This pattern does not really follow the function of the 5 -H T ib 
receptor but the experiments examining the levels of cAMP were carried out in vitro and 
under constant darkness. In animals maintained under a 12:12 light:dark cycle, the 
levels of endogenous cAMP may follow 5 -H T ib receptor activity. If cAMP levels were 
low towards the end of the light period and throughout the dark period, one might 
speculate that the low availability of substarate for the enzyme adenylate cyclase 
accounts for the variation in receptor function. However, the 5 -H T iB receptor is 
negatively coupled to adenylate cyclase; stimulation of the receptor will prevent rather 
than promote cAMP conversion. It would therefore be a more accurate parameter to 
measure the activity of the enzyme adenylate cyclase itself. Prosser and Gillette (1991)
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did measure adenylate cyclase activity in addition to cAMP levels in the same setup, but 
found no significant variation in activity over the four different sampling times. Once 
again this is a measurement of circadian variation, and not diumal variation as we have 
identified the 5 -H T ib autoreceptor to exhibit. It is still possible that underlying 
variations in adenylate cyclase activity account for the variation in 5 -H T ib autoreceptor 
function in the SCN.
Another exciting candidate for why this variation in autoreceptor function exists in 
rodent and bovine brains. It was proposed in 1996 that an endogenous ligand may be 
present in cerebral tissue capable of interacting with the 5-HTi receptor function and 
more specifically the 5 -H T ib receptor. This simple 4 amino acid peptide (Leu-Ser-Ala- 
Leu) was purified and named 5-HT moduline (Massot et a l, 1996). This molecule 
specifically inhibited the binding of tritiated 5-HT to 5 -H T ib receptors, thus acting as an 
allosteric modulator at the 5 -H T ib site, and was shown in behavioural experiments to 
have an antagonistic effect on 5 -H T jB receptor activity. Since that time, 5-HT moduline 
has been localised immunocytochemically in rodent brain after an antibody was raised 
against the peptide (Grimaldi et a l, 1997) Localisation of 5-HT moduline appeared to 
overlap binding at 5 -H T ib receptors, giving strength to the suggestion that it specifically 
interacts with 5 -H T ib receptors. Indeed in mutant mice lacking the gene encoding the 5- 
HTib receptor there was no binding of 5-HT moduline (Cloez-Tayarani et al., 1997). If 
5-HT moduline were present in the hypothalamus, as indeed has been shown (Grimaldi 
et al., 1997), at levels that fluctuated throughout the course of a 24 hour day, then this 
would be a leading candidate for variation of 5 -H T iB receptor function in vivo. At this 
time no detection system other than that set up in the laboratory of Grimaldi and 
collaborators is available to us. If the four amino acid compound were readily 
detectable by HPLC-ED in microdialysate samples, then it paves the way for a 24 hour 
analysis of SCN samples to determine if the levels correlate with the function of the 5- 
HTib autoreceptor as identified in this study.
Many studies have centred on the effect of 5 -H T iB autoreceptor stimulation in the 
hippocampus (Sharp et al., 1989; Hjorth and Tao, 1991; Martin et al., 1992; Bolanos- 
Jimenez et al., 1995; Bosker et a l, 1995). The hippocampus was dialysed as a 
comparison between this serotonergic rich terminal area and that of the SCN, to 
determine whether the diumal variation in 5 -H T ib receptor function was site-specific for
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the SCN. In the SCN mid-light and mid-dark 5 -H T ib receptor stimulation had very 
different effects; these two time points were therefore chosen for investigation of the 
hippocampus. In all the studies quoted above experiments were performed during the 
light phase, and application of an agonist for the 5 -H T iB autoreceptor produced 
comparable reductions in 5-HT overflow (between 33 and 67 % reduction of basal). In 
my experiments at both mid-light and mid-dark, infusion with RU24969 produced 
significant and prolonged decreases in dialysate 5-HT concentration (figure 3.6). 
Although the maximal decrease in 5-HT overflow was greater at mid-light (32.3 ± 15.0 
% of basal) compared to mid-dark (58.4 ± 9.63 % of basal), the statistical significance 
level reached was the same (p <0.01) and the time course of the decrease was similar. 
The hippocampal terminal 5 -H T ib autoreceptors therefore do not exhibit such 
pronounced diumal variation in function as seen in the SCN. The diumal rhythm in 5- 
HTib autoreceptor function, which manifests itself with a complete absence of a 
response at mid-light upon agonist stimulation appears region-specific for the SCN.
3.4.2 The5-HTiB heteroreceptor
Basal glutamate (Glu) levels recorded in this study were very similar to those obtained 
in the SCN previously (Srkalovic et a l , 1994; 800 ± 90 nanomol) and in the the basal 
hippocampus by Rowley et a l (1995; 0.60 ± 0.02 picomol). As in our study, many 
authors have observed higher basal Glu during the dark phase than during the light 
phase of animals synchronised to an environmental light:dark cycle (Glass et a l , 1993; 
Selim et a l, 1993; Srkalovic et a l, 1994). Glutamate is released at RHT terminals 
(Liou et a l, 1986) after stimulation by light. Therefore, one might assume that the Glu 
concentration measured during the light phase will be greater than that during the dark 
phase. However, measured Glu concentration does not necessarily reflect Glu released. 
The microdialysis samples record fluctuations in extracellular tissue concentrations, and 
it may be that during the light period the Glu is taken up and utilised more quickly by 
neurones. This possibility cannot be ruled out since the perfusing medium did not 
contain a selective Glu reuptake blocker.
A recent paper (Timmerman and Westerink, 1997) highlighted the problems associated 
with brain microdialyis of Glu. The authors reviewed a number of papers and 
highlighted that a number of studies failed to fulfill the classical criteria for exocytotic
57
release for Glu, whilst assuming that the origin of measured Glu in their dialysates was 
neuronal. However, I have shown that the Glu measured in the SCN dialysates is both 
calcium- and potassium-dependent. One problem that was quite obvious during the 
sampling of Glu was the fluctuation in Glu concentration from one collection sample to 
the next, an effect that was in contrast to the majority of studies collecting for 5-HT. 
This is apparent in the size of the error bars, i.e. inter-sample variation, of the pre­
intervention control samples. However, the effect of the voltage-dependent calcium 
channel blocker, NiCl, and an increase in perfusing potassium ion concentration, was 
such that the effects were quite striking. The maximal increase in Glu efflux following 
stimulation with potassium ions was similar to that in hippocampus (Lu et a l , 1996; 
280-320 % of baseline and Rowley et a l, 1995; 298 ±11 % of baseline). Removal of 
calcium ions from the perfusing aCSF by Rowley and coworkers (1995) reduced Glu 
levels to 38 ± 3 % of baseline, which is not disimilar to our results.
Infusion with the mixed 5 -H T ia/ ib receptor agonist RU24969 for 15 min, produced a 
decrease in dialysate Glu concentration, which is consistent with the view that 5 -H T ib 
heteroceptors are present on retinal afferent terminals (Pickard et a l, 1996). The 
agonist produced comparable maximal decreases in Glu overflow during the light and 
dark phases. However, the 5 -H T ia/ ib receptor mediated reduction in dialysate Glu 
during the light phase occurred sooner (20 min after the start of the infusion) than that 
during the dark phase (50 min after the start of the infusion), which may reflect changes 
in the ability of the RU24969 to activate the 5 -H T ib inhibitory heteroceptors during the 
dark phase. Whether this effect is attributable to 5 -H T iA or 5 -H T iB receptor stimulation 
we cannot be certain. Although RU24969 is known to be a specific agonist at the 5- 
HTib receptor site (Sills et a l, 1984) it does show moderate agonist properties at the 5- 
HTia receptor site. Srkalovic and co-workers (1994) infused both a 5 -H T iA receptor 
agonist (8-OH-DPAT) and a 5 -H T ib receptor agonist (TFMPP) into the SCN region and 
compared effects on Glu overflow at ZT 18. Both drugs significantly decreased 
extracellular Glu concentration when infused separately, although the inhibitory effect 
of 8-OH-DPAT was greater than that of TFMPP; a reduction by 60 % of basal compared 
with a reduction by only 20% of basal, respectively. The RU24969 induced reduction in 
dialysate Glu by approximately 60 % may thus be attributable only to 5 -H T jA receptor 
stimulation. The likelyhood is that both 5 -H T iA and 5 -H T iB receptors lead to this 
reduction, because both 5 -H T iA and 5 -H T ib receptor stimulation can decrease Glu
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overflow from the SCN (Srkalovic et a l, 1994). The degree of 5 -H T ib receptor 
involvement in the inhibition of Glu overflow in the SCN must therefore be clarified by 
further experimentation.
In the rat SCN approximately 40 % of all cells respond to 5-HT with a dose-dependent 
suppression of the spontaneous or glutamate-evoked discharge (Meijer and Groos, 
1988). This is further evidence for 5-HT modulation of RHT transmission, although the 
receptor subtype(s) involved were not identified. In another terminal projection site 
originating from the retina, the superior collicuius, 5 -H T ib hereroceptors have been 
shown to modulate retinotectal neurones (Mooney et a l, 1994). Stimulation of the optic 
tract in vitro in hamsters evoked excitatory postsynaptic potentials (EPSPs) in the 
superior collicuius, which was consistently inhibited by application of 5-HT, and more 
specifically, the 5 -H T jb receptor agonists TFMPP and CGS12066B. With this in mind, 
if one extrapolates the effects of 5 -H T ib receptor agonists from one retinal projection 
area to another, 5 -H T ib inhibitory heteroceptors are likely to modulate the 
retinohypothalamic neurones
Other studies have provided data indicating that 5-HT and more specifically 5 -H T ib 
receptor stimulation has presynapic inhibitory effects in other structures. Singer et a l 
(1996) measured glutamate EPSPs in rat hyperglossal motomeurones, which were 
inhibited by 5-HT and the 5 -H T iB receptor agonist CP93129. In the guinea pig 
substantia gelatinosa frequency-mediated and spontaneous EPSPs were reduced by 5- 
HT and agonists acting at the 5 -H T id receptor site, which is equivelent to the rat 5 -H T ib 
receptor (Travagli and Williams, 1996). More specific to our studies, in the SCN of 
anaestheised hamsters, light-activated neurones have been shown to be inhibited by 
microiontophoretic application of 5-HT (Ying and Rusak, 1994). These authors tested 
the ability of the 5 -H T iA receptor agonists 8-OH-DPAT and 5-CT to mimic the effects 
of 5-HT but failed to test other classes of 5-HT receptor, specifically the 5 -H T ib 
receptor. Using the experimental setup of Ying and Rusak (1994) it is likely that 5 -H T ib 




The activity of the 5-HTiB autoreceptor in the suprachiasmatic nucleus is not constant 
across the lightidark cycle and this seems to be a phenomenon unique to the SCN. This 
may be significant in terms of control and release of 5-HT with subsequent influence on 
clock functioning in the SCN. The mechanism(s) by which variation in receptor 
function is mediated remains to be elucidated.
Although at this stage one is speculating that the actions of RU24969 are via the 5-H T ib 
heteroceptor, it can be concluded that the inhibitory action of the drug on Glu release 
does not exhibit variation at mid-light versus mid-dark, unlike the 5-HTiB autoreceptor. 
The maximal reduction on Glu overflow is similar when the agonist is applied at ZT 6 
or ZT 18. It is possible that the receptor regulating presynaptic inhibition of Glu does 
undergo a diumal variation which we have failed to detect because we have only 
sampled at two time points across the light:dark cycle. As is evident from the 
experiments on the function of the 5-H T iB autoreceptor, it is necessary to sample at 




5-HT1B a u t o -, h e t e r o - a n d  p o s t s y n a p t ic
RECEPTOR mRNA AND 5-HT1B RECEPTOR 
EXPRESSION IN THE SCN
4.1 INTRODUCTION
In the preceding chapter I described how the function of the 5 -H T ib autoreceptor in the 
SCN varied over the course of a 24 hour day. Many suggestions were put forward as to 
why the function might fluctuate, but at this stage the mechanisms behind this variation 
are purely speculative. Before examination in minute detail of the intricate intracellular 
mechanisms of receptor regulation, one might begin to examine the initial cascade of 
receptor production i.e. the amount of message produced that might be subsequently 
transcribed into receptor, and then the amount of 5 -H T ib receptor protein present in the 
brain tissue.
One study has examined the amount of mRNA present in the rat SCN by in situ 
hybridization (Roca et al., 1993). These authors detected a weak signal for the 5 -H T iB 
receptor and found no variation in signal intensity at two time points; mid-subjective 
day and mid-subjective night. The animals used in their study had been allowed to free- 
run in constant darkness, and so although no circadian variation in receptor expression 
was identified, it still remains possible that the 5 -H T ib receptor undergoes a diurnal 
rhythm in animals entrained to a light:dark cycle. Therefore, although 5 -H T ib receptor 
expression in the SCN itself represents a postsynaptic receptor it would be of 
considerable interest to the chronobiologist to evaluate whether the receptor mRNA 
levels were influenced by the light dark cycle.
In Chapter 3, in addition to investigating the function of the 5 -H T ib autoreceptor, the 
function of the 5 -H T ib heteroceptor was examined. Although no variation was 
observed in the heteroceptor function at the two time points studied it was nevertheless 
of interest to examine whether the mRNA for the heteroceptor varied across the 24 hour 
light:dark cycle, extending the study to incorporate eight equally spaced time points. 
Assuming that the heteroceptor is located on retinal afferents, the mRNA for this 
receptor will be produced in the cell body region located in the retina. Indeed, 
enucleation of hamsters significantly decreases the density of 5 -H T ib receptors in the 
SCN suggesting a retinal terminal location (Pickard et al., 1996).
The mRNA for the terminal 5 -H T ib autoreceptor will be located in the cell body o f  the 
serotonergic neuron in the midbrain raphe nuclei (Moore et a l, 1978). Rats lesioned
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with the selective serotonergic neurotoxin 5,7-dihydroxytryptamine show a significant 
decline in the amount of 5 -H T ib receptor mRNA level in the median and dorsal raphe 
nuclei as measured by in situ hybridization (Doucet et al, 1995). This indicates that the 
synthesis of the 5 -H T ib receptor is within the serotonergic neurones, as predicted by 
their presynaptic autoreceptor function at the level of the serotonergic neuron. A diurnal 
variation at the level of 5 -H T iB receptor mRNA in the raphe nuclei projecting to the 
SCN might contribute to the diurnal variation in function observed in the in vivo 
microdialysis studies. However, the exact location of the cell body projecting to the 
SCN i.e. whether the median raphe nuclei (MRN) or the dorsal raphe nuclei (DRN) 
project to the SCN is in dispute (see Chapter 6 Discussion).
5-HT receptor binding experiments have utilized radioligand binding combined with 
autoradiagraphy detection to localize 5 -H T ib receptors in the mammalian brain (Hoyer 
et a l,  1985; Engel et a l, 1986). Only one such study to date has investigated 5 -H T ib 
receptor binding in the circadian pacemaker at two time points across the light:dark 
cycle (Prosser et a l, 1993) and demonstrated increased receptor binding during the dark 
phase. The number of available receptors present in the brain tissue at a given time 
point will determine the ability of an exogenously applied agonist to produce a response. 
The aim was to do a more thorough investigation of the 5-HTiB receptor protein present 
in the SCN across the light:dark cycle, sampling brain tissue every three hours and to 
show whether levels in 5 -H T ib receptor protein in the SCN correlated with the receptor 
function.
It was therefore the aim of the experiments described in this chapter to first investigate 
the amount of mRNA present in the SCN (postsynaptic receptor), the retina 
(heteroceptor) and the raphe nuclei (autoreceptor) at eight equally spaced time points 
over the 24 hour light:dark cycle using the sensitive semi-quantitative technique of 
reverse-transcriptase polymerase chain reaction (RT-PCR). Secondly, I intended to 
investigate the amount of 5 -H T ib receptor protein in the SCN. The initial aims were to 
use immunocytochemistry using a specific antibody raised against the 5 -H T ib receptor 
to quantitatively detect and localize the 5 -H T ib receptor in the SCN. Subsequent to 
detection of the 5 -H T ib receptor in the SCN, it was intended to use double labelling 
studies using a combination of 5 -H T jb /glutamate immunoreactivity and 5 -H T ib 
/serotonin immunoreactivity to quantify the number of receptors present on retinal
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terminals (glutamate immunoreactivity) and/or ascending raphe projections (serotonin). 
The amount of 5 -H T jb receptor protein present in the SCN brain tissue was then to be 




Male Wistar rats (University of Bath strain; 260-320 g) were maintained under a 12:12 
light:dark cycle regime (lights on 07.00; temperature 22 ± 2°C) with food and water 
available ad libitum.
4.2.1 REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION (RT-PCR)
4.2.1.1 Preparation of tissue samples
The animals were killed by CO2 asphyxiation, brains removed and snap-frozen onto dry 
ice. Not allowing the brains to become brittle with prolonged freezing, the dissections 
were carried out quickly within a couple of minutes whilst the brains were still 
malleable. The dissection of blocks of tissue containing the SCN and the midbrain raphe 
was achieved by using ‘landmarks’ on the surface of the brain as indicators of location. 
The eyes were removed and placed in cold physiological saline for the dissection of the 
retina. Tissue from four animals were pooled for the RT-PCR reaction.
(1) SCN. The optic chiasm was used as the main indicator of the location of the SCN. 
Against the pinkish tinge of the whole brain, the optic nerves are easily visible as white 
thread-like structures, extending from the orbit encapsulating the eyes, along the base of 
the brain. The optic nerves join in the midline and are seen to form a cross as they 
bifurcate continuing in their path into the brain where they disappear out of sight of the 
whole brain. Two cuts are made with a clean razor blade perpendicular to the midline 
of the brain, the first at the point on the surface of the brain where the optic chiasm 
bifurcates, and the second approximately 1.5 mm rostral to this point, cutting the optic 
chiasm. A coronal brain slice of approximately 1.5 mm thickness remained (see figure 
4.1a). Roughly 1 mm either side of the midline, two cuts were made leaving a section 
of brain requiring one further cut. Approximately 2 mm above the base of the optic 
chiasm a final cut was made, and a small block of tissue remained (2 x 2 x 1.5 mm) 
encapsulating the whole rostral caudal extent of the SCN. The tissue was stored at 
-70°C.
(2) Raphe. The initial cut in the brain was made using the cerebellum as a point of 
reference. With the brain dorsal surface up, a cut was made between the cerebellar and
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cerebral cortices perpendicular to the midline of the brain. Using the stereotaxic atlas of 
Paxinos and Watson (1982) as a guide, tissue was cut away in very fine strips until all 
cerebellar tissue was removed except for a small part lobule 2 encapsulated in the centre 
of the brain surrounded by what is to become the cerebral aqueduct. At this point in the 
dissection, the shape of the brain and the amount of entorhinal cortex present were the 
principal guiding factors. A second major cut was made approximately 1.5 mm rostral 
to the exposed segment of brain to leave a 1.5 mm thick coronal slice of brain (see 
figure lb). Two cuts were made approximately 1 mm parallel to either side of the 
midline, using the central grey area as a marker; so called due to the grey appearance of 
the tissue surrounding the cerebral aqueduct. The block of tissue containing the 
midbrain raphe nuclei was then isolated with two further cuts; one through the centre of 
the aqueduct, and one 4 mm ventral to that site. The small block of tissue remaining 
was approximately 2 x 4 x 1.5 mm in size and was stored at -70°C.
(3) Retina. The dissection of the retina was carried out under a standard bifocal 
dissecting microscope. The stump of the optic nerve was held with broad forceps in an 
attempt to maintain the eye in a fixed position, whilst the cornea was punctured using a 
sharp 23 gauge needle. A pair of fine microdissecting scissors were then inserted into 
the puncture hole, and the cornea cut and removed to leave a ‘cup’. The lens was also 
removed at this point, and the vitreous humor expelled using a pair of fine forceps. The 
retina was visible as the ‘lining’ of the cup and slightly orange in colour. A small 
incision was made on the edge of the cup and the retina gently teased away. The retina 
was then rinsed in physiological saline, placed on foil and frozen onto dry ice. The 
tissue was stored at -70°C.
4.2.1.2 Isolation of total RNA
The isolation of total RNA from SCN samples was achieved using the TRIzol™ 
Reagent (GlBCO BRL, Life Technologies).
50 mg of frozen SCN tissue was homogenized in 1 ml of TRIzol Reagent, before being 
incubated for 5 min at room temperature to permit the complete dissociation of 
nucleoprotein complexes. After adding 0.2 ml chloroform and mixed thoroughly by 
shaking vigorously by hand for 15 sec, the samples were incubated at room temperature 








Figure 4.1. Dissection of (a) SCN and (b) raphe tissue. A 2 mm coronal section of the 
SCN or raphe was dissected from the rat brain, and two cuts were made approximately 1 
mm either side of the midline, designated by X, to leave a columnar section of brain 
tissue. For the SCN dissection, a further cut was made approximately 2 mm from the 
base of the brain to leave a block of tissue 2 x 2 x 1.5 mm (a). For the midbrain raphe 
dissection, two further cuts were made; one in line with the cerebral aqueduct, and one 4 
mm ventral to this site, to leave a block of tissue 2 x 4 x 1.5 mm (b).
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mixture into a lower red, phenol-chloroform phase, an interphase, and a colourless 
upper aqueous phase was now visible with the RNA present exclusively in the aqueous 
phase. The aqueous phase was transferred into a fresh tube and the organic phase 
discarded. Using 0.5 ml isopropyl alcohol, the RNA was precipitated from the aqueous 
phase, incubated for 30 min at room temperature and then centrifuged at 12,000 x g for 
15 min at 4°C. The supernatant was removed to expose the RNA pellet remaining, and 
the pellet washed with 1 ml 75% ethanol, mixed thoroughly and then centrifuged at 
7,500 x g for 5 min at 4°C. The Pellet was then exposed and air-dried for 10 min, 
ensuring that it did not dry completely. The pellet was redisolved in 20 jil 
diethylpyrocarbonate-treate Milli Q water (DEPC/Q) to make a final ‘stock’ solution of 
total RNA and stored at -80°C.
4.2.1.3 Isolation of mRNA
The separation of mRNA from the retinal (RET), raphe (RAP) and SCN samples was 
achieved using a Dynabeads® mRNA DIRECT kit (DYNAL®, Norway). The solutions 
supplied with the kit are shown in the appendix.
50 mg of frozen RAP and SCN sample and 100 mg of frozen RET sample were 
homogenized in Lysis/binding buffer (1 ml per 50 mg of tissue) until complete lysis was 
obtained, and the samples then spun in a microcentrifuge for 1-2 mins to remove debris. 
1 ml of the supernatant (lysate) was then mixed with the prewashed Dynabeads Oligo 
(dT) 25 on a roller for 5 min at room temperature. The vials containing the lysate and 
Dynabeads Oligo (dT) 25 (1.5 ml eppendorf tubes) were then placed in a Dynal magnetic 
particle concentrator (MPC) for 5 min before discarding the supernatant. The poly-(A)+ 
RNA will now have annealed to the Oligo dT sequence that is bound to the Dynabeads 
surface. The Dynabeads were then washed twice with 1 ml washing buffer with LiDS 
and once with 1 ml washing buffer using the Dynal MPC. The beads were then washed 
a further two times with 0.5 ml washing buffer before elution of the mRNA from the 
Dynabeads Oligo (dT) 25 with 20 jxl of elution solution. The tubes were maintained at 
65°C for 2 min, and the supernatant containing the mRNA was transferred to RNase- 
free tubes. The Dynabeads Oligo (dT) 25 were then regenerated ready for subsequent use 
as directed in the Dynabeads® mRNA DIRECT kit handbook.
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The quantity of total and mRNA in the individual samples was assessed by the 
absorbance at 260 nm and calculated by:
Amount of RNA (pg/ml) = A260 x dilution factor x 40*
* 1 pg/ml of RNA gives an A26o reading of 40 
(A280 assesses the amount of DNA in the sample)
4.2.1.4 Reverse-Transcriptase reaction (RT)
Total or Poly-(A) mRNA was reverse transcribed to generate cDNA. 200 ng of RNA in 
a volume of 9.75 pi was required for the RT. All RET, RAP and SCN samples ZTs 0- 
21 plus a blank solution containing no RNA underwent the RT reaction in duplicate. To 
9.75 pi of the RNA/blank was added 4 pi 25 mM MgCl2, 2 pi lOxPCR buffer 2, 2 pi 10 
mM dNTPs, 1 pi RNAse inhibitor 35 units/pl, 0.25 pi Moloney-murine leukemia virus 
(M-MLV) R.T. 200 units/pl and 1 pi Oligo (dT) 0.5 mg/ml into PCR tubes to make 
final concentration of 5 mM, lx, 1 mM, 1.75 units/pl, 2.5 units/pl and 25 pg/pl for each 
of MgCl2, PCR buffer 2, dNTPs, RNAse inhibitor, M-MLV R.T. and Oligo (dT), 
respectively and a total volume of 20 pi. The tubes were then allowed to stand for 10 
minutes at room temperature before being subjected to 42°C for 1 hour and 94°C for 3 
minutes.
Following generation of the first strand cDNAs, the tubes were stored on ice for 5 
minutes before being used in the cDNA amplification step.
4.2.1.5 cDNA Amplification
(1) PCR
To the 20 pi of cDNA produced from the RT reaction was added 4 pi 25 mM MgCl2 (2 
mM final concentration), 8 pi lOxPCR buffer (final concentration lx), 47.5 pi DEPC/Q, 
0.5 pi 5 U/pl Amplitaq DNA polymerase (final concentration 2.5 U/100 pi) and 10 pi of 
each of the forward and reverse primers 50 pg/ml (GlBCO BRL) for p-actin and 5-HT IB, 
to give a total volume of 100 pi. Each tube was topped with 4 drops of mineral oil 
before being subjected to cDNA amplification in a 35 cycle PCR reaction; one cycle of 
94°C for 5 min followed by 35 cycles of 94°C for 45 sec, 60°C for 45 sec and 72°C for 
90 sec and a final cycle of 72°C for 10 min.
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(2) “Hot Start” PCR
To a sterile PCR tube was added 4  pi 25  mM MgCk (2  mM final concentration) and 10 
pi of each of the forward and reverse primers 5 0  |Lig/ml for p-actin and 5 -H T jb. A wax 
pellet (Ampliwax PCR Gem 100, Perkin Elmer) was then added, and heated at 77°C for 
7 min. Once re-solidified a mixture of 20 pi cDNA (produced by the RT reaction), 8 pi 
lOxPCR buffer (final concentration lx), 4 7 .5  pi DEPC/Q water and 0 .5  pi 5 U/pl (final 
concentration 2 .5  U/100 pi) Amplitaq DNA Polymerase was added to each tube. The 
tubes containing a final total volume of 100 pi was then subjected to 3 5  cycles as 
described previously.
Primers (51 - 31):
5 -H T ib : Forward CTA TGG AGG AGC AGG GTA TTC
Reverse CCG TGT ACA TGG TGC TGA TG
P-Actin: Forward CCT AGC ACC AAG AAG ATC AA
Reverse TTT CTG CGC AAG TTA GGT TTT GTC AA
4.2.1.6 Visualization of RT-PCR product
The RT-PCR products were run on a 2.5% agarose gel. 5 pi of the p-actin product and 
20 pi of the 5 -H T ib product were loaded with dye (lx final concentration). The gel was 
then stained with ethidium bromide (0.5 pg/ml) for 30 minutes, before being visualized 
under U.V. light. The density of each 5 -H T jb band was calculated at each time point 
and normalized to the corresponding p-actin band using a Molecular Analyst computer 
package.
4.2.1.7 Statistics
Each 5 -H T ib mRNA band that was normalized to the corresponding p-actin band 
produced a value that represented ‘adjusted volume counts per mm2’. The mean number 
of counts was calculated for each gel run (ZTs 0, 3, 6 , 9, 12, 15, 18 and 21), and at each 
zeitgeber time a percentage value of this mean count value was obtained. Since the gels 
were run three times with the SCN, RET and RAP samples, the mean ± s.e.m. of the 
three gel ‘percentage average counts’ were plotted against the zeitgeber time. Statistical
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differences between the density of each band of the RT-PCR reaction product across the 
eight zeitgeber times in the SCN, RET or RAP tissue was calculated using a one way 
analysis of variance with a Tukey-Kramer multiple comparison post hoc test, p < 0.05 
was considered significant.
4.2.2 IMMUNOCYTOCHEMISTRY
The antibody raised against the rat 5 -H T ib receptor corresponding to amino acids 3 6 5 -  
3 8 3  mapping at the carboxy terminus was obtained from Santa Cruz Biotechnology 
(Autogen Bioclear UK Ltd, Wiltshire). The method of immunocytochemistry using 
frozen tissue sections was provided by the company, and it was this protocol that was 
followed and amended.
Brains were collected at zeitgeber times 0, 3, 6 , 9, 12, 15, 18 and 21 (n=3 per time point) 
from animals that had been asphyxiated with CO2. The brains were rapidly removed 
and snap frozen onto dry ice. During the dark phase brains were removed under low red 
light illumination. Brains were wrapped in silver foil and stored at -80°C prior to 
immunocytochemical processing. Consecutive coronal sections (15 J im )  were cut on a 
cryostat (Bright Instruments) set at -20°C. Sections were taken of the full rostrocaudal 
extent of the SCN and every third section mounted onto gelatinized slides. Sections 
were air dried and stored at -80°C in sealed plastic slide boxes containing a small sachet 
of silica gel.
One hour prior to commencement of immunocytochemical staining, the slide boxes 
were removed from the freezer and allowed to stand at room temperature. Slides were 
then placed into glass slide racks and placed on a rocking platform, where all subsequent 
stages were carried out unless specified. Sections were fixed in a solution of either cold 
acetone (15 min) or 4% paraformaldehyde (30 min). After two washes (all washes were 
carried out over a 15 min period) in phosphate buffer saline (PBS) the slides were 
incubated for 30 min in 1 % hydrogen peroxide (H2O2) in a solution of 2 0  % methanol 
in PBS to block endogenous peroxidase activity. The sections were then washed twice 
in PBS before incubating the sections in 1.5 % normal rabbit serum (NRS) in PBS for 
60 min. After two further washes in PBS the sections were incubated in primary 
antibody (0.1-2.0 p.g/ml; 60 min-30 hours) in PBS containing 1 % NRS at 4°C in a
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humidified chamber on a level surface. Sections were then washed three times in PBS, 
and incubated in peroxidase labeled rabbit antigoat secondary antibody (Sigma) diluted 
1:200 in PBS containing 1 % NRS for 60 min in the humidified chamber at room 
temperature. The tertiary ABC complex (Dako) was prepared according to the 
manufacturers instructions and allowed to incubate at 4°C prior to use. Sections were 
washed twice in PBS and then incubated in ABC complex for 30 min in the humidified 
chamber at room temperature. Sections were then washed twice in PBS prior to a 
further wash in PBS containing 0.5 % triton-X 100 for 60 seconds. The chromagen 
diaminobenzidine (DAB) was available in tablet form in which each tablet weighed 1 
mg, and came supplied with a tablet of H2O2 (Sigma). To 1 ml PBS was added the 
DAB tablet and H2O2 tablet, and vortexed before use. The slides were incubated for a 
period of time in the DAB mixture (10-20 min), during which time the antigenic site 
should be exposed with a brown precipitate. The reaction was stopped rinsing in 50:50 
PBS: H2O for 5 min before rinsing in distilled water. The slides were passed through 
graded alcohols (70, 80, 100 %) to dehydrate the sections, and then passed through a 
clearing agent, citroclear. The sections were mounted using a non-aqueous mounting 
medium, DPX.
4.2.2.1 Chymotrypsin treatment
Some sections were treated with the enzyme chymotrpsin. 2 jig/ml of chymotrypsin was 
prepared in Tris-buffered HC1 (pH 7.8) containing 2 p.g/ml CaCl2 and warmed to 37°C. 
Sections were incubated for 15 min at 37°C prior to blocking endogenous peroxidase 
activity. Sections were washed twice in PBS before continuing the 
immunocytochemical protocol.
4.2.2.2 Heat treatment
After the fixation process some sections were placed in a container, covered with 10 
mM citrate buffer, pH 3.5 containing 0.01 % (w/v) EDTA. The sections were 
microwaved for 5 min, then immersed in fresh citrate buffer prior to a further 5 min 




4.2.3.1 Preparation of tissue samples
Brain tissue samples were dissected as previously described in section 4.2.1.1, and 
stored at -70°C until use. Samples from two animals were pooled, weighed and 
homogenized, in ice cold RIPA buffer (PBS containing 1% nonidet P40 (NP40), 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS); 6  ml / gram tissue) 
containing 100 fxg/ml PMSF, 30 |ig/ml aprotonin and ImM sodium orthovanadate, until 
there was no visible solid matter remaining. The samples were then transferred into a 1 
ml Eppendorf tube and 10 jliI of 10 mg/ml PMSF stock added. An incubation period of 
30 min was allowed prior to centrifugation at 15,000xg for 20 min at 4°C. The 
supernatant was decanted and contained the total cell lysate.
4.2.3.2 Bradford protein assay
This is a relatively simple and accurate method for the determination of most proteins. 
Prior to the assay, the ‘Bradford Reagent’ was prepared by dissolving 200 mg 
Coomassie Blue (G form) into 200 ml of 85% phosphoric acid, made up to 1 L with 
distilled water, and stored in the dark. A series of protein samples were prepared (0-10 
p.g) with bovine serum albumin in 500 jil distilled water for a standard curve. 1 |il of 
tissue extract to be assayed for protein concentration was added to 500 jil distilled water 
(the same medium in which the protein standards were prepared). To each standard and 
sample solution was added 500 fil Bradford Reagent and vortexed thoroughly. 100 j l i I  of 
each solution was added to a well of a 96 well tray and the absorbance read at 595 nm. 
The protein concentration in the tissue extracts were expressed as p,g/jil.
4.2.3.3 Electrophoresis
Total proteins were separated on a 10% running polyacrylamide gel under denaturing 
conditions using a Bio-Rad Mini Protean system. 20 - 80 jxg of total protein were loaded 
per well in a total volume of 20 p,l electrophoreis sample buffer. Molecular weight 
markers were run in parallel on each gel. Gels were submerged in SDS-PAGE running 
buffer and run at 80 V for 20 min through the stacking gel (4%), and at 180 V for a 
further 60 min through the running gel. Following electrophoresis, the stacking gel was 
removed and the gel rinsed in semi-dry transfer buffer.
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4.2.3.4 Immunoblotting
Transfer of proteins onto a nitrocellulose membrane (Bio-Rad) was achieved by 
sandwiching the gel with the nitrocellulose membrane and placing it between absorbent 
paper soaked in semi-dry transfer buffer. The gel-membrane sandwich was placed 
between carbon plate electrodes and run at 100 V and 40 mA for 60 min (0.8 mA per 
cm2 of gel).
The membrane was blocked overnight in blocking buffer prior to incubation with 
primary antibody (anti-5-HTie polyclonal raised in goat, Santa Cruz Biotechnology, 
Inc.; 0.1 - 2.0 pg) diluted in blocking buffer. After 3 hours the membranes were washed 
once in TBS, three times in TBS containing 0.05% Tween-20 (TBS-T) and a further 
wash in TBS (all washes 10 min). The secondary antibody (peroxidase-conjugated anti­
goat IgG raised in rabbit, DAKO; 1:5,000 - 1:40,000) diluted in TBS-T was applied for 
1.5 hours. The secondary antibody was removed by repeating the washes following 
primary antibody incubation with an additional TBS wash. Bound antibody was 
detected by incubating the membranes in Amersham Enhanced Chemiluminescence 
(ECL) reagents for exactly 1 min, and being exposed in a darkroom to Kodak Scientific 
Imaging Film for 1 min, 5 min and 2 hours.
Optimal conditions for Western blotting were first identified and then SCN samples 
were obtained at ZTs 0, 3, 6 , 9, 12, 15, 18 and 21. At each zeitgeber time 2xSCN were 
dissected and the tissue pooled. This was performed in duplicate providing two sets of 
SCN samples at each ZT. The density of the protein band was taken as an indication of 
the amount of 5-HTib receptor protein present in each SCN sample.
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4.3 RESULTS
4.3.1 REVERSE-TRANSCRDPTASE POLYMERASE CHAIN REACTION
4.3.1.1 Total RNA extraction from SCN tissue
Using the TRIzol™ Reagent, total RNA was extracted from SCN tissue (ZTs 0, 3, 6, 9, 
12, 15, 18 & 21). The purity of each sample was estimated using the A260/A280 ratio; 
ratios less than 1.6 were deemed contaminated by proteins and DNA and consequently 
RNA was re-extracted. The quantity of RNA present in each sample was calculated 
using A26o (see Table 4.1). The mean RNA concentration for all the samples (± s.e.m) 
was 0.51 ±0.10.
Sample ZT 0 3 6 9 12 15 18 21
[RNA]|ig/jil 0.43 0.50 0.53 0.52 0.67 0.57 0.35 0.48
Table 4.1: Total RNA concentration expressed as p.g/p.1 in each SCN sample calculated 
by the absorbance at 260 nm.
To ensure that the RNA was intact, and to verify that there was no DNA contamination, 
a 1 % agarose gel was run loading 1 pg of RNA for each sample against a ribosomal 
RNA marker. Figure 4.2 shows the separation of the rRNA bands into 18S and 28S 
sized fragments. There was no DNA contamination and samples 0, 3, 6, 9, 12 & 15 all 
had intact rRNA bands. Samples 18 and 21 did not appear to have rRNA bands which 
would suggest that the RNA in these samples had broken down, but it was decided to 
proceed with the RT-PCR reaction with all the samples. Sample 0 had very feint rRNA 
bands due to loss of sample upon loading onto the gel.
4.3.1.2 RT-PCR reaction
Figure 4.3 shows the products of the first RT-PCR reaction run on a 2.5% agarose gel. 
(3-actin primed-samples showed clear bands between the 200 and 300 base pair (bp) 
marker, being 276 bp in length. Unfortunately, the samples primed for 5 -H T ib mRNA 
displayed a double band between 300 and 400 bp (5 -H T ib mRNA - 356 bp using 
primers), implying that the primers used in the reaction had annealed non-specifically
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during the cDNA amplification stage. To eliminate the contaminating band, a protocol 
for “hot-start” PCR was followed. This involved the prior separation of the specific 
primers from the cDNA and Amplitaq polymerase by a solid wax pellet. This prevents 
non-specific annealing by the primers at temperatures below that of the specified 
annealing temperature of the individual primers. When the samples reach the annealing 
temperature during the PCR reaction, the wax melts allowing the total volume in each 
PCR tube to mix thoroughly, so commencing the reaction.
A ‘test-run’ was performed on two samples (ZTs 0 and 12) and a further brain-RNA 
sample, in duplicate, using both the original PCR method and the ‘hot-start’ method for 
each p-actin and 5 -H T ib primers. The results are shown in figure 4.4, and demonstrates 
quite clearly that the ‘hot-start’ method eliminates the non-specific bands associated 
with the 5 -H T ib primers. The ‘hot-start’ PCR method was therefore employed 
hereafter.
The RT-PCR reaction was repeated a further three times on all samples. Unfortunately, 
the bands corresponding to the 5 -H T ib mRNA was so feint on all three runs that the 
computer program was unable to differentiate the density of the bands from background. 
If the bands were intensified using the computer program to make them visible, the 
bands corresponding to the p-actin mRNA became so intense that it was no longer 
possible to quantitate the PCR reaction (see figure 4.5). The RT-PCR reaction can be 
quantified by normalizing the density of each 5 -H T ib band to the corresponding P-actin 
band to give a value of ‘adjusted volume counts x mm2’. However, it is only possible to 
do so if the value for ‘maximum counts’ i.e. the density of an individual band, is less 
than 255 as calculated by the computer package. On all three RT-PCR reactions, the 
density of the p-actin bands gave values greater than 255, and were thus saturated.
The level of 5 -H T ib mRNA in the extracted RNA from these SCN samples must 
therefore be minimal. It was consequently decided to ‘start from scratch’ and repeat the 
RNA extraction using a different method. The Dynabead® mRNA separation kit has the 
advantage of extracting only mRNA, and not total RNA as extracted using the TRIzol 
reagent. The extraction product is therefore more specific and more concentrated.
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4.3.1.3 mRNA extraction from SCN, retinal and raphe brain samples 
Using the Dynabead® mRNA DIRECT kit mRNA was extracted from SCN, RET and 
RAP samples at ZTs 0, 3, 6, 9, 12, 15, 18 & 21. The quantity of RNA present in each 
sample was calculated using the absorbance value at 260 nm (see Table 4.2). The mean 
mRNA concentration for SCN, RET and RAP samples (± s.e.m) were 0.15 ± 0.04, 0.16 
± 0.02 and 0.24 ± 0.07 pg/pl, respectively.
Sample ZT 0 3 6 9 12 15 18 21
SCN 0.22 0.14 0.14 0.14 0.10 0.12 0.18 0.12
RET 0.16 0.15 0.14 0.18 0.16 0.17 0.12 0.19
RAP 0.37 0.24 0.32 0.20 0.24 0.22 0.16 0.20
Table 4.2: mRNA concentration of SCN, retinal (RET) and Raphe (RAP) brain tissue 
expressed as pg/pl, calculated by the absorbance at 260 nm.
4.3.1.4 RT-PCR reaction
To ensure that the mRNA separated by following the protocol from the Dynabead® 
mRNA DIRECT kit would produce bands of a sufficient intensity to quantify the 
reaction, an RT-PCR reaction was performed on each brain region at a single time 
point, and different volumes of RT product loaded onto the gel. Figure 4.6 shows the 
effect of differential loading of 5 -H T iB RT product of RET, RAP and SCN samples 
taken at ZT 0. For each sample, 5 and 10 pi of 5 -H T ib  product was loaded along with 5 
jil of the P-actin product. As anticipated, the p-actin product produced a very intense 
signal. Loading 5 j l l I  of 5-H T jb  product was sufficient to produce detectable bands, 
although for SCN sample this was only very feint. Loading 10 pi of product was an 
improvement and produced bands of greater intensity, although these were still not as 
intense as the signal generated from the p-actin product. For subsequent RT-PCR 
reaction products, it was decided to load 20 pi for the 5-HTiB-primed samples so that 
the samples would be of equal intensity to the 5 pi of loaded p-actin product.
All SCN, RET and RAP samples at ZTs 0, 3, 6, 9, 12, 15, 18 and 21 underwent an RT- 
PCR reaction which was repeated three times. Figures 4.7, 4.8 and 4.9 respectively,
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show representative gels for SCN, RET and RAP tissues. The 5-HTiB mRNA was 
quantified by normalizing each band to the corresponding p-acin mRNA band.
The intensity of the band produced by the RT-PCR reaction product across the eight 
zeitgeber times showed significant variations in both the SCN and the RET tissues, but 
not in the RAP tissue. In the SCN, the signal for the 5 -H T ib mRNA at both ZTs 0  and 3 
were significantly higher than that at ZT 12 (p < 0 .05 ; p < 0 .0 1 ) , and ZT 3 was 
significantly higher than ZT 21 (p < 0 .0 5 ). In the RET tissue the intensity at ZT 0  was 
significantly higher than at all other zeitgeber times (p < 0 .0 5 ).
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Figure 4.2. Separation of the isolated total RNA from rat brain SCN samples. 1 j L X g  of 
each sample was loaded and run against a ribosomal RNA marker (M) which separates 
the 28S and 18S fragments (annotated on the left hand side of the gel). Zeitgeber times 
are indicated above the corresponding band. Samples 0, 3, 6, 9, 12 and 15 all have 
intact 28S and 18S fragments. Samples 18 and 21 do not appear to have rRNA bands, 




Figure 4.3. Initial RT-PCR analysis using total RNA from rat brain SCN tissue resulted 
in non-specific annealing of the 5 -H T iB mRNA primer producing a double band 
indicated by the black arrows to the right of the gel. p-actin mRNA is shown on the left 
and 5 -H T ib mRNA on the right of the gel. Zeitgeber times are indicated above the 
corresponding band. M=100bp molecular weight marker; B=blank.
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Figure 4.4. “Hot Start” PCR (A) versus “normal” PCR (B) on rat brain SCN tissue. 
Hot start PCR eliminates the double bands due to the non-specific annealing of the 5- 
H T ib primer (refer to figure 4.3). P-actin mRNA is shown on the left and 5-H T ib 
mRNA on the right of the gel. M=100bp molecular weight marker, indicated on the left 
hand side of the gel; 0=ZT 0; 12=ZT 12; Br=whole brain; B=blank.
i
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Figure 4 .5 . RT-PCR on total mRNA extracted from rat brain SCN tissue. The bands 
corresponding to 5 -H T ib mRNA (left) are too feint for analysis by density, and the P- 
actin bands (right) are too intense. Zeitgeber times are indicated above the 
corresponding band. M=100bp molecular weight marker, indicated on the right hand 
side of the gel; B=blank.
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Figure 4.6. Effect of differential loading of the 5 -H T iB RT-PCR product. 200 ng of 
retinal (RET), raphe (RAP) and SCN mRNA were used in the RT-PCR reaction. 5 p.1 of 
p-actin product (left) was loaded against 5 |il (middle) and 10 jil (fight) of 5 -H T jb 
product. M=100bp molecular weight marker, indicated on the left hand side of the gel; 
B=blank.
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Figure 4.7. (A) A representative blot from isolated rat brain SCN tissue at eight
zeitgeber times over twenty four hours. P-actin expression is shown on the left and 5- 
HTib expression on the right of the gel. Zeitgeber times are indicated above the 
corresponding band. M=100bp molecular weight marker, indicated on the left hand 
side of the gel. (B) SCN 5-H T ib mRNA at ZTs 0, 3, 6, 9, 12, 15, 18 arid 21 normalised 
to P-actin levels and plotted as a percentage of the mean value. Values are mean ± 
s.e.m. (n=3). *p < 0.05; **p < 0.01.
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Figure 4.8. (A) A representative blot from isolated rat retinal mRNA at eight zeitgeber 
times over twenty four hours. P-actin expression is shown on the left and 5 -H T jb 
expression on the right of the gel. Zeitgeber times are indicated above the 
corresponding band. M=100bp molecular weight marker, indicated on the left hand 
side of the gel. (B) Retinal 5 -H T jb mRNA at ZTs 0, 3, 6, 9, 12, 15, 18 and 21 
normalised to P-actin levels and plotted as a percentage of the mean value. Data are 
mean ± s.e.m. (n=3). *p < 0.05.
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Figure 4.9. (A) A representative blot from isolated rat brain raphe nuclei mRNA at 
eight zeitgeber times over twenty four hours. (3-actin expression is shown on the left 
and 5-HT ib expression on the right of the gel. Zeitgeber times are indicated above the 
corresponding band. M=100bp molecular weight marker, indicated on  the left hand 
side of the gel. (B) Raphe 5-HT iB mRNA at ZTs 0, 3, 6, 9, 12, 15, 18 and 21 




The SCN is known to contain a high density of 5-HT]B receptors as verified by receptor 
binding experiments of the hypothalamus (Prosser et al, 1993; Manrique et al, 1994), 
and it is on this basis that the microdialysis experiments were performed in the 
preceding chapter to investigate the 5 -H T ib hetero- and auto-receptors. Thus, the SCN 
serves as its own positive control for immunocytochemical staining for the 5 -H T ib 
receptor protein.
Each slide had four brain sections mounted on them. The first set of experiments 
involved two slides from two of the three triplicate brains chosen from ZTs 0 and 12 i.e. 
a total of eight slides. Four groups of two slides were fixed in a solution of 4 % 
paraformaldehyde and incubated separately in 0.1, 0.5, 1.0 and 2.0 jug of primary 
antibody for an initial period of 60 min. Figure 4.10A represent a photomicrograph of a 
brain section at the level of the mid SCN which was incubated in 2.0 |ig of primary 
antibody. There is a complete absence of staining in the region of the SCN and indeed 
on any of the brain tissue in any of the sections incubated in the range of the primary 
antibody. There was however, an intense staining above that of the background in the 
cerebral arteries/choroid plexus present in the lateral ventricles (figure 4.10B). This 
observation that no staining was evident anywhere in the brain tissue but was seemingly 
picked up in non-neuronal tissue was very puzzling.
The experiment was repeated on a further eight slides changing the fixative to cold 
acetone, using 2.0 pg of the primary antibody and increasing the primary antibody 
incubation period to 30 hours on half of the slides. Once again there was a complete 
absence of 5-HTiB receptor staining in any of the brain tissue above that of background 
staining (data not shown). It was thus decided to enzyme treat and heat treat some of the 
sections in case the antigenic determinant was being masked by the fixation process. It 
was hoped that the antigenic site might be exposed by the chymotrypsin or heat 
treatment. Half of the sections prepared for the enzyme or heat treatment were fixed in 
4 % paraformaldehyde, whist the other half were fixed in cold acetone. The 
chymotrpsin treated sections looked no different to those sections that had not been 
treated with enzyme, whereas the microwave treatment, as recommended by Santa Cruz
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Biotechnology, seemingly destroyed the tissue, and nothing was detected post-DAB 
incubation (data not shown).
In addition to following the protocol supplied, other brain sections were treated slightly 
differently. Triton-X 100 is a detergent often used to permeabilise the section to allow 
entry of the antibody without opening up the tissue so far that you lose the target. It is 
most often used in all PBS washes and incubation solutions up until the DAB incubation 
stage. Due to the nature of the 5-HTiB receptor being present on the surface of the cell, 
it is not necessary to add Triton-X 100 to the PBS wash stages. However, in an attempt 
to aid detection of the 5-HTib receptor protein in the neuronal tissue Triton-X 100 was 
added to all PBS washes (0.3 %). Again, the antibody failed to detect any antigenic 
sites within the neuronal tissue (data not shown).
Communicating directly with Santa Cruz Biotechnology who developed the antibody 
failed to shed light onto the inability of the antibody to detect 5 -H T ib receptor protein in 
neural tissue. Upon further communication with the company it was revealed that the 
antibody had never been tested for its ability to immunocytochemically detect the 
protein in animal tissue, let alone brain tissue, and no institution had ever used the 
antibody successfully so that they had published papers quoting Santa Cruz as the 
suppliers.
This failure to detect the 5 -H T jb receptor protein in the brain tissue was very 
disappointing, and also prevented the planned double labeling studies (5- 
HTis/glutamate and 5-HTiB/serotonin) to proceed. The antibody was thus tested in a 
homogenate of brain tissue and detected by Western blotting, which in itself is a far 






Figure 4.10. Representative brain sections at the level of the hypothalamus after 
immunocytochemical detection with an antibody raised against the 5 -H T ib receptor. 
For methods see text. Brain sections were fixed using a solution of 4 % 
paraformaldehyde and incubated in 2 jug primary antibody for a period of 60 min. (A) 
At the level of the suprachiasmatic nucleus (sen). Note the complete absence of 
immunocytochemical staining in the brain tissue, oc = optic chiasm; ID = third 
ventricle. (B) Immunolabelled cells were observed in the lateral ventricles (LV) in non­




4.3.3.1 Determination of tissue protein concentration
The Bradford Protein Assay was used to assess total protein concentration of the 
prepared SCN, raphe (RAP) and whole brain (WB) tissue. Table 4.3 shows the protein 
concentration of SCN samples at ZTs 0, 3, 6, 9, 12, 15, 18 and 21 (2xSCN at each ZT, 
duplicated). The average protein concentrations were 12.2 ± 0.78 and 13.0 ± 0.62 jxg/jLLl 
for duplicate A and duplicate B, respectively. The total protein concentration of whole 
brain, raphe (2xRAP) and SCN ‘test’ (4xSCN) samples were 27.02 jig/jil, 10.81 jig/|il 
and 15.56 jig/jil, respectively.
Sample ZT 0 3 6 9 12 15 18 21
A:[protein]jig/jil 10.65 14.39 12.81 15.18 12.23 8.27 13.02 10.86
B; [protein] jig/jil 11.29 15.47 14.03 13.81 13.02 12.81 13.74 9.78
Table 4.3: Total protein concentration expressed as jig/jil in each SCN sample as 
determined by the Bradford Protein Assay. A and B represent the two sets of samples 
for each zeitgeber time (ZT). Each ZT represents 2xSCN samples.
4.3.3.2 Optimization of conditions for Immunoblotting
In order to optimize the conditions for immunoblotting 4x SCN samples were dissected 
at ZT 6, pooled and used as SCN ‘test’ samples, along with one whole brain and 2x 
raphe samples (ZT 6) for use as positive controls. It was necessary to optimize each of 
the following parameters; blocking buffer, primary antibody concentration, secondary 
antibody concentration and total protein concentration loaded per well on the gel.
A preliminary experiment was performed varying the primary antibody concentration 
(0.1 and 0.5 jig), varying the amount of total protein loaded (20 - 80 jig; SCN and WB) 
and utilizing a blocking buffer consisting of 5% BSA, 1% ovalbumin and 0.05% azide 
in TBS. Secondary antibody concentration was 1:40,000. Figure 4.11 shows the 
resultant blots with very high background and no distinct band at approximately 43 KD 
(molecular weight of 5-HTib receptor 43,162 KD), which would suggest either non­
specific binding of the secondary antibody or insufficient ‘blocking’ by the blocking
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buffer, providing that the primary antibody was specific and sensitive enough to detect 
the low amount of 5-HTiB protein anticipated in the samples. The specificity of the 
secondary antibody was confirmed when another membrane was prepared for 
immunoblotting as above, but with the primary antibody step excluded. The developed 
blot had no staining (data not shown) which was to be expected if the secondary 
antibody was not responsible for the non-specific bands. Therefore the non-specific 
binding was due either to the primary antibody or the blocking buffer. Repeating the 
experiment using 2 pg primary antibody in an attempt to increase binding to the 5-HTiB 
protein, 1:40,000 secondary antibody, loading 60 pg total protein (SCN, RAP and WB) 
and replacing the blocking buffer with a solution of 5% dried milk (Marvel), 0.05% 
azide in TBS-T resulted in much ‘cleaner’ blots with a single intense band just below 
the 45 KD molecular weight marker (see Figure 4.12). From this result it was decided 
to run RAP as a positive control as it gave a more intense signal than the WB.
Using 5% dried milk in TBS-T as the blocking buffer of choice, the experiment was 
repeated once again in a bid to optimize the primary and secondary antibody 
concentration as well as the amount of total protein loaded. Six gels were run in 
parallel varying the primary antibody concentration (0.1, 0.5 and 1.0 pg), secondary 
antibody concentration (1:10,000 and 1:20,000) and running RAP and SCN tissue at 20, 
40 and 60 pg total protein (see Figure 4.13). The most intense signal was generated by a 
primary antibody concentration of 1 pg and a secondary concentration of 1:10,000 
(Figure 4.13E). All three blots blotted with 1:10,000 secondary antibody had higher 
non-specific binding than those blotted with 1:20,000, although there remained some 
background staining at this dilution. The lower primary antibody concentrations 
resulted in very weak staining of the 5-HTiB protein and at the lowest concentration 
failed to result in specific staining (Figure 4.13A and B). Taking these results into 
consideration, a primary antibody concentration of 1.0 pg in combination with a 
secondary antibody concentration of 1:40,000 was postulated to result in the ‘cleanest’ 
blots - it was thought that lowering the secondary antibody concentration further would 
eliminate background staining.
With regard to varying the total protein concentration loaded per well, the intensity of 
the protein band of interest varied; 20 pg resulted in weakest staining and 60 pg resulted
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in the greatest staining, most evident in Figure 4.13F. Occasionally loading a high 
protein concentration results in characteristic ‘smearing’ of the bands but this was 
absent and it was therefore decided to load 60 p,g of total protein per well.
Consequently, the optimal conditions for analysis of the 5 -H T ib receptor protein in SCN 
samples were identified as being: 1 jig primary antibody; 1:40,000 secondary antibody 
dilution whilst loading 60 |ig total protein and using 5% dried milk in TBS-T as a 
blocking buffer.
The SCN samples (ZT 0, 3, 6, 9, 12, 15, 18 and 21) were run on a gel with RAP as a 
positive control. Each set of samples were run twice. Figure 4.14 shows the effect of 
zeitgeber time on SCN 5 -H T ib receptor protein expression in the two groups of samples, 
measured by Western blotting. There is no marked difference in the density of the 
bands at any zeitgeber time.
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Figure 4.11. Preliminary Western blot analysis of SCN (S) and whole brain (Wb) tissue 
varying the primary antibody concentration and total protein loading. Secondary 
antibody dilution 1:40,000; blocking buffer 5 % BSA, 1 % ovalbumin, 0.05 % azide in 
TBS. Differential total protein loading is displayed along the bottom of blot B. Primary 
antibody concentration 0.1 fig (A) and 0.5 [ig (B). M = M olecular weight markers (100 
bp), indicated on the left hand side of the gel.
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Figure 4.12. Western blot analysis of raphe (RAP), whole brain (WB) and SCN tissue. 
60 jxg of total protein was loaded in each lane and blotted with 2 |ig  of primary antibody 
with a secondary antibody antibody dilution of 1:40,000. The blocking- buffer utilised 
consisted of 5 % dried milk in TBS-T. M = molecular weight marker (100 bp), 
indicated on the left hand side of the gel.
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Figure 4.13. W estern blot analysis of SCN (S) and raphe (RAP) tissue using 5% milk in 
TBS-T as the blocking buffer. Varying the primary antibody concentration; (a) and (b) 
0.1 jig; (c) and (d) 0.5 |Lig; (e) and (f) 1.0 |ig , the secondary antibody dilution; (a), (c) 
and (e) 1:10,000; (b), (d) and (f) 1:20,000, and the total protein loaded per well 
(displayed along the bottom of the blots).
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Figure 4.14. W estern blot analysis of 5 -H T jb receptor protein in SCN tissue at 
zeitgeber times (ZTs) 0, 3, 6, 9, 12, 15, 18 and 21. At each ZT 2x SCN were dissected 
and the tissue pooled. This was performed in duplicate to provide two sets of SCN 
samples at each ZT. a) and b) represent the results from each duplicate. Proteins were 
extracted from the tissue and separated on a 10% SDS-PAGE gel (60 jig of total protein 
loaded per sample) and transferred to a nitrocellulose membrane. The 5 -H T ib receptor 
protein was probed using 1 jug of primary antibody and 1:40,000 dilution of secondary 
antibody. The blocking buffer used was 5% dried milk in TBS-T. ; M = molecular 
weight marker; RAP = raphe sample (positive control).
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4.4 DISCUSSION
4.4.1 5 - H T ib  r e c e p t o r  mRNA l e v e l s  i n  SCN, r a p h e  a n d  r e t i n a
Reverse transcriptase-polymerase chain reaction was used to identify day-night 
differences in the expression of the 5 - H T ib  receptor in the SCN, retina and midbrain 
raphe nuclei of the rat. RT-PCR is a method widely used to identify different mRNA 
products in various brain areas and has been used previously to identify day-night or 
circadian changes in gene expression in SCN (e.g. Ghosh et al., 1997) and retina (e.g. 
Gauer et a l, 1995) and to analyse 5-HT receptor subtypes in a presumptive serotonin 
cell line derived from the rat raphe (Jackson et al., 1997). The method of RT-PCR can 
produce results with small quantities of total RNA as it is based on significant signal 
amplification and is relatively sensitive. This is crucial when working with limited 
sample size such as the dissected SCN, retina or raphe, which will contain limited 
amounts of mRNA.
The primer used for the amplification of the 5 - H T i b  receptor was specific for the rat 5- 
HTib receptor, as the PCR product of the “hot-start” PCR produced a single band with 
the ethidium bromide under UV light (figure 4.12). When the “normal” PCR reaction 
was performed, multiple bands were present, indicative of non-specific annealing of the 
primers, before the commencement of the reaction i.e. before the reaction mixture has 
reached the starting temperature of 94°C.
The amount of total mRNA isolated by the TRIzol reagent in this study was similar to 
total RNA isolated from mouse SCN (O’Hara et al, 1 9 9 5 ) .  O’Hara and colleagues 
( 1 9 9 5 )  isolated 0.6 pg of total RNA from 1 mm3 sections of SCN, which although a 
smaller block of tissue than obtained in this study, they were using mouse brain which is 
expected to yield a smaller amount of brain tissue. The method of isolation of total 
RNA with the TRIzol Reagent produced only very feint bands upon amplification with 
the 5 - H T i b  primers (figure 4 . 1 3 ) ,  possibly because of loss of mRNA fragments in the 
separation procedure, which is a somewhat lengthy process. However, the isolation of 
mRNA with the Dynabeads® mRNA DIRECT kit, produced a much cleaner and more 
intense signal (figure 4 . 1 5 ) ,  and was therefore the separation method of choice for the 
SCN, raphe and retinal mRNA. It can be seen from the amount of total RNA versus the 
amount of mRNA isolated from similar sized blocks of tissue that a vast amount of total
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RNA is lost during the isolation procedure. mRNA constitutes only about 5 % of total 
RNA and if one compares the amount of total RNA (0.51 ±0.10  jug/jil) with that of 
mRNA (0.15 ± 0.04 jug/jil) in the SCN tissue, it would appear that the mRNA represents 
almost 30 % of the total RNA. The actual total RNA concentration is most probably 
higher than the value reported here and it can be assumed to have been lost during the 
separation procedure.
Because of the semi-quantitative and subjective nature of the densitometry of the PCR 
products, this method of detection of mRNA within the tissue cannot be expected to 
provide us with definitive answers, but rather to give a perspective on what is going on. 
However, changes in receptor expression in different tissue samples are visible. For 
example, the expression of 5-HTib mRNA in the retina, appears to be greater than in the 
raphe, which is greater than in the SCN (figure 4.14). It is known that the SCN contains 
very little 5 -H T iB mRNA (Roca et a l , 1993), which is often missed by in situ 
hybridization analysis (Neumaier et a l , 1996). Bruinvels et a l (1994) failed to detect 
high 5 -H T ib mRNA in the SCN, although they did so in the arcuate hypothalamic 
nuclei. Since the dissection of the SCN also included a small section of surrounding 
hypothalamic tissue, it is possible that the mRNA amplified by the RT-PCR reaction 
originated from hypothalamic nuclei other than the SCN. Indeed, Neumaier and 
colleagues (1996) detected high levels of 5 -H T ib mRNA in the dorsomedial 
hypothalamic area and in the anteroventral preoptic area, which might have 
contaminated the SCN tissue. However, since the PCR reaction is a very sensitive 
technique, it will be able to detect changes in expression in the SCN against a constant 
background in other nuclei. Bruinvels and his coworkers (1994) also measured a more 
intense signal in the midbrain raphe nuclei than in the hypothalamus, and this is visible 
in my data as a higher density band.
In the SCN the peak signal was generated at ZTs 0 and 3 and the nadir at ZT 12 and 21. 
None of the other 4 time points were significantly different from each other, although as 
a general trend, intensity was lower than at ZT 0 and 3. Gene expression, measured by 
in situ hybridization, of peptides (somatostatin; Nishiwaki et a l , 1995; vasointestinal 
peptide and gastrin releasing peptide; Zoeller et a l, 1991), immediate early genes (c-fos; 
Prosser et a l, 1994a) and receptors (vasointestinal peptide 2 receptor; Cagampang et a l, 
1998) have all been shown to exhibit day-night differences in the SCN of rats.
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Therefore, the finding of a day-night difference in 5 -H T ib mRNA is not surprising, and 
allows us to add another receptor to the list of a growing number of factors displaying 
fluctuating levels throughout the 24 hour cycle of darkness and light in the SCN. Only 
one study performed to date has investigated the relationship between the 5 -H T iB 
receptor and the SCN and involved detection by in situ hybridization of brain tissue 
from animals maintained in constant darkness (Roca et al., 1993). As outlined in the 
Introduction to this chapter, maintainance of the animals in constant darkness will 
measure circadian rather than diurnal variation. The results presented in this thesis are 
the first to demonstrate that light can influence the regulation of the 5 -H T jb receptor 
gene. The fluctuation in 5-HTiB mRNA in the SCN represents variations in the number 
of terminal region 5 -H T ib receptors, located in SCN projection sites (for efferent 
projection of SCN neurones see Watts and Swanson, 1987). mRNA is generated in the 
cell body region, and in the case of the 5 -H T iB receptor, is transported to neuronal 
terminals where it exerts its effects. Therefore, this fluctuation in expression would not 
account for a variation in SCN 5 -H T iB receptor sensitivity.
As mentioned in the discussion section of the preceding chapter behavioural 
investigation of the 5 -H T jb postsynaptic receptor suggests that the function of the 
receptor undergoes diurnal variation, with the ability of a receptor antagonist to block 
the behavioural response to administration of the 5 -H T ib agonist R U 2 4 9 6 9  more 
pronounced during the light phase (Martin et al., 1 987). Similarly a study by Moser and 
Redfem (1 9 8 4 )  identified a diurnal variation in the ability of a serotonergic agonist to 
produce a behavioural response with peak activity occurring at mid-light. Although in 
their study they could not identify the receptor subtype involved, it is possible that the 
agonist is acting via 5 -H T ib receptors. The results of these behavioural experiments 
may be explicable by variation in the number of 5 -H T ib receptors produced in the SCN 
across the light:dark cycle as identified in this study. An increased expression of the 
receptor will probably manifest itself by an increase in available receptors and a greater 
cumilative response to agonist stimulation.
In the retina, there was a peak signal generated at ZT 0, which was significantly 
different from all other time points. None of the other seven time points were 
significantly different from each other. Circadian changes in gene expression in the 
retina have previously been examined by the use of Northern blot analysis (Sakamoto
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and Ishida, 1998) and RT-PCR analysis (Gauer et a l , 1995), but to my knowledge no 
author has looked at 5 -H T ib receptor expression across the light dark cycle in the retina. 
Isolation of the mRNA from the retina, with subsequent amplification of the 5 -H T ib 
signal, unfortunately does not identify the cell types in which the signal was generated. 
Retinal ganglion cells project to the SCN (Moore et a l , 1995), but one cannot establish 
using this method, whether it is these cells are displaying the variation in expression. 
Therefore, we cannot be sure that the variation in expression shown here will ultimately 
lead to a variation in the number 5 -H T ib receptors on RHT nerve terminals in the SCN. 
Other retinal projection sites include the lateral geniculate nucleus, raphe nuclei, 
thalamic nuclei and the superior colliculus (e.g. Shen and Semba, 1994), all of which 
might synthesize the 5 -H T ib receptor. Indeed, the afferents to the superior colliculus are 
known to have 5 -H T iB heteroceptors at their terminals (Mooney et a l , 1994), and it is 
possible that the variation in 5 -H T ib receptor mRNA in the retina will lead to a variation 
in receptor expression in the superior colliculus, or one of the other projection sites. 
The presence of the 5 -H T iB mRNA in the retinal ganglion cells projecting to the SCN 
must therefore be verified by techniques such as in situ hybridization in which the cells 
producing the mRNA can be identified.
If the increased production of 5 -H T iB receptor mRNA at ZT 0 was indeed located in the 
retinal ganglion cells projecting to the SCN, it is important to remember that these 
receptors are heteroceptors. A variation in the density of 5 -H T ib heteroceptors would 
not explain the variation in 5 -H T ib autoreceptor function as identified by the in vivo 
microdialysis studies. The relevant tissue here is the raphe, in which the serotonergic 
neurones projecting to the SCN would house the 5 -H T ib receptor mRNA production.
In the raphe tissue there was no difference in signal intensity generated over the eight 
zeitgeber times i.e. the expression of the 5 -H T ib receptor was constant across the light 
dark cycle. The block of tissue containing the midbrain raphe, was the largest of the 
three dissected tissues, and contained the largest quantity of total mRNA (table 4.3). 
Because of the uncertainty about whether the MRN or the DRN sends projections to the 
SCN (see discussion Chapter 6), the block of tissue dissected had to encapsulate both 
the MRN and DRN. It is possible that variation in MRN and DRN could display 
different phases and thus cancel each other out. Therefore, a fluctuation in expression in 
the raphe neurones projecting to the SCN was masked by a reversed fluctuation in gene
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expression in other neurones within the block of tissue. However, it is unlikely that 
gene expression for a single receptor will show such contrasting rhythms as to cancel 
each other out, in what is still a relatively small amount of tissue. High levels of 5 -H T jb 
receptor mRNA have previously been located to the raphe nuclei using in situ 
hybridization (Bruinvels et a l , 1994). The DRN has been shown to express higher 
levels than the MRN (Neumaier et a l , 1996). The observation that 5 -H T ib receptor 
mRNA levels are reduced by 75 % in the MRN and DRN after serotonergic lesioning by 
5,7-dihydroxytryptamine (Doucet et a l , 1995) indicates that this receptor is synthesized 
in serotonergic neurones. However, the remaining 25 % of receptor mRNA not 
destroyed by the neurotoxin may represent 5 -H T ib receptors that are present on non- 
serotonergic neurones in the raphe. In my study I could not distinguish between 
receptors in serotonergic or non-serotonergic neurones. In addition, firing rate of raphe 
neurones has been shown to be controlled by 5 -H T ib receptors on the cell body 
(Davidson and Stamford, 1995) and the RT-PCR reaction will also include these 
receptors in its amplification.
Assuming that the lack of diurnal variation in the whole block of raphe tissue represents 
those receptors projecting to the SCN, the SCN will receive a constant signal for this 
receptor across the light:dark cycle. If so, one must assume that the number of receptors 
expressed and transported to the SCN terminals will be constant during the day and 
night.
4.4.2 5 -H T ib receptor protein in the SCN
Immunocytochemistry and Western blotting were the techniques employed to detect 5- 
HTjb receptor protein in the SCN at eight equally spaced time points across the 
light:dark cycle.
Immunocytochemistry is a commonly used technique capable of giving a high degree of 
spatial information in locating specific proteins either within individual cells or to a 
small sub-population of cells within a tissue sample. It is therefore the method of choice 
to detect small changes in receptor numbers in a given area of tissue in the brain due to 
the quantitative nature of the technique. Unfortunately, I was unable to detect any 
staining in the neuronal tissue using the antibody supplied to us by Santa Cruz 
Biotechnology. In biological tissues proteins can be lost by metabolism if the biological
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processes of the tissue are not arrested. However, because of the rapid freezing of the 
brain after removal, one cannot assume that the 5 -H T ib receptor protein was lost due to 
inadequate handling of the tissue. Indeed, confirmation by Western blotting showed 
that the 5 -H T ib receptor protein was present in the neuronal tissue. Changing the 
fixative, incubating the primary antibody for much longer periods and even trying to 
expose the antigenic site by enzymatic digestion and heat treatment failed to result in the 
antibody detecting the 5 -H T ib receptor in the neuronal tissue, and I was forced to 
conclude that the antibody is not suited to this method of detection.
The method of Western blotting to detect proteins in a supernatant fraction of brain 
tissue thus had to be relied upon. Once the system has been optimized for each 
particular antibody and tissue sample, this method is a reliable way of detecting 
proteins. However, it has the disadvantage of not giving a spatial relationship between 
brain nuclei and protein location. That is, immunocytochemistry can locate proteins in 
brain nuclei and individual neurones, whereas Western blotting can only give an 
indication that a protein is present in the tissue, and in that respect the technique is much 
like that of RT-PCR. Also, a relatively large block of tissue is dissected which 
encapsulates the SCN and, like the experiments using RT-PCR, the amount of protein 
detected may be contaminated by nuclei other than the one of interest. That does not 
mean however that changes in receptor protein levels cannot be detected by this method.
Western blotting has served to locate proteins in the SCN of rats in previous studies 
(Reuss et a l, 1995; Spessert et a l, 1995). The methodology followed in both of these 
studies was similar to that used here, in which the SCN of four animals were pooled for 
subsequent analysis. One of these studies (Spessert et a l, 1995) tried to identify 
variations in tissue protein levels of the enzyme neuronal nitric oxide synthase during 
manipulation of the light:dark cycle. Although they failed to detect changes in protein 
levels in the SCN using Western blotting at two time points across the light dark cycle, 
they were able to detect differences in another important structure, the pineal gland. 
This study thus demonstrates that Western blotting can be used to identify changes in 
protein levels in tissue samples.
As is evident from the sample blots shown in figure 4.14 there were no marked 
differences in the intensity of bands corresponding to any zeitgeber time tested. A
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densitometer was not used to compare the density of each band, because although the 
amount of total protein loaded was equal, there was no ‘internal standard’, unlike the p- 
actin housekeeping gene in the RT-PCR studies. It therefore remains subjective whether 
a change is visible. From the blots shown in figure 4.14, it appears the band 
corresponding to ZT 9 is more intense than the other bands, and that the band at ZT 15 
is less intense (figure 4 .14A). However, from the second set of samples run one can see 
that the bands are of a more equal density (figure 4.14B). This stresses the importance 
of repeating the immunoblotting on more than one set of samples.
5 -H T ib receptor detected by radioligand binding in the SCN has been shown to be 
significantly higher during the dark than during the light phase (Posser et a l , 1993). 
The results from my Western blot analysis do not agree with these findings. However, 
from the limitations of the Western blot technique outlined already, one must be 
cautious to come to a definite conclusion. The difference between the results from the 
binding study (Prosser et a l , 1993) and the Western blot analysis (present study) may 
reflect the fact that the two methods are identifying different receptor populations. The 
functional 5 -H T ib receptor is located on the cell surface in situ and radioligand binding 
will detect the receptors that are at the cell surface. Western blotting on the other hand 
will detect all protein in the tissue homogenate that the antibody recognises. It may be 
that at different phases in the circadian cycle, the receptor is internalised and so not 
functional, although still detected by the Western blotting technique. By contrast, the 
radioligand binding study would only detect receptors expressed at the external surface 
of the cell. The advent of a commercially available antibody raised against the 5 -H T ib 
receptor that can be used immunologically to detect the receptor in brain slices is much 
awaited.
4.5 CONCLUSIONS
The expression of the 5 -H T ib receptor in the rat has been shown, using RT-PCR, to 
differ across the light dark cycle in the SCN and retina, but not in the midbrain raphe 
nuclei. In the SCN the highest levels of 5 -H T ib mRNA were seen at the start of the 
light period at ZTs 0 and 3, whilst the lowest levels were at ZT 12, the very start of the 
dark period, and at ZT 21, towards the end of the dark period. In the retina, there was a
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very distinct peak in expression at ZT 0, with expression across the remainder of the 
light dark cycle showing no fluctuation.
Because the 5 -H T ib mRNA levels in the block of raphe tissue did not vary across the 
lightidark cycle, as measured by RT-PCR, it is unlikely that changes in 5 -H T ib mRNA, 
leading ultimately to changes in receptor levels on neuronal terminals, will account for 
the variation in the 5 -H T jb receptor sensitivity as measured by in vivo microdialysis 
experiments.
On the basis of these Western blotting experiments, the amount of 5 -H T ib receptor 
protein present in the dissected SCN tissue remains constant across the light:dark cycle. 
The variation in 5 -H T ib receptor function detected using in vivo microdialysis is 
therefore unlikely to be due to variation in the total number of receptors available, but 
rather to internalisation/phosphorylation of the receptor rendering it insensitive to 




GLUTAMATERGIC RECEPTOR AGONIST 
REGULATION OF 5-HT RELEASE IN THE SCN
5.1 INTRODUCTION
The significant number of serotonergic and glutamatergic fibres and pathways in the 
mammalian brain give rise to the possibility of an interaction between these two 
transmitter systems. 5-HT often serves as a neuromodulator for glutamatergic 
transmission in many different animal species and brain regions including cerebellum 
(Maura et al., 1988; Maura and Raiteri, 1996), substantia gelatinosa of the spinal cord 
(Travagli and Williams, 1996), the locus coeruleus in the midbrain (Aston-Jones et a l , 
1991) and even human neocortical slices (Maura et a l, 1998). Likewise, excitatory 
amino acid regulation of serotonergic transmission is evident in many midbrain and 
forebrain areas (Whitton et a l, 1994; Fink et a l, 1996; Tao and Auerbach, 1996; Tao et 
a l, 1997).
The SCN of the hypothalamus receive a dense innervation from the retina, terminating 
in the ventral-lateral aspect of the nuclei (Moore and Lenn, 1972). The putative 
transmitter of this pathway is glutamate (see Chapter 1: 1.2.1). Another principle 
pathway to the SCN is that originating in the midbrain raphe (Moore et a l, 1978), 
releasing 5-HT at its terminals (see Chapter 1: 1.2.2), which also terminates in the 
ventral-lateral region of the nuclei. The close proximity of the serotonergic and 
glutaminergic terminals in the SCN lead to the possibility that interaction between these 
two systems is necessary to maintain efficient functioning of the circadian pacemaker. 
Data from several laboratories suggest that the serotonergic projection to the SCN may 
serve to modulate the responses of the circadian system to light (e.g. Bradbury et a l, 
1997).
The brief insight into the role of the serotonergic system as outlined in the General 
Introduction (Chapter 1) in regulating circadian rhythms gives some indications of the 
complexity of the interactions between just these two systems amongst the plethora of 
neurotransmitter substances within the pacemaker (van den Pol and Tsujimoto, 1985; 
Watts and Swanson, 1987). In the preceding chapter we confirmed (Selim et a l,  1993; 
Srkalovic et a l, 1994) that stimulation with a 5-HTia/ib receptor agonist decreases 
extracellular glutamate in the SCN region, presumably at the terminals of the RHT. The 
aim of the experiments described in this chapter was to establish the role of exitatory 
amino acid (EAA) receptor stimulation in the SCN on the response to 5-HT. NMDA-
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(Whitton et a l, 1994; Fink et a l, 1995; 1996; Tao et a l, 1996; Pallotta et a l, 1998), 
AMP A- (Ohta et a l, 1994; Maione et a l, 1997; Tao and Auerbach, 1997; Singewald et 
a l, 1998) and kainate- (Tao et a l, 1997) induced changes in extracellular 5-HT levels as 
measured in vitro using brain slices or more often in vivo using microdialysis have all 
been recorded in various brain nuclei. The ionotropic NMDA, AMPA, kainate and the 
metabotropic glutamate receptor mRNA levels have all been detected in the SCN of 
rodents (Gannon and Rea, 1994; van den Pol, 1994; Mick et a l, 1995; O’Hara et a l, 
1995; van den Pol et a l, 1995; Ghosh et a l, 1997), and thus the possibility exists that 
stimulation of these EAA receptors might affect 5-HT release within the SCN.
It was the aim of this study to elucidate a role for the excitatory amino acid agonists in 
the release of 5-HT from the circadian pacemaker. In vivo microdialysis was utilised in 
this study to determine the effect of a local infusion of ionotropic and metabotropic 
glutamate receptors on 5-HT overflow in the SCN. Ampa, kainate and NMDA were 
used to elucidate a role for each class of ionotropic glutamate receptor in the regulation 
of 5-HT release from the SCN. To date, there are eight subtypes of metabotropic 
glutamate receptors grouped into three classes (group I,II and HI) (Pin and Duvoisin, 
1995), but only mRNA for group I and II receptors have been located to the SCN (van 
den Pol, 1994; Mick et a l, 1995; van den Pol et a l, 1995). Therefore, the group I / 
group II metabotropic agonist 1S,3R-ACPD was chosen to establish a role of this class 
of receptor in the control of 5-HT release in the SCN. Experiments were carried out at 





Male Wistar rats (University of Bath strain; 260-320 g) were maintained under a 12:12 
lightidark cycle regime (lights on 07:00 “normal” light:dark cycle; lights on 19:00 
“reverse” light:dark cycle; temperature 22 ± 2°C). The animals were housed in cages of 
six prior to experimentation, with food and water available ad libitum.
5.2.2 Microdialysis
Each animal was implanted with a microdialysis probe as described in chapter 2 section
2.2.3 directed at the SCN, and introduced to the experimental cage. The probe was 
continuously perfused with aCSF (1.2 jil/min) containing 1 |iM of the SSRI citalopram. 
Six 15 min control samples were collected, and the three samples immediately before 
drug infusion served as the pre-intervention controls. At zeitgeber times 6 or 18 drugs 
were infused for a period of 60 min via the probe. For antagonistic studies, the 
antagonist was infused for an additional 30 min prior to and during the 60 min infusion 
with the agonist. Dialysate samples were collected every 15 min over a period of 2 
hours post-drug infusion, and analysed for 5-HT content using HPLC-ED, as described 
in chapter 2 section 2.3.5. Samples not being analysed immediately were snap frozen 
and maintained on dry ice until analysis. At the end of the experiments the animals 
were killed by CO2 asphyxiation and the brains removed and frozen onto dry ice. 
Slicing freehand with a sharp razor blade, the probe tract was clearly visible as a fine 
line through the brain tissue. With the aid of a stereotaxic atlas (Paxinos and Watson, 
1982) the position of the probe tract within the hypothalamus was established. The 
animals whose probe tracts were not in the target area were discarded for analysis.
5.2.3 Drugs
NMDA (A-methy 1-D-aspartate), kainic acid (kainate), AMPA (a-amino-3-hydroxy-5- 
methyl-4-isoxazolapropionate) and idazoxan were obtained from Sigma Chemical Co.; 
ACPD [(lS,3R)-l-aminocyclopentane-l,3-dicarboxylic acid], AP5 [(±)-2-amino-5- 
phosphonopentanoic acid] and E4CPG [(RS)-a-ethyl-4-carboxyphenylglycine] from 
Tocris Cookson Ltd.; MK-801 [(5R,10S)-(+)-5-methyl-10,l l-dihydro-5H-
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dibenzo[a,d]cyclohepten-5,10-imine / dizocilpine) was provided by Dr. Chris Bolton 
and citalopram hydrobromide by Lundbeck (Copenhagen-Valby)
5.2.4 Statistics
5-HT concentration in the dialysate samples (not-corrected for probe recovery) were 
expressed as a percentage of the three pre-intervention controls samples. Values post­
drug treatment were analysed by one-way analysis of variance (ANOVA) with repeated 
measures with Student Newman Keuls post hoc test to detect differences between pre­
intervention controls samples, p < 0.05 was considered statistically significant.
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5.3 RESULTS
Control infusion of the SCN with aCSF at ZT 6 and 18 resulted in a stable 5-HT output 
for the duration of the 120 min collection period (figure 5.1). The 5-HT concentration in 
the dialysate fractions did not vary significantly from the three pre-intervention control 
samples. Basal 5-HT concentrations at ZT 6 and 18 were 36.3 ± 8.89 and 28.1 ± 5.34 
fmol respectively.
5.3.1 Effect of local infusion of AMPA into the SCN
A 60 min infusion of AMPA (10 mM and 1 mM) into the SCN at ZT 6 resulted in an 
increase in dialysate 5-HT (figure 5.2A). Unfortunately at these doses the animals died 
between 30 and 90 minutes after the start of the infusion. Infusion of 100 pM AMPA 
did not kill the animal but failed to affect 5-HT overflow at either ZT 6 or ZT 18 (figure 
5.2B).
5.3.2 Effect of local infusion of kainate into the SCN
A 60 min infusion of kainate (100 pM) into the SCN at ZT 6 and 18 resulted in a 
significant increase in dialysate 5-HT concentration (figure 5.3). Maximal increase at 
ZT 6, expressed as a percentage change relative to three pre-intervention controls, was 
233 ± 19.8 % (p < 0.001), and occurred 60 min after the start of the infusion. Thirty 
min after the end of the AMP infusion, 5-HT had returned to baseline levels. Maximal 
increase at ZT 18 was 198 ± 45.5 % (p < 0.05), 45 min after the start of the infusion. 
Before the end of the AMPA infusion the 5-HT levels were not significantly different 
from control levels.
5.3.3 Effect of local infusion of NMDA into the SCN
The effect of a 60 min infusion of NMDA into the SCN on 5-HT overflow was 
dependant upon the concentration, and the zeitgber time at which NMDA was applied. 
At ZT 6 (figure 5.4A), 100 pM NMDA failed to affect SCN 5-HT, whilst 1 mM NMDA 
resulted in a significantly elevated 5-HT overflow from the SCN (162 ± 26.9 %; p < 
0.05) 30 min after the start of the infusion. Although the 5-HT levels remained elevated 
for the duration of the collection period, they were not significantly different from 
control levels. At ZT 18, 100 pM and 1 mM NMDA had contrasting effects (figure
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5.4B). 100 pM NMDA resulted in a significant decrease in measured 5-HT 45 min after 
the start of the infusion (52.0 ± 21.5 % of baseline levels; p < 0.05). The 5-HT 
concentration then returned to basal before becoming significantly elevated 60 min after 
the end of the infusion (183 ± 38.3 %; p < 0.05). 1 mM NMDA significantly increased 
dialysate 5-HT levels 30 min after the start of the infusion; 5-HT levels remaining 
elevated until the end of the infusion (peak increase 206 ± 24.8 %; p < 0.01). After 
cessation of the infusion, the 5-HT concntration returned to levels not significantly 
different from baseline.
The effectiveness of the non-competitive NMDA antagonist (+)-MK801 was also 
dependant upon the zeitgeber time at which it was applied. Thirty min pretreatment 
with MK801 (10 pM) blocked the effect of 1 mM NMDA at ZT 6 (figure 5.5A), but 
failed to prevent the increase in 5-HT overflow following 1 mM NMDA, or the decrease 
following 100 pM NMDA (figure 5.6A and 5.6B, respectively). MK801 infusion (10 
pM) alone for 90 min at ZT 6 resulted in a prolonged and significant decrease in 
dialysate 5-HT concentration (maximal decrease 48.6 ± 7.00 % of baseline; p < 0.01; 
figure 5B). MK801 infusion (10 pM; 90 min) at ZT 18 did not produce significant 
changes in dialysate 5-HT overflow (figure 5.7).
Thirty min pretreatment with the competitive NMDA antagonist AP5 (100 pM) 
prevented the increase in dialysis 5-HT overflow after 1 mM NMDA infusion, and the 
decrease after 100 pM NMDA at ZT 18 (figures 5.8A and 5.8B respectively).
Concurrent application of the ot2-adrenoreceptor iantagonist idazoxan (1 pM) with 100 
pM NMDA at ZT 6 significantly elevated the dialysate 5-HT concentration 30 min after 
NMDA infusion to 137 ± 9.20 % of pre-intervention control levels (p < 0.01; figure 
5.9A), whereas when given alone the NMDA had failed significantly to affect the 5-HT 
levels. At ZT 18, application of idazoxan (1 pM) with NMDA (100 pM) resulted in a 
significantly increased dialysate 5-HT level (225 ± 58.2 % of pre-intervention controls; 
p < 0.05), 45 min after the start of the infusion, which exactly mirrored the effect of 
application of NMDA alone. A 60 min infusion of idazoxan alone (1 pM) failed 
significantly to change SCN 5-HT concentration at ZT 18 (figure 5.10).
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5.3.4 Effect of local infusion of ACPD into the SCN
The effect of a 60 min infusion of ACPD into the SCN was both concentration- and 
zeitgeber time- dependant. At ZT 6 (figure 5.11 A), 100 jiM ACPD failed to 
significantly affect dialysate 5-HT concentration, although the trend was toward a drop 
in 5-HT levels; maximal decrease was 70.5 ± 14.2 % of the pre-intervention controls. 1 
mM ACPD produced an immediate and significant increase in dialysate 5-HT to 183 ±
31.7 % of pre-intervention controls (p < 0.05). AT ZT 18, neither 100 pM or 1 mM 
ACPD produced significant changes in measured 5-HT (figure 5.1 IB).
30 min pretreatment with the metabotropic antagonist E4CPG (100 p.M) completely 
blocked the effect of 1 mM ACPD at ZT 6 (figure 5.12A). Infusion of E4CPG alone 
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Figure 5.1: Control 5-HT concentration ([5-HT]) expressed as mean ± s.e.m percentage 
values of of three pre-intervention controls, at zeitgeber times (ZT) 6 and 18. Time 0 on 
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Figure 5.2. Effect of AMPA on 5-HT overflow in the SCN. Results are mean ± s.e.m. 
values expressed as a percentage of three pre-intervention controls. AMPA was infused 
into the SCN via the dialysis probe for 60 min as indicated by the hatched bar. Time 0 
on the X-axis denotes the zeitgeber time. A: 10 mM, 1 mM and 100 (iM AMPA, ZT 6. 
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Figure 5.3. Effect of kainate (100 JiM) on 5-HT overflow in the SCN. Results are mean 
± s.e.m. values expressed as a percentage of three pre-intervention controls. Kainate 
was infused into the SCN via the dialysis probe for 60 min as indicated by the hatched 
bar. Time 0 on the X-axis denotes the zeitgeber time. For ZT 18 * p < 0.05; For ZT 6 # 
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Figure 5.4. Effect of NMDA (1 mM and 100 (iM) on 5-HT overflow in the SCN. 
Results are mean ± s.e.m. values expressed as a percentage of three pre-intervention 
controls. AMPA was infused into the SCN via the dialysis probe for 60 min as 
indicated by the hatched bar. Time 0 on the X-axis denotes the zeitgeber time. A: ZT 
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Figure 5.5. A: Effect of the non-competitive NMDA antagonist (+)-MK801 on the 
response to NMDA in the SCN at ZT 6. Results are mean ± s.e.m. values expressed as 
a percentage of three pre-intervention controls. MK801 (10 pM) was infused 30 min 
prior to, and 60 min concurrently with NMDA (100 pM), via the dialysis probe. The 
solid bar denotes MK801 infusion and the hatched bar NMDA infusion. B: Effect of 
MK801 (10 pM) infusion alone on SCN 5-HT concentration at ZT 6. MK801 was 
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Figure 5.6. Effect of the non-competitive NMDA antagonist (+)-MK801 on the 
response to NMDA in the SCN at ZT 18. Results are mean ± s.e.m. values expressed 
as a percentage of three pre-intervention controls. MK801 (10 JiM) was infused 30 
min prior to, and 60 min concurrently with NMDA (1 mM, A; 100 JiM, B), via the 
dialysis probe. The solid bar denotes MK801 infusion and the hatched bar NMDA 

























Figure 5.7. Effect of MK801 (10 jliM) infusion alone on SCN 5-HT concentration at 
ZT 18. MK801 was infused via the dialyis probe for 90 mins, denoted by the solid bar. 
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Figure 5.8. Effect of the competitive NMDA antagonist AP5 on the response to 
NMDA in the SCN at ZT 18. Results are mean ± s.e.m. values expressed as a 
percentage of three pre-intervention controls. AP5 (100 |iM) was infused 30 min prior 
to, and 60 min concurrently with NMDA (1 mM, A; 100 pM, B), via the dialysis probe. 
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Figure 5.9. Effect of concurrent application of the (^-antagonist idazoxan (1 jiM) with 
NMDA (100 jiM) at A: ZT 6 and B: ZT 18. Results are mean ± s.e.m. values 
expressed as a percentage of three pre-intervention controls. The hatched bar denotes 
infusion of NMDA, or NMDA + idazoxan, for 60 min via the dialysis probe. * p < 
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Figure 5.10. Effect of idazoxan (1 p,M) infusion on SCN 5-HT concentration at ZT 18. 
Idazoxan was infused via the dialyis probe for 60 mins, denoted by the hatched bar. 
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Figure 5.11. Effect of the metabotropic agonist 1S,3R.-ACPD (1 mM and 100 pM) on 
5-HT overflow in the SCN. Results are mean ± s.e.m. values expressed as a percentage 
of three pre-intervention controls. ACPD was infused into the SCN via the dialysis 
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Figure 5.12. A: Effect of the metabotropic antagonist E4CPG on the response to 
1S,3R-ACPD in the SCN at ZT 6. Results are mean ± s.e.m. values expressed as a 
percentage of three pre-intervention controls. E4CPG (100 pM) was infused 30 min 
prior to, and 60 min concurrently with ACPD via the dialysis probe. The solid bar 
denotes E4CPG infusion and the hatched bar the ACPD infusion. B: Effect of a 90 




In the preceding chapter I have shown that the 5 -H T ib heteroceptor can regulate 
glutamate release in the SCN during the light phase and during the dark phase of 
animals synchronised to an environmental light:dark cycle. The data presented here 
suggest that there is reciprocal regulation between the glutamatergic and serotonergic 
systems in the rat SCN, because both ionotropic and metabotropic glutamate receptor 
agonists can regulate 5-HT overflow in the SCN.
Previous studies have investigated the effects of serotonin and sertonin receptor agonists 
on photically responsive cells (Huang and Pan, 1993; Ying and Rusak, 1994), photically 
induced Fos immunoreactivity in the SCN (Selim et al., 1993; Reico et al., 1996), 
photic phase shifting of the circadian activity rhythm (Rea et al., 1995) and more 
specifically using microdialysis, serotonergic inhibition of extracellular glutamate in the 
SCN region (Selim et al., 1993; Srkalovic et al., 1994). All these studies centred on the 
effects of serotonin on photic or glutamatergic transmission in the SCN, whereas I have 
investigated the effects of glutamatergic agonists on 5-HT overflow in the SCN region, 
to further our understanding of the regulation of circadian entrainment.
A few studies have utilised microdialysis to investigate the effects of L-glutamate and 
selective agonists on 5-HT overflow in the raphe nuclei and/or forebrain projection 
sites, namely hippocampus, striatum, nucleus accumbens, locus coeruleus or frontal 
cortex (Ohta et a l, 1994; Whitton et al., 1994; Tao and Auerbach, 1996; Maione et al., 
1997; Pallotta et al., 1998; Tao et al., 1997; Singewald et al., 1998). In my experiments 
local infusion of AMPA into the SCN region at 1-10 mM increased 5-HT overflow in 
this area, but associated with a significant increase in locomotor activity, eventually 
leading to death before the end of the experiment. The reason for the animals’ death 
was not ascertained, although upon a rough post-mortem, the animals appeared to have 
severe oedema of the lungs, and to have effectively asphyxiated. Infusing AMPA at the 
lower concentration of 100 pM did not result in death, nor did it appear to place the 
animals in any discomfort, although it still increased locomotor activity. At this 
concentration the AMPA infused into the SCN region at both ZT 6 and ZT 18 failed 
significantly to affect 5-HT overflow. In other forebrain areas such as the striatum 
(Ohta et al., 1996; Maione et a l, 1997) and the locus coeruleus (Singewald et al., 1998)
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AMPA has the ability to increase dialysate 5-HT in a concentration dependent (10-500 
JiM) manner, but Tao and co-workers (1997) infused AMPA into either the DRN 
(300/1000 JiM) or the nucleus accumbens (300 JiM) without significant effect. 
However, AMPA receptors are known to desensitise rapidly (see Bettler and Mulle,
1995). This desensitisation can be prevented by pre-treatment with cyclothiazide or 
diazoxide. Indeed, the effect of pre-treating the DRN with either cyclothiazide or 
diazoxide was to produce a transient increase in 5-HT release (Tao et a l , 1997). The 
effect of AMPA in the SCN may thus be masked by desensitisation of the AMPA 
receptor. However, Tao et a l (1997) also pre-treated the nucleus accumbens (a 
forebrain projection site of the DRN) with diazoxide with no enhancement of 5-HT 
release. In the absence of data on the effect preventing AMPA receptor desensitisation 
in the SCN, one must assume that AMPA receptor stimulation in this brain area does 
not produce any effect on 5-HT overflow. 5-HT release following AMPA receptor 
stimulation is obviously dependent on the brain area studied.
Kainate infusion into the SCN produced comparable effects on 5-HT overflow in the 
SCN at ZT 6 and ZT 18. Stimulation of SCN neurones by kainate significantly 
enhanced 5-HT release. Infusion of kainate (30-300 jiM) into the ventral hypothalamus, 
ventral hippocampus, nucleus accumbens (Tao et a l , 1997), locus coeruleus (Singewald 
et a l , 1998) or the striatum (Ohta et a l, 1994) increases 5-HT overflow. In the ventral 
hypothalamus the effect of kainate on 5-HT overflow was only apparent after the highest 
concentration of 300 |iM was infused. The authors have suggested that this effect of 
kainate was due to excitotoxic effects of the drug as the increase in 5-HT overflow was 
delayed and prolonged. The results presented here do not appear to be due to neurotoxic 
lesions because at ZT 18 (Tao and co-workers performed their experiments during the 
dark phase) I observed an immediate and significant enhancement of 5-HT release in the 
SCN region, and at ZT 6 there was significant enhancement 45 min after the start of the 
infusion; in both cases, the increase did not last beyond the termination of the infusion 
with levels returning to values not significantly different from controls. Kainate is a 
drug often used to produce excitotoxic lesions. At the concentration of dmg used here 
(100 pM) it is unlikely that 5-HT release results from cell death. Kainate (300 jliM ) 
infused into the nucleus accumbens for a period of 60 min produced no evidence of 
neuronal degeneration as determined by silver staining (Tao et a l, 1997).
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Although retinohypothalamic transmission is a combination of non-NMDA and NMDA 
receptor effects, NMDA receptor stimulation is regarded as playing a key role in brain 
photic entrainment of circadian rhythms (e.g. Cahill and Menaker, 1989; Ohi et al., 
1991). It is for this reason that a large part of this investigation concentrated on NMDA 
receptor stimulation. The effect of an infusion of NMDA on 5-HT overflow in the SCN 
was dependent largely on the concentration of drug infused, and the zeitgeber time at 
which the drug was applied. During the light phase (ZT 6) 100 pM NMDA produced 
no significant change in 5-HT overflow, whereas increasing the concentration ten-fold 
resulted in a significant enhancement of SCN 5-HT release. There was a striking effect 
of NMDA infusion during the dark phase (ZT 18). At the lowest concentration (100 
pM) NMDA induced a decrease in measured 5-HT to 52 ± 21.5 % of baseline, evident 
45 min after the start of the infusion. In contrast, 1 mM NMDA produced a large and 
prolonged increase in 5-HT release, starting 30 min after the start of the infusion and 
lasting for the duration of the infusion. The ability of NMDA to enhance 5-HT release 
in the SCN was greater when NMDA was administered during the dark phase (206 ±
24.8 % at ZT 18 compared with 162 ± 26.9 % of pre-intervention controls at ZT 6). 
There was an obvious diurnal variation in the function of the NMDA receptor.
Rat brain (Fink et al., 1995) or guinea pig brain (Fink et al., 1996) cortical slices pre­
incubated with tritiated 5-HT in the presence of a specific noradrenaline reupake 
inhibitor, show concentration dependent release of 5-HT by NMDA. Although the 
circadian phase was not reported, it seems reasonable to assume that these experiments 
were undertaken during the light phase. Another experiment performed during the light 
phase involving microdialysis of the hippocampus and striatum also showed a dose- 
dependent increase in dialysate 5-HT concentration after a 30 min infusion of NMDA 
(1-100 pM; Whitton et al., 1994). Tao and Auerbach (1996), who perform their 
experiments during the dark phase, observed a decrease in dialysate 5-HT concentration 
during a 60 min infusion of NMDA (100 and 300 pM) of the nucleus accumbens, 
frontal cortex and hippocampus. This is consistent with the observation in my 
experiments that 100 pM NMDA infused at ZT 18 into the SCN region produced a 
significant decline in dialysate 5-HT concentration. These authors did not, however, use 
NMDA at 1 mM, which in my experiments produced a contrasting increase in SCN 5-
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HT overflow when administered at ZT 18. Pallotta and co-workers (1998) measuring 5- 
HT overflow from raphe dialysate samples during the light phase, also demonstrated 
opposing effects of the same drugs on 5-HT release. At a low concentration of NMDA 
(25 jiM), raphe dialysate 5-HT concentration decreased, whereas a four-fold increase in 
the concentration of infused NMDA (.100 jjM) significantly enhanced 5-HT levels. In 
the SCN, this differential activation of NMDA receptors leading to a significantly 
different outcome on measured 5-HT release appears to be important only during the 
dark phase. It is still possible however, that this effect would have become evident 
during the light phase if a broader range of concentration of NMDA had been used.
The ability of the non-competitive NMDA receptor antagonist MK-801 to antagonise 
the effects on dialysate 5-HT concentration elicited by NMDA infusion into the SCN, 
was dependent upon the zeitgeber time at which it was applied. MK-801 was able to 
block the increase in 5-HT overflow from the SCN induced by NMDA (1 mM) at ZT 6, 
whilst having no effect on the decrease induced by NMDA (100 JiM) or the increase 
following NMDA (1 mM) at ZT 18.
For MK-801 to exert its effects the voltage dependent ion channel must be open and 
active. During the light phase, light falling on the retinal ganglion cells activate the 
retinal hypothalamic tract (RHT) sending signals to the SCN. During the dark phase, 
the RHT is not stimulated. Therefore, one might assume that in the light the NMDA 
receptors in the SCN have been activated, whilst the same receptors are quiescent during 
the dark phase. Thus, at ZT 6, the MK-801 is able to gain access to the ion channel. At 
ZT 18 the channel remains closed until the receptor is activated by NMDA; presumably 
under these circumstances the MK-801 cannot surmount the effects of the agonist. This 
phenomenon that MK-801 administration during the dark phase does not block NMDA 
responses is possibly unique to the SCN, because MK-801 infused into the DRN by 
microdialysis has been used successfully to antagonise NMDA-induced increases during 
the dark phase (Tao and Auerbach, 1996).
MK-801 when administered alone had a significant effect on SCN 5-HT overflow at ZT 
6 and no effect at ZT 18. During the light phase MK-801 significantly reduced 5-HT 
overflow indicative of tonic NMDA receptor mediated glutamatergic control over 5-HT
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release in the SCN. This tone is absent during the dark phase, and may possibly reflect 
the absence of RHT stimulation.
In direct comparison to pre-infusing MK801, the competitive NMDA receptor 
antagonist AP5, prevented the NMDA from significantly increasing (1 mM) or 
decreasing (100 JiM) dialysate 5-HT concentration at ZT 18. This reflects the ability of 
AP5 to access the NMDA site directly and prevent stimulation of the receptor by 
exogenously applied agonist.
The release of 5-HT can be regulated by pre-synaptic receptors such as (X2- 
adrenoceptors. Electrically stimulated tritium release from rat brain cortex slices pre­
incubated with tritiated 5-HT is reduced by application of the a-adrenoceptor agonist 
noradrenaline and increased with the a-adrenoceptor antagonist phentolamine (Gothert 
and Huth, 1980). Additional characterisation of this inhibitory receptor present at pre- 
synaptic serotonergic terminals in rat hippocampal or cortical slices classified it as an 
a 2-autoreceptor (Frankhuyzen and Mulder, 1982; Trendelenburg et al., 1994)). It has 
been suggested that within the SCN, 5-HT release and metabolism is influenced by tonic 
adrenergic inputs, because idazoxan administered intravenously was shown by 
voltametric recordings to increase the height of the indole oxidation peak in vivo 
(Marsden and Martin, 1986). Moreover, NMDA-induced tritiated 5-HT overflow from 
rat brain cortex was facilitated by the addition of the a 2-adrenoceptor antagonist 
idazoxan (Fink et a l, 1995). It was on this basis that idazoxan was co-infused with 
NMDA (100 pM) at ZT 6 and 18, to establish whether the response to NMDA in the 
SCN could be augmented by the a 2-adrenoceptor antagonist.
The response to NMDA at ZT 6 was indeed augmented by the addition of the a 2- 
adrenoceptor antagonist, suggesting that during the light period NMDA-induced 5-HT 
release was inhibited by endogenous a 2-adrenoceptor agonists, namely noradrenaline, 
released at the same time. During the dark phase, the NMDA-induced decrease in 5-HT 
release is evidently a result of inhibition by endogenous noradrenaline, as this decrease 
is prevented by idazoxan and the effect is to significantly elevate the 5-HT overflow. 
The possibility exists during the dark phase that more noradrenaline is released by 
NMDA receptor stimulation to act upon a 2-adrenoceptors thereby inhibiting 5-HT
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terminal release, or that these (X2-adrenoceptors are more receptive to stimulation at this 
time as opposed to during the light phase. Pronounced fluctuations in hippocampal 
noradrenaline output over the normal light:dark cycle do suggest that levels are higher 
during the period of darkness, and when the animal is most active (Kalen et al, 1989). 
During the dark phase there does not appear to be any tonic control of 5-HT release by 
endogenous ot2-adrenoceptor agonists, as infusion of idazoxan at ZT 18 failed 
significantly to affect the 5-HT concentration collected in the dialysate. Indeed, in rat 
hypothalamic slices selective (X2-adrenoceptor antagonists failed to enhance the release 
of tritiated 5-HT (Blier et al, 1990), corroborating the data that indicate that there is no 
tonic control of 5-HT by (^-adrenoceptors in the hypothalamus, which is contrary to the 
data of Marsden and Martin (1986). The cx2-adrenoceptor influence over 5-HT release 
in the SCN appears to rely upon neuronal release of transmitter.
The metabotropic glutamate receptors (mGluR) constitute a family of G-protein coupled 
receptors that can exert their effects by influencing cytoplasmic second messenger 
systems. The ability of the mixed Group I / group II agonist 1S,3R-ACPD (ACPD) to 
influence 5-HT release in the SCN was concentration- and zeitgeber time-dependent. 
During the dark phase, ACPD had no influence over SCN 5-HT release. At ZT 6 on the 
other hand, although 100 pM ACPD failed significantly to affect 5-HT release, 1 mM 
caused an immediate and significant increase in 5-HT overflow, which was blocked by 
the group I / group II antagonist E4CPG. There is no evidence to date that expression of 
mGluR in the SCN or immunoreactivity for the mGluR shows circadian variation. In 
vitro preparations of hamster SCN cells show increased neuronal activity following 
ionophoretic application of ACPD, but this was only tested during the light phase (Scott 
and Rusak, 1996). It may be that SCN cells do not respond to ACPD during the dark 
phase.
The effect observed here after stimulation with the metabotropic glutamate receptor 
agonist ACPD on 5-HT overflow might be an indirect effect of glutamate. ACPD has 
been used to look at the effects of mGluR stimulation on glutamate and aspatate levels 
by in vivo microdialysis of the nucleus tractus solitarius (Jones et al, 1998). ACPD 
significantly elevated glutamate and aspatate overflow, which is blocked by the 
antagonist E4CPG. However, the effect observed in my experimenst is immediate, and
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one might expect the response to take longer to establish if it was caused by indirect 
stimulation of glutamate release. An interesting aspect of mGluR stimulation is the 
facilitation of NMDA depolarisation of cortical wedges (Rahman and Neuman, 1996). 
It may be that in the SCN mGluR and NMDA receptors work together to modulate 5- 
HT neurotransmission to the SCN.
5.5 CONCLUSIONS
With the exception of the AMPA receptor, ionotropic and metabotropic glutamate 
receptor activation has the ability to affect serotonergic transmission in the SCN. 
During the light phase NMDA receptor stimulation exerts tonic control over the 
terminal release of 5-HT, which is absent during the dark phase. This is presumably 
influenced by the activation of the retinohypothalamic tract during the day, releasing 
excitatory amino acids at it terminals. NMDA receptor activation has the ability to 
increase 5-HT release in the SCN during both the light and the dark phase, but the 
degree of receptor activation during the dark period is important in mediating the effects 
on 5-HT overflow. The difference between an NMDA-induced decrease in 5-HT 
release during the dark phase, and an NMDA-induced increase may be important for 
phase resetting of the circadian pacemaker during the dark phase. This NMDA-induced 
decrease in 5-HT release is mediated by parallel activation of monoamine transmitter 
systems activating inhibitory ot2-adrenoceptor heteroceptors present on the serotonergic 
nerve terminals. Endogenous monoamines in the SCN serve to regulate neuronally 
released 5-HT, and therefore must be taken into consideration when examining the 
effects of drugs on 5-HT release in this brain region. The regulation of 5-HT by 
metabotropic glutamate receptors exhibits a definite diurnal variation. The activation of 
these receptors can only regulate 5-HT release during the light phase and may thus be 
influenced by activation of the retinohypothalamic tract.
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CHAPTER 6
THE RAPHE 5-HT1A SOMATODENDRITIC 
AUTORECEPTOR AND NMDA RECEPTOR 
REGULATION OF 5-HT RELEASE IN THE SCN
6.1 INTRODUCTION
Although not a recognised pathway for the integration and regulation of circadian 
rhythms, there is growing evidence of a retinal-raphe-SCN projection. The raphe-SCN 
projection is a well established pathway sending serotonergic nerve fibres to the 
circadian pacemaker (Moore et al., 1978). Anterograde tracers injected into the 
posterior chamber of the eye reveal a bilateral projection to the DRN in the cat (Foote et 
a l, 1978) and rat (Villar et al., 1987; Shen and Semba, 1994; Kawano et al., 1996), 
although these fibres are scarce in comparison to well established retinal projections 
such as the SCN (Moore and Lenn, 1972) and IGL (Card and Moore, 1989). Retrograde 
tracers injected into the DRN of the rat have confirmed the presence of this pathway, by 
detecting equivalent numbers of labeled ganglion cells in the retina (Shen and Semba, 
1994). Whether there is a reciprocal projection from the raphe to the retina is under 
dispute with retrograde retinal labeled fibres reportedly present (Villar et al., 1987) or 
absent (Kawano et al., 1996) from the DRN.
The growing controversy about whether the raphe-SCN projection originates in the 
median or dorsal raphe nuclei (see Discussion, this chapter) might tempt the interested 
reader to dispute the existence of a retino-raphe-SCN projection, as from the evidence 
presented, the retinal fibres terminating in the raphe nuclei do so solely in the DRN and 
in small numbers. Indeed, one paper dedicated to answering the question of “Is there a 
direct retina-raphe-suprachiasmatic nucleus pathway in the rat?” (Kawano et a l, 1996) 
suggests that this presumed third visual input to the circadian pacemaker may include 
further neuronal connections or brain sites. These authors anterogradely labeled fibres 
from the retina, labeled SCN neurones with retrograde tracers, and identified DRN 
neurones by means of serotonin immunohistochemistry of brain sections. 
Approximately half of the retrograde-labeled SCN neurones detected in the DRN were 
serotonin-immunoreactive, but no close spatial relationship between anterogradely and 
retrogradely labeled structures in the DRN were observed, and at best, only a very few 
neurones retrogradely labeled from the SCN were distributed in the rostral DRN where 
retinal afferents terminated.
Structural evidence therefore suggests that the retinal-raphe pathway exists, but whether 
this pathway is functional in the regulation of SCN neurotransmitters, namely serotonin,
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and the control of circadian rhythms remains unanswered. The leading contender for the 
transmitter of the retinal afferents to the SCN and IGL is glutamate (e.g. Liou et a l, 
1986; de Vries et a l, 1993; 1994) and the involvement of ionotropic and metabotropic 
glutamate receptors in neurotransmission of photic information through the RHT is well 
established (Cahill and Menaker, 1989; Ohi et a l, 1991). It seems reasonable to 
extrapolate this to the retinal-raphe pathway until the transmitter of the retinal-raphe 
pathway has been identified.
The aim of this chapter was first to investigate the feasibility of a dual probe paradigm 
which would involve implanting two dialysis probes into a single animal to measure the 
5-HT overflow simultaneously in the midbrain raphe and SCN. For this, the 5-HTia 
receptor agonist 8-OH-DPAT was infused via the probe implanted into the raphe nuclei 
and terminal 5-HT release monitored in the SCN. Stimulation of the somatodendritic 5- 
HTia receptor has been shown to decrease raphe neuronal firing and thus decrease 
terminal release (Sprouse and Aghajanian, 1987). Therefore, for the dual probe 
paradigm to function efficiently, after stimulation with 8-OH-DPAT, terminal 5-HT 
release is expected to decline. Once this was established, the aim was to investigate the 
application of the ionotropic glutamate agonist NMDA to the raphe nucleus of the rat, 
whilst measuring the effects on 5-HT release in the SCN and thus examining the 




Male Wistar rats (University of Bath strain; 260-320 g) were maintained under a 12:12 
lightidark cycle regime (lights on 07:00 “normal” light:dark cycle; lights on 19:00 
“reverse” light:dark cycle; temperature 22 ± 2°C). The animals were caged in groups of 
six prior to experimentation, with food and water available ad libitum.
6.2.2 Microdialysis
Each animal was implanted with two microdialysis probes as described in chapter 2 
section 2.3.3 directed at the SCN and the midbrain raphe, and introduced to the 
experimental cage. The probes were continuously perfused with aCSF (1.2 p,l/min); 
only the probe to the SCN region receiving the SSRI citalopram. Six 15 min control 
samples were collected, and the three samples immediately before drug infusion served 
as the pre-intervention controls. At zeitgeber times 6 or 18 drugs were infused for a 
period of 60 min into the raphe nuclear region via the probe. For antagonistic studies, 
the antagonist was infused for an additional 30 min prior to and during the 60 min 
infusion with the agonist. Dialysate samples were collected every 15 min 
simultaneously from the SCN and raphe regions over a period of 2 hours post-drug 
infusion, and analysed for 5-HT content using HPLC-ED, as described in chapter 2 
section 2.3.5. Samples not being analysed immediately were snap frozen and 
maintained on dry ice until analysis. At the end of the experiments the animals were 
killed by CO2 asphyxiation and the brains removed and frozen onto dry ice. Slicing 
freehand with a sharp razor blade, the probe tract was clearly visible as a fine line 
through the brain tissue. With the aid of a stereotaxic atlas (Paxinos and Watson, 1982) 
the position of the probe tract within the hypothalamus or midbrain raphe was 
established. The animals whose probe tracts were not in the target area were discarded 
for analysis.
6.2.3 Drugs
8-OH-DPAT [(±)-8-Hydroxy-2-(di-n-propylamino)tetralin] and NMDA (N-methyl-D- 
aspartate) were obtained from Sigma Chemical Co., AP5 [(±)-2-amino-5- 
phosphonopentanoic acid] from Tocris Cookson Ltd. and WAY 100635 (N-[2-[4-(2-
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methoxyphenyl)-l-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide 
trihydrochloride) from Wyeth-Ayerst Research. Citalopram hydrobromide was 
provided by Lundbeck (Copenhagen-Valby)
6.2.4 Statistics
5-HT concentration in the dialysate samples (not-corrected for probe recovery) were 
expressed as a percentage of the three pre-intervention controls samples. Values post­
drug treatment were analysed by one-way analysis of variance (ANOVA) with repeated 
measures with Student Newman Keuls post hoc test to detect differences between pre­
intervention controls samples, p < 0.05 was considered statistically significant.
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6.3 RESULTS
At ZT 6, the basal 5-HT concentration prior to any drug treatment for raphe and SCN 
dialysates were 23.39 ± 5.14 and 15.48 ± 2.80 fmol respectively. At ZT 18 basal 5-HT 
overflow was 62.77 ± 17.20 and 19.98 ± 2.52 femtomols for raphe and SCN dialysates 
respectively.
6.3.1 Effect of local infusion of 8-OH-DPAT in the midbrain raphe nuclei on 5-HT 
overflow in the raphe and SCN
At ZT 18 two concentrations of 8-OH-DPAT were infused into the raphe for a period of 
60 min. The initial concentration of 1 fiM failed to affect significantly either raphe or 
SCN 5-HT overflow (figure 6.1 A and 6. IB, respectively). It was therefore decided to 
increase the concentration 1000-fold to 1 mM. In raphe dialysate 1 mM 8-OH-DPAT 
appeared to produce a transient rise in 5-HT overflow, although this was not statistically 
significant. Thereafter, 5-HT levels became significantly lower than pre-intervention 
controls 30 min after the end of the infusion, and remained low for the duration of the 
experiment (figure 6.1 A). Maximal drop in raphe 5-HT levels was 33.3 ± 15.7 % of 
baseline (p < 0.01). The effect of 1 mM 8-OH-DPAT applied to the raphe was to 
decrease SCN 5-HT overflow to levels significantly lower than pre-intervention controls 
45 min after the start of the infusion; 5-HT levels staying low for the remainder of the 2 
hour collection period, reaching a nadir of 21.7 ± 8.19 % of baseline (p < 0.01; figure 
6.1B).
At ZT 6, 1 mM 8-OH-DPAT into the raphe caused a dramatic and significant increase in 
raphe 5-HT 45 min after the start of the infusion, reaching a peak of 516 ± 104 % of 
baseline (p < 0.001). Thirty min after the end of the infusion, raphe 5-HT concentration 
fell to levels not significantly different from pre-intervention controls (figure 6.2A). In 
the SCN dialysate, 5-HT levels decreased significantly 45 min after the start of the raphe 
infusion and remained low for the duration of the collection period, reaching a nadir of
32.3 ± 9.61 % of baseline (p < 0.01; figure 6.2B).
Pretreatment and co-infusion of the specific 5-HTiA receptor antagonist WAY 100635 
(10 pM) with 8-OH-DPAT (1 mM) failed to prevent the decrease in SCN 5-HT levels at
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ZT 6 (figure 6.3B). In the SCN, 5-HT overflow fell significantly within 30 min of the 
start of the infusion, and remained so for the whole of the collection period, reaching a 
nadir of 13.4 ± 9.87 % of baseline (p < 0.001). This concentration of WAY100635 did, 
however, prevent the increase in raphe 5-HT (figure 6.3A). Forty five min after the end 
of the infusion, raphe 5-HT fell to 55.6 ± 14.5 % of baseline (p < 0.05). At ZT 18, the 
concentration of WAY 100635 was increased 100-fold to match that of the infused 8- 
OH-DPAT (1 mM). In the presence of the antagonist, 8-OH-DPAT failed to decrease 
SCN 5-HT throughout the duration of the infusion, although the last collection sample, 
60 min after the end of the infusion, SCN 5-HT did fall to 35.7 ± 13.5 % of baseline (p 
< 0.05; figure 6.4B). The effect of pretreatment with WAY100635 on raphe 5-HT, on 
the other hand, was to augment the increase in 5-HT to levels significantly higher than 
baseline 30 min after the start of the infusion, reaching a peak of 460 ± 110 % (p < 0.01; 
figure 6.4A). WAY100635 did prevent the decrease in raphe 5-HT observed after 8- 
OH-DPAT alone, during the period after the infusion, (figure 6.1 A).
6.3.2 Effect of local infusion of NMDA in the midbrain raphe nuclei on 5-HT overflow 
in the raphe and SCN
Similar effects of NMDA (100 pM) were observed at ZT 6 and 18 (figure 6.5A and 
6.5B, respectively). At ZT 6, a 60 min infusion of NMDA into the raphe increased 
raphe 5-HT, reaching significance 15 min after the end of the infusion (214 ± 29.3 % of 
baseline; p < 0.05). This increase was mirrored by a decrease in SCN 5-HT, reaching 
significance 30 min after the end of the infusion (54.6 ± 16.0 % of baseline; p < 0.05). 
At ZT 18, a 60 min infusion of NMDA into the raphe also increased raphe 5-HT levels. 
Peak levels were achieved 60 min after the start of the infusion (158 ± 31.7 % of 
baseline). A decrease in SCN 5-HT levels were observed after the infusion in the raphe, 
reaching significance 15 min after the end of the infusion, but reaching a nadir of 17.7 ±
17.7 % (p < 0.01) 45 min after the end of the infusion.
The decrease in SCN 5-HT overflow following NMDA (100 pM) infusion of the raphe 
nuclei at ZT 18 was prevented by pretreatment and co-infusion with the NMDA 
antagonist AP5 (100 jiM; figure 6.6B). However, the increase in raphe 5-HT observed 
after NMDA infusion was not blocked by the antagonist, and still reached statistical 
significance 60 min after the start of the experiment (173 ± 26.3 % of baseline; p <
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0.01). However, 45 min after the end of the infusion, raphe 5-HT levels fell 
significantly to 59.3 ± 8.61 % of baseline (p < 0.05).
To establish whether the decrease in 5-HT overflow from the SCN following NMDA 
infusion into the raphe at ZT 18 was due to stimulation of the 5-HTiA autoreceptor on 
the serotonergic neurones, WAY 100635 (1 mM) was infused before and during the 
NMDA infusion (100 pM). WAY 100635 failed to prevent the decline in SCN 5-HT 
overflow 30 min after the end of the infusion, although the drop in SCN 5-HT levels 
was less pronounced than with NMDA alone, reaching a nadir of only 57.4 ± 13.5 % of 
baseline (p < 0.05; figure 6.7B), in comparison to 17.7 ± 17.7 % (figure 6.5B). A very 
striking effect of WAY100635 pretreatment was observed in the raphe nuclei. The 
increase in raphe 5-HT concentration following NMDA alone (100 pM; figure 6.5B) 
was augmented considerably after treatment with WAY100635 (figure 6.7A), evident 
after 15 min of the NMDA infusion and remaining elevated for the whole collection 
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Figure 6.1. Effect of 8-OH-DPAT infusion (1 jliM  and 1 mM) in the midbrain raphe 
nuclei on 5-HT overflow in raphe nuclei (A) and in the SCN (B) at ZT 18. 
Simultaneous collection of samples was carried out in a single animal implanted with 
two microdialysis probes. Values are mean ± s.e.m. expressed as a percentage of three 
pre-intervention control samples. 8-OH-DPAT was infused for 60 min denoted by the 
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Figure 6.2. Effect of 8-OH-DPAT infusion (1 mM) in the midbrain raphe nuclei on 5- 
HT overflow in raphe nuclei (A) and in the SCN (B) at ZT 6. Simultaneous collection 
of samples was carried out in a single animal implanted with two microdialysis probes. 
Values are mean ± s.e.m. expressed as a percentage of three pre-intervention control 
samples. 8-OH-DPAT was infused for 60 min denoted by the hatched bar. * p < 0.05;
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Figure 6.3. Effect of the specific 5-HTiA antagonist WAY100635 (10 |iM) on the effect 
of 8-OH-DPAT (1 mM) infusion in the midbrain raphe on 5-HT overflow in the raphe 
(A) and the SCN (B) at ZT 6. WAY100635 was infused 30 min prior to, and 60 min 
concurrently with 8-OH-DPAT. The solid bar denotes WAY100635 infusion and the 
hatched bar the 8-OH-DPAT. Values are mean ± s.e.m. expressed as a percentage of 
three pre-intervention controls. * p < 0.05; *** p < 0.001. Compare the effect of 
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Figure 6.4. Effect of the specific 5-HTiA antagonist WAY100635 (1 mM) on the effect 
of 8-OH-DPAT (1 mM) infusion in the midbrain raphe on 5-HT overflow in the raphe 
(A) and the SCN (B) at ZT 18. WAY100635 was infused 30 min prior to, and 60 min 
concurrently with 8-OH-DPAT. The solid bar denotes WAY100635 infusion and the 
hatched bar the 8-OH-DPAT. Values are mean ± s.e.m. expressed as a percentage of 
three pre-intervention controls. * p < 0.05; ** p < 0.01. Compare the effect of 
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Figure 6.5. Effect of NMDA infusion (100 pM) in the midbrain raphe nuclei on 5-HT 
overflow in raphe nuclei and in the SCN at ZT 6 (A) and ZT 18 (B). Simultaneous 
collection of samples was carried out in a single animal implanted with two 
microdialysis probes. Values are mean ± s.e.m. expressed as a percentage of three pre­
intervention control samples. NMDA was infused for 60 min denoted by the hatched 
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Figure 6.6. Effect of the specific antagonist AP5 (100 jiM) on the effect of NMDA (100 
jiM) infusion in the midbrain raphe on 5-HT overflow in the raphe (A) and the SCN (B) 
at ZT 18. AP5 was infused 30 min prior to, and 60 min concurrently with NMDA. The 
solid bar denotes AP5 infusion and the hatched bar the NMDA. Values are mean ± 
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Figure 6.7. Effect of the specific 5-HTjA antagonist WAY100635 (1 mM) on the effect 
of NMDA (100 fiM) infusion in the midbrain raphe on 5-HT overflow in the raphe (A) 
and the SCN (B) at ZT 18. WAY100635 was infused 30 min prior to, and 60 min 
concurrently with NMDA. The solid bar denotes WAY 100635 infusion and the hatched 
bar the NMDA. Values are mean ± s.e.m. expressed as a percentage of three pre- 
intervention controls. * p < 0.05; ** p < 0.01.
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6.4 DISCUSSION
The double probe paradigm used in these experiments has been employed to detect 
changes in 5-HT concentration in the midbrain raphe and SCN dialysate samples 
simultaneously. Previous studies have successfully implanted two microdialysis probes 
into different areas of the brain to measure local changes in neurotransmitter release 
(Adell et a l, 1993; Matos et a l, 1996a; Tao and Auerbach, 1996; Bosker et a l , 1997; 
Morari et al., 1998 and Pallotta et al., 1998). With the exception of Matos et a l (1996a) 
and Morari et a l (1998) all these cited authors infused drugs by ‘reverse-dialysis’ into 
either the median or dorsal raphe nuclei, and detected changes in 5-HT concentration in 
forebrain projection sites, namely the nucleus accumbens, hippocampus, amygdala or 
the frontal cortex.
The application of drugs via one microdialysis probe implanted in the midbrain raphe 
enables us to detect changes in neurotransmitter release in a forebrain projection area. 
Because of the local area of the infusion via the microdialysis probe one has a 
reasonable idea of where the drug is acting. This provides an advantage compared to 
systemic administration of drugs, with subsequent detection of changes in a given 
transmitter in a particular area of the brain by microdialysis. For example, Hjorth and 
Sharp (1991) administered 8-OH-DPAT subcutaneously to anaesthetised animals, and 
measured 5-HT release in six separate forebrain sites by microdialysis. The 8-OH- 
DPAT decreased the 5-HT overflow in all forebrain sites, but the authors were left to 
speculate about the location of drug action, although they did postulate the midbrain 
raphe nuclei. They were however, unable to verify at which midbrain raphe nucleus the 
drug was exerting its effect. In experiments using a dual probe system, the experimenter 
is able to specifically apply drugs to particular brain nuclei, for example, separately to 
the median (MRN) or dorsal raphe nuclei (DRN) (Tao and Auerbach, 1996).
In the experiments reported in this thesis, I used a microdialysis probe with a functional 
membrane length of 4 mm which, when implanted, spanned the whole of the raphe 
nuclei -7.8 mm relative to Bregma (coordinates relative to Paxinos and Watson, 1982). 
This implantation site incorporated both MRN and DRN. Early autoradiaographic 
studies utilizing anterograde tracers combined with selective lesions of the serotonergic 
neurones with 5,6-dihydroxytryptamine in the rat, identified the midbrain raphe as the
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principle source of the serotonergic terminals in the SCN (Moore et al., 1978). 
However, since then there has been dispute over which raphe nucleus sends its 
projection to the SCN. Azmitia and Segal (1978) used anterograde tracing of the raphe 
nuclei in the rat, and concluded that the SCN receive input from both MRN and DRN. 
However, van de Kar and Lorens (1979) lesioned the MRN and DRN in separate groups 
of rats and measured isolated hypothalamic nuclei for serotonin content. A significant 
decrease in 5-HT content of the SCN was only achieved in animals that had received 
lesions to the MRN (by 70 %); electrolytic lesion of the DRN failed to significantly 
affect SCN 5-HT content. Retrograde tracer injected into the hamster SCN supports 
input from both MRN and DRN (Pickard, 1982), whereas functional studies looking at 
the effects of specific lesions on wheel running activity in hamsters (Meyer-Bemstein 
and Morin, 1996) have implicated only the MRN. More recent studies are still in 
disagreement as to the site of the projection from the midbrain raphe in the rat. Kawano 
et a l (1996) labeled SCN neurones with retrograde tracer and detected deposits in the 
DRN, whereas Moga and Moore (1997), using complimentary retrograde and 
anterograde tracers, suggested that the majority of fibres originate in the MRN. On the 
basis of this disagreement amongst individual groups, it was decided to incorporate both 
MRN and DRN in our experiments.
Basal 5-HT concentration collected in the dialysate collected from the raphe nuclei in 
this study was very similar to those of many authors who detected levels between 5 and 
50 femtomols in the MRN or DRN with or without an SSRI in the perfusing aCSF 
(Agneter and Singer, 1993; Casanovas and Artigas, 1996; Matos et a l,  1996a; Bosker et 
a l, 1997; Casanovas et a l, 1997). However, Tao et a l (1997) were able to detect much 
higher basal levels, between 4 and 7 picograms, with the inclusion of an SSRI in the 
aCSF. Interestingly, Tao et a l, (1997) Casanovas and Artigas (1996), and Casanovas et 
a l (1997) were all able to detect higher basal 5-HT overflow from the MRN compared 
to the DRN. In my experiments, the basal raphe 5-HT concentration was higher during 
the dark phase compared to the light phase. Agren et a l (1986) measured the 5-HT 
concentration in micropunches of rat raphe nuclei assayed by HPLC, and detected 
highest levels at the end of the light phase with a nadir at end dark, which directly 
opposes our results. This may simply reflect differences in total tissue concentration 
(Agren et al 1986) versus extracellular 5-HT concentration (this study).
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To determine the effectiveness of this dual probe experimental model, initial 
experiments were performed infusing the 5-HTiA agonist 8-OH-DPAT. 5-HTiA receptor 
agonists are known to decrease firing of raphe neurones when administered systemically 
(Mundey et a l , 1996) or microiontophoretically (Dong et al., 1997), and thus I 
postulated that administration of 8-OH-DPAT locally via the microdialysis probe would 
also decrease raphe neuronal firing. A decrease in neuronal firing should produce a 
concomitant decrease in 5-HT released at the terminal region, in this case the SCN. 
Initial experiments were performed at ZT 18. Lu and Nagayama (1996) demonstrated 
that the effectiveness of systemically applied 8-OH-DPAT to produce 5-HTiA 
behavioural syndrome was dependent on circadian phase. Peak responses were 
observed in the mid-dark phase, and it was on this basis that preliminary experiments 
were performed at ZT 18, in an attempt to demonstrate what was expected to be a peak 
effect.
Bosker et a l (1997) successfully applied lpM  of the 5-HTiA agonist flesinoxan via a 
microdialysis probe to produce an effect in the nucleus accumbens, and therefore I chose 
a concentration of 1 pM. At this concentration 8-OH-DPAT failed to demonstrate any 
significant effects on either raphe or SCN 5-HT overflow (figure 6.1). This may be due 
to different specificity of flesinoxan versus 8-OH-DPAT, or the diffusable properties of 
the agonist through the membrane. Casanovas and Artigas (1996) and Matos et a l 
(1996a) failed to detect changes in raphe 5-HT levels following administration of the 
lowest concentration of agonist in their experiments (0.3 mg/Kg and 5 mg/Kg 
respectively), and more specifically, 8-OH-DPAT (1 pM) infused via the probe into the 
raphe nuclei in rats implanted with two dialysis probes (raphe and hippocampus) failed 
to significantly affect 5-HT overflow in either midbrain or forebrain (Adell et a l , 1993). 
Additionally, a study by Bosker et a l (1994) also failed to demonstrate any effect of 8- 
OH-DPAT (1 pM) in MRN. Some forms of stress, such as placing rats in novel 
uncontrolled environmental conditions for 16 hours has been shown to decrease 
significantly DRN cell responses to the 5-HTiA agonist iasaspirone, indicating a 
decreased sensitivity of somatodendritic 5-HTiA autoreceptors (Laaris et a l , 1997). The 
rats in my study may therefore be undergoing a form of mild stress, as they have been 
placed in an unfamiliar experimental cage, and the inability of 1 pM 8-OH-DPAT to 
affect either SCN or raphe 5-HT overflow might thus be explained.
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The concentration of 8-OH-DPAT was therefore increased to 1 mM. The ability of 8- 
OH-DPAT (1 mM) to reduce raphe 5-HT levels at ZT 18 was consistent with data from 
in vivo microdialysis experiments following systemic or local administration during the 
dark phase (Tao and Auerbach, 1996) and other in vitro (Davidson and Stamford, 1995) 
and in vivo (Casanovas et a l , 1997) data following application of 8-OH-DPAT in which 
the authors do not state the circadian phase. Other 5-HTia agonists administered 
systemically also significantly decreased raphe 5-HT overflow (isaspirone, Casanovas 
and Artigas, 1996; BMY14802, Matos et al., 1996a; alnespirone, Casanovas et al., 
1997) and the 5-HTiA agonist flesinoxan delivered via the dialysis probe significantly 
decreased caudal linear raphe and MRN 5-HT concentration (Bosker et a l, 1996).
In my experiments, raphe 5-HT levels fell significantly 90 min after the start of the 
infusion, which is similar to Matos et al. (1996a) who observed an effect 125 min post- 
systemic administration of the 5-HT iA agonist BMY-14802 but longer than Casanovas 
and Artigas (1996) (40 min post-systemic injection of the 5-HTJA agonist isaspirone), 
Casanovas et a l (1996) (40 min post-systemic injection of the 5-HT]A agonist 
alnespirone and 8-OH-DPAT) and Bosker et al. (1996) (25 min post reverse dialysis 
infusion of the 5-HT iA agonist flesinoxan). It is likely that the decrease in raphe 5-HT 
concentration induced by 8-OH-DPAT at ZT 18 is due to activation of 5-H T iA receptors 
located on the soma and dendrites of the neurones in the serotonergic neuronal pool in 
the DRN and MRN. Additionally, 8-OH-DPAT which shows moderate affinity for the 
5-H T ib receptor may stimulate 5-HT iB autoreceptors present on serotonergic nerve 
terminals in the raphe nuclei. Stimulation of the 5-HT ib autoreceptor would be 
expected to decrease terminal 5-HT release (see Chapter 3).
The reduction in 5-HT overflow from the SCN following 1 mM 8-OH-DPAT to the 
raphe nuclei at ZT 18 is in keeping with the assumption that the applied 8-OH-DPAT is 
stimulating somatodendritic 5-HT]A autoreceptors in the raphe. However, Romero et al. 
(1994) raised the possibility that other 8-OH-DPAT-sensitive serotonergic receptors 
different from 5-HT]A autoreceptors, may be involved in the control of terminal 5-HT 
release. They monitored the effects of striatal 5-HT release (a forebrain projection site 
of the DRN) after subcutaneous administration of 8-OH-DPAT, before and after 
application of pertussis toxin to selectively destroy Gi/G0 proteins. Surprisingly, the
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destruction of the G-proteins failed to modulate the effect of 8-OH-DPAT, and on this 
their conclusions were based. Further experiments need to be carried out before one can 
speculate if the 8-OH-DPAT in my experiments was stimulating receptors in the raphe 
other than the 5-HTiA autoreceptor. Until some evidence is produced to the contrary I 
will assume that the 8-OH-DPAT was stimulating 5-HTiA cell body autoreceptors.
The effect of 1 mM 8-OH-DPAT applied during the light phase at ZT 6 on SCN 5-HT 
levels is comparable to the effect demonstrated at ZT 18 during the dark phase, resulting 
in a decreased 5-HT overflow. The effect on raphe 5-HT overflow, on the other hand 
was quite dramatic. The 5-HTiA agonist produced a huge increase in raphe 5-HT to a 
peak of 516 ± 104 % of pre-intervention controls.
The ability of 8-OH-DPAT to increase raphe 5-HT concentration at ZT 6 represents 
differences in the route of administration of the drug. Most studies (with the exception 
of Tao and Auerbach, 1996, who performed their experiments during the dark phase) 
have involved systemic administration of the 5-HTiA agonist with subsequent 
measurement of raphe 5-HT levels from microdialysis probes implanted into the raphe 
nuclei. Three studies that have involved infusion of a 5-HTiA agonist locally via reverse 
dialysis to the raphe nuclei have all reported an increase in 5-HT concentration (Adell et 
al., 1993; Bosker et al., 1994; Matos et a l, 1996b). All three studies also demonstrated 
that systemic administration of the same agonists consistently decreased significantly 
raphe 5-HT overflow. Local application of the 5-HTjA agonist buspirone, at low 
concentration (10-100 nM) had no effect, whilst at the highest concentration (1 mM), 
equivalent to that used in my experiments, significantly enhanced DRN 5-HT release 
(Matos et al., 1996b). The two other studies infused 8-OH-DPAT. At concentrations 
between 0.1-10 jiM (Bosker et al., 1994) and 1-100 |iM (Adell et al., 1993), 8-OH- 
DPAT infusion had no effect on raphe 5-HT overflow, whilst higher concentrations 
(100 JiM, Bosker et a l, 1994; 1-10 mM, Adell et al., 1993) enhanced significantly raphe 
5-HT concentration. In addition, this response to locally infused 8-OH-DPAT appears 
to be a biphasic response as very low concentrations (30-100 nM) significantly 
decreased raphe 5-HT overflow (Bosker et al., 1994).
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The application of the 5-HTiA agonist via the probe represents a local effect on neurones 
in close proximity of the probe tip, whereas with systemic administration one cannot 
ascertain where the drug is acting. The systemically administered drug may act at brain 
areas other than the raphe nucleus to produce an overall effect of lowering raphe nuclei 
5-HT concentration. At high concentrations, 8-OH-DPAT has the ability to bind to the 
5-HT reuptake system. Tritiated 8-OH-DPAT has been shown to label two sites in 
preparations of human platelets (Ieni and Meyerson, 1987) and homogenates of raphe 
nuclei from rat brain (Wootton and Hazelwood, 1990). The higher affinity site 
corresponds to the 5-HTiA binding site, and the lower to the 5-HT uptake sites. Indeed, 
8-OH-DPAT competitively inhibited tritiated 5-HT uptake into rat cortical 
synaptosomes (Hamon et al., 1984). Therefore, the increase in raphe 5-HT 
concentration may be a consequence of reuptake blockade, since the aCSF perfusing the 
raphe did not contain a 5-HT reuptake blocker. However, if the 8-OH-DPAT did bind 
to the reuptake system, I would have expected the effect to be apparent during both the 
light and dark phase. The possibility remains that the affinity of 8-OH-DPAT to bind to 
the 5-HT uptake site exhibits a diurnal variation. Bearing in mind that the results of my 
experiments performed at ZT 18 and those performed by Tao and Auerbach (1996) 
during the dark phase, did not exhibit a significant increase in raphe 5-HT concentration 
after 8-OH-DPAT infusion, the effect of locally infused 8-OH-DPAT appears to 
undergo a diumal variation.
The experiments of Lu and Nagayama (1996; Nagayama and Lu, 1997) demonstrated a 
circadian rhythm in the behavioural response to subcutaneous (s.c.) or 
intracerebroventricular (i.c.v.) administration of 8-OH-DPAT. Stimulation of the 
central 5-HTiA receptors with 8-OH-DPAT at mid-dark produced maximal responses in 
forepaw treading, head weaving (s.c. and i.c.v. administration) and flatbody posture (s.c. 
administration). The results presented in this thesis do not support the hypothesis that 
the somatodendritic 5-HTiA autoreceptor exhibits diumal variation in function. The 
ability of 8-OH-DPAT applied to the raphe nuclei to decrease 5-HT concentration in the 
SCN did not vary at ZT 6 versus ZT 18. However, the experiments by Lu and 
Nagayama (1996) suggest that it is a port-synaptic 5-HTiA receptor that exhibits a 
circadian rhythm in its function. Therefore, my results, stimulating a pre-synaptic 
receptor in the raphe nuclei, cannot explain the variation demonstrated by these authors. 
Indeed, behavioural experiments performed by Moser and Redfem (1985) in which they
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measured the hypothermic response to 8-OH-DPAT did not demonstrate variation in the 
ability of the drug to induce a hypothermia. The 8-OH-DPAT induces hypothermia in 
rodents through an action on 5-HT cell body autoreceptors (Goodwin et a l, 1985), thus 
suggesting that the somatodendritic 5-HTiA autoreceptor does not exhibit diumal 
variation, as confirmed in my study. As mentioned above, the variation lies in the 
ability of 8-OH-DPAT to influence raphe 5-HT levels. At ZT 18, 8-OH-DPAT 
significantly decreased 5-HT overflow, whereas at ZT 6, 8-OH-DPAT significantly 
increased 5-HT overflow. Whether this is a direct effect 5-HTiA receptor stimulation, or 
an indirect effect, remains to be elucidated.
WAY100635 is a potent and selective 5-HT!A receptor antagonist (Fletcher et a l, 1994). 
Subcutaneous administration of 8-OH-DPAT (1 mg/Kg) can inhibit the firing rate of 
dorsal raphe neurones and induce specific behaviours in the guinea pig (Mundey et a l,
1996). The effect of 8-OH-DPAT can be antagonised by prior administration of 
WAY 100635 (1 mg/Kg s.c.). Similarly in rat DRN slices, reduction in electrically 
stimulated 5-HT release by application of 8-OH-DPAT (1 JiM) was prevented by 
WAY 100635 (0.1 pM) (Davidson and Stamford, 1995). Administration of 
WAY100635 (s.c.) also antagonised the reduction in forebrain 5-HT levels following 
systemic administration of a 5-HTiA agonist (Bosker et a l, 1996; Matos et a l, 1996a; 
Bosker et a l, 1997) in addition to blocking the reduction in raphe 5-HT levels.
In my study, 30 min pre-treatment with 10 pM WAY 100635 followed by 60 min 
concomitant infusion with 1 mM 8-OH-DPAT at ZT 6, successfully attenuated the 
increase in raphe 5-HT concentration following 8-OH-DPAT infusion. The increase in 
5-HT can, therefore, be assumed to be due to stimulation of 5-HTiA receptors. 
Interestingly, 45 min after the end of the combined infusion of WAY100635 and 8-OH- 
DPAT, raphe 5-HT levels fell significantly. Unfortunately, the concentration of 
WAY100635 was insufficient to block the decrease in 5-HT levels in the SCN. It 
appears that the concentration of antagonist required to block the 5-HTjA autoreceptor is 
greater than that required to block the 5-HTjA receptors responsible for the local 
increase in raphe 5-HT concentration. Interestingly, Matos et a l (1996b) also observed 
that different concentrations of antagonist was required to block 5-HTjA-induced 5-HT 
decrease in the forebrain (hippocampus) and in the raphe nuclei. They applied the 5-
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HTja agonist systemically. whilst the antagonist was applied locally to the raphe. A 
greater concentration of antagonist was required to block the decrease in raphe 5-HT 
versus the hippocampal 5-HT. Although this runs counter to my data (a greater 
antagonist concentration was required to prevent the decrease in SCN 5-HT 
concentration versus the increase in raphe 5-HT), this might reflect a difference in 
systemic versus local administration of the 5 - H T ia  agonist.
Increasing the concentration of WAY 100635 onehundred-fold (1 mM) successfully 
antagonised the effect of 8-OH-DPAT on terminal 5-HT concentration at ZT 18. 
However, the concentration in the final dialysate fraction collected 60 min after the end 
of the drug infusion remained significantly below pre-intervention control samples 
(figure 6.4B). The decrease in raphe 5-HT overflow following infusion of 8-OH-DPAT 
at ZT 18 was also prevented by pretreatment with the antagonist. However, the 
combined effect of 5 -H T iA agonist and antagonist was to increase dramatically raphe 5- 
HT release. It was assumed that WAY100635 was not acting as a partial agonist 
(Fomal et al., 1994) and that the effect was due to the antagonism of the 5 -H T ia 
receptor.
There is evidence of serotonergic tone in the DRN, possibly modulated by an inhibitory 
5-HTia autoreceptor. WAY100635 administration in the cat increases raphe neuronal 
firing in the dark phase, and not in the light phase (Fomal et al., 1994), whereas in the 
guinea pig, WAY100635 (s.c.) causes a dose dependent increase in DRN firing in the 
light phase (Mundey et a l , 1996). The circadian phase of this appears to be species 
dependent. Additionally, local infusion of the 5-HTiA antagonist (-)pindolol in the rat 
DRN increased 5-HT levels (circadian phase not stated) (Matos et al., 1996b). It is 
possible that in situ, somatodendritic 5-HTjA autoreceptors on raphe intemeurones are 
activated by extracellular 5-HT to produce inhibition of 5-HT release in the soma 
region. Administration of the 5-HTiA antagonist would thus remove the tonic inhibition 
thereby increasing extracellular 5-HT at the cell body region.
The dual probe paradigm has thus successfully applied drugs to the raphe with 
subsequent monitoring of release from the terminal SCN region. The effect of direct 
application of the ionotropic glutamate receptor agonist NMDA via the probe to the 
midbrain raphe was next investigated. Similar effects of NMDA (100 JiM) on raphe and
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SCN 5-HT overflow were obtained at mid-light and mid-dark. Maximal increase in 
raphe 5-HT levels was slightly higher at ZT 6 versus ZT 18; 214 ± 19.3 versus 158 ±
31.7 % of baseline respectively. Conversely, at ZT 18, the decrease in SCN 5-HT 
following NMDA infusion of the raphe nuclei was greater than that produced at ZT 6;
17.7 ± 17.7 versus 54.6 ± 16.9 % of baseline respectively. Tao and Auerbach (1996) 
infused NMDA via ‘reverse’ dialysis into the DRN and MRN during the dark phase, and 
at a concentration of 100 pM produced an increase in 5-HT overflow comparable to that 
produced in my experiments. They also monitored the effect of NMDA into either the 
DRN or MRN on 5-HT release in the projection sites (nucleus accumbens and 
hippocampus respectively). Unlike the decrease in SCN terminal 5-HT release I 
observed with 100 JiM NMDA, they could not produce an effect with 100 pM. They 
did, however, elicit an increase in terminal 5-HT release upon increasing the NMDA 
concentration to 300 pM. Pallotta et al. (1998) used the dual probe model to monitor 5- 
HT release in the raphe nucleus and concomitant release in the frontal cortex after 
infusion of NMDA. Not unlike the results presented here, the authors reported an 
increase in raphe 5-HT overflow, with a parallel decrease in frontal cortex 5-HT 
concentration. The effect of increased 5-HT in the nucleus accumbens and 
hippocampus, reported by Tao and Auerbach (1996), may be pathway-specific.
Pre-treatment and co-administration with the competitive NMDA antagonist AP5 at ZT 
18 failed to antagonise the increase in raphe 5-HT concentration evident after NMDA 
alone, but did block the decrease in 5-HT levels in the SCN. This would lead to the 
suggestion that the increase in raphe 5-HT overflow post-NMDA infusion was not 
mediated by NMDA receptors but was a non-specific effect of the amino acid agonist. 
However, the decrease in terminal 5-HT levels measured in the SCN was a direct 
consequence of the stimulation of NMDA receptors. The ability of AP5 to prevent the 
decrease in SCN 5-HT levels is a positive result, but it is unusual that the AP5 was 
unable to block the increase in raphe 5-HT overflow. Results from in vitro raphe culture 
preparations suggest that the rise in raphe 5-HT overflow following application of 
NMDA is mediated by NMDA receptors as it is prevented by pre-treatment with AP5 
(Becquet et al., 1993). Tao and Auerbach (1996) were able to block the rise in DRN 5- 
HT levels with the application of both non-competitive and competitive antagonists. 
Indeed, the same concentration of agonist and antagonist used in these experiments were
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used by Tao and Auerbach (1996) (i.e. 100 fiM NMDA and AP5 by ‘reverse’ dialysis). 
Pallotta et al. (1998) also demonstrated that AP5 (100 jiM by ‘reverse’ dialysis) was 
able to prevent the rise in raphe 5-HT levels following 100 pM NMDA. The reason for 
the inability of AP5 to antagonise the NMDA-induced increase in raphe 5-HT overflow 
in my experiments is not clear and requires further experiments perhaps using higher 
concentrations of AP5.
NMDA receptors are excitatory. Stimulation would be expected to increase neuronal 
firing due to an influx of calcium ions into the cell. It is, therefore, unlikely that NMDA 
receptors are present on the ascending raphe neurones projecting to the SCN, 
considering that stimulation of these receptors produced a decrease in 5-HToverflow in 
the SCN. The ability of NMDA to decrease SCN 5-HT levels is more likely to be an 
indirect effect. The NMDA receptors may be located on inhibitory GABA-ergic 
intemeurones in the raphe nuclei. Stimulation of these receptors would be expected to 
increase the local concentration of GABA in the raphe, thus decreasing neuronal firing. 
Alternatively, the NMDA receptors might be present on serotonergic intemeurones in 
the raphe nuclei. NMDA receptor stimulation would, therefore, increase the 
concentration of 5-HT within the raphe nuclei (as was observed after NMDA infusion 
via the probe in my experiments at both ZT 6 and ZT 18), increasing the amount of 5- 
HT available to stimulate the somatodendritic 5-HTjA autoreceptor. Stimulation of the 
5-HTia autoreceptor would then be expected to decrease the 5-HT concentration in the 
SCN. Consistent with the suggestion that NMDA receptor stimulation can indirectly 
affect ascending serotonergic neuronal firing, intravenous administration of the non­
competitive (MK801) or competitive (CPP) NMDA receptor antagonist to rats, 
facilitated DRN firing of ascending serotonergic neurones (Lejeune et a l , 1994). 
However, these authors reported that NMDA administered alone did not significantly 
modify DRN firing.
To examine the theory that the NMDA infused into the raphe nuclei was indirectly 
stimulating the 5-HTiA cell body autoreceptor, the 5-HTJA antagonist WAY100635 was 
pre- and co-infused with NMDA. At a concentration previously shown to attenuate the 
decrease in SCN 5-HT levels by 1 mM 8-OH-DPAT at ZT 18, 1 mM WAY100635 did 
not prevent the inhibition of terminal 5-HT release in the SCN by NMDA (100 JiM).
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However, the maximal decrease in SCN 5-HT concentration was attenuated (57.4 ±13.5 
versus 17.7 ± 17.7 % of baseline, respectively). From this it would appear that the 
decrease in SCN 5-HT concentration following NMDA infusion in the raphe is only 
partially, if at all, mediated by the 5-HTia autoreceptor. The rise in raphe 5-HT release 
post-NMDA infusion was not blocked by WAY100635, but was augmented ten-fold by 
co-application with the 5-HTiA receptor antagonist. Pallotta et a l (1998) were able to 
block the fall in frontal cortex 5-HT overflow following 100 pM NMDA with 
WAY 100635 (1 pM) administered to the raphe nuclei via ‘reverse’ dialysis, but unable 
to prevent the increase in raphe 5-HT. The difference in the results obtained by these 
authors and the data presented here is the large difference in concentration of 
WAY 100635 administered although the concentration of NMDA was comparable. The 
concentration of WAY 100635 I used was 1000 times greater than that used by Pallotta 
and co-workers (1998), and this may go a little way to explaining the observed 
differences.
In the absence of a 5-HTiA agonist but in the presence of NMDA, WAY100635 may 
result in a disihibition of serotonergic intemeurones. Postulating that there is 
serotonergic tone in the raphe modulated by inhibitory 5-HTiA autoreceptors (as 
discussed previously), stimulation by the antagonist would increase local 5-HT 
concentration. 5-HTiA receptors and NMDA receptors may co-exist on serotonergic 
intemeurone cell bodies or be present on separate groups of serotonergic intemeurones. 
The regulation of local raphe 5-HT concentration may be a balance between stimulation 
of 5-HTiA receptors decreasing intemeurone output of 5-HT, and NMDA receptor 
stimulation increasing the output. Simultaneous blockade of the 5-HTjA receptor and 
stimulation of the NMDA receptor might therefore evoke a greater response than would 
be predicted from the responses of the two drugs administered alone. This however, 
might lead to depletion of neuronal stores of 5-HT because the increase in raphe 5-HT 
following both WAY100635 and NMDA is sustained for the whole experimental 
collection period. However, the area that the probe is spanning is quite large, and 
activation of all neurones might have led to a sustained increase in 5-HT overflow.
The combined effect of the 5-HTiA antagonist and NMDA receptor stimulation might be 
an indirect effect of glutamate. A study by Dijk an co-workers (1995) applied drugs
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topically to the striatum, collected samples from the frontal cortex by means of 
microdialysis, and measured glutamate release. Although these workers did not 
measure 5-HT and they did not monitor levels in the raphe nuclei, they did demonstrate 
a significant potentiation of glutamate release in the frontal cortex after co-application 
of WAY100635 with NMDA as compared to release with NMDA stimulation alone. 
This potentiating effect of WAY100635 on NMDA-induced glutamate release is 
obviously occurring at the cell body region, as they were applying drugs to the cell body, 
whilst monitoring terminal transmitter release. The possibility remains that the 
disinhibition of a glutaminergic neurone by WAY 100635 increases glutamate release, 
thereby activating NMDA receptors in addition to other ionotropic glutamate receptors 
present on serotonergic intemeurones, to increase 5-HT release in the raphe nuclei. Of 
course all of the possibilities proposed in this discussion to explain the combined effect 
of NMDA and the 5-HTiA antagonist, and others, might occur in the raphe nuclei. It is 
only with further studies that the mechanisms behind the potentiation of NMDA- 
induced 5-HT release in the raphe by a 5-HTiA receptor antagonists will be elucidated.
6.5 CONCLUSIONS
The dual probe paradigm has been a very useful tool in examining the effects of dmgs 
administrated locally to the midbrain raphe nuclei, whilst measuring 5-HT overflow in 
the raphe itself and in a terminal projection area, the SCN.
The somatodendritic 5-HTjA inhibitory autoreceptor, stimulated by 8-OH-DPAT does 
not exhibit a diumal variation in function as tested at mid light versus mid dark phases. 
On the other hand, the local raphe response to a high concentration (1 mM) of 8-OH- 
DPAT does exhibit a diumal variation. A significant decrease in raphe 5-HT overflow 
is observed following infusion at ZT 18 (dark phase) compared with a significant 
increase at ZT 6 (light phase).
These results give support to a functional role of a retino-raphe-SCN projection in the 
rat, which may be important in the control of circadian rhythms. NMDA released from 
retinal afferents might, indirectly by the incorporation of raphe intemeurones, result in a 
decrease in SCN terminal 5-HT release. The increase in 5-HT release in the raphe by
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stimulation of NMDA receptors, in part stimulates inhibitory 5-HTiA autoreceptors to 




In the following chapter I shall summarize the data collected in this thesis, discuss the 
relevance of the results and discuss possibilities for future work.
7.1 SUMMARY OF THESIS
The microdialysis technique has proved to be an excellent method of sampling in vivo 
neurotransmitter levels from the SCN, hippocampus and raphe nuclei regions. Using 
this technique the terminal 5 - H T ib  auto- and hetero-receptor and somatodendritic 5- 
HTia autoreceptor function have been examined in the conscious rat. In addition, the 
interaction between the serotonergic and glutamatergic systems were examined in the 
somatodendritic (raphe nuclei) and terminal (SCN) regions. The aims were to further 
the understanding of the regulation of 5-HT release within the circadian pacemaker and 
to examine the relationship between the serotonergic and glutamatergic systems.
The striking feature of the 5 -H T ib autoreceptor in the SCN was the difference in 
responsiveness to agonist stimulation at the different zeitgeber times examined. This 
variation in function did not follow either the pattern of extracellular 5-HT 
concentration or the lightrdark cycle, although in general the greatest response to agonist 
stimulation occured during the light period. This variation in function seemed to be 
specific to the SCN; when the 5 -H T ib autoreceptor was tested in another serotonergic 
rich brain region, namely the hippocampus, at mid-light and mid-dark, the inhibition of 
neuronal 5-HT following agonist stimulation did not follow that of the SCN. That is, in 
the hippocampus agonist stimulation at mid-light and mid-dark produced a significant 
reduction in dialysate 5-HT overflow, whilst in the SCN the response is absent during 
mid-dark. The variation in 5 -H T iB receptor function also seemed specific to the 
autoreceptor because the 5 -H T ib heteroceptor showed no variation to agonist 
stimulation at the two time points tested (mid-light and mid-dark).
The reason behind the variation in function of the 5-HT]B autoreceptor was unknown. 
Thus, I next examined whether the messenger RNA for the 5 - H T i B receptor varied in 
parallel to the variation in SCN receptor function. The reverse transcriptase-polymerase 
chain reaction method was utilised to examine the 5 - H T i B postsynaptic, auto- and 
hetero- receptor mRNA in dissected SCN, raphe, and retinal tissues, respectively. The 
variation in function of the 5 - H T ib  autoreceptor could not be explained by alterations in
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mRNA for the receptor since no variation in 5-HTib autoreceptor mRNA was detected 
using this method. Interestingly, the mRNA for both the 5 -H T ib heteroreceptor and the 
postsynaptic receptor did show variation over 24 hours. The variation in SCN 5 -H T ib 
receptor mRNA may contribute to a variation in the number of postsynaptic receptors in 
the SCN, and a diumal variation in receptor function. The variation in retinal 5 -H T ib 
receptor mRNA may also reflect variation in the number of 5 -H T ib heteroreceptors 
present on retinal afferents in the SCN, and perhaps receptor function. The absence of a 
diumal variation in the function of the 5 -H T ib heteroreceptor in the SCN demonstrated 
in this thesis may reflect the two sampling times. It remains a possibility that the 5- 
HTib heteroceptor exhibits a diumal variation evident at time points other than those 
sampled in my experiments.
The absence of variation in mRNA for the 5 -H T ib autoreceptor led me to speculate that 
it was the number of receptors available for agonist stimulation that was important in 
determining the receptor function. The method of choice to examine the receptor 
protein was immunocytochemistry. Unfortunately the antibody raised against the 5- 
HTib receptor was unable to detect the receptor protein in brain slices. Therefore, 
Western blotting was employed to detect 5 -H T jb receptor protein levels in dissected 
SCN tissue. There were a number of limitations of this technique as outlined in Chapter 
4 but from the results obtained there did not appear to be significant differences in 
receptor protein level over the eight zeitgeber times tested. Thus, the mechanism(s) 
behind this variation of receptor function has yet to be elucidated.
The extensive sampling across the light:dark cycle whilst examining the 5 - H T ib  
autoreceptor function demonstrates the need for more than one time point when 
examining the function of a particular receptor. Some authors (e.g. Tao and Auerbach) 
who detect 5-HT in microdialysate samples collect only during the dark phase. If I had 
applied RU24969 to the SCN during the mid-dark phase only, I might have eroneously 
concluded that in the SCN there was no function of a 5 - H T i B autoreceptor. Although 
this effect appeared to be specific to the SCN when compared to the hippoampus, other 
brain regions such as SCN effector areas might be likewise affected.
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In contrast to the terminal 5-HTib autoreceptor, the somatodendritic 5-HTiA 
autoreceptor failed to exhibit variation in function as examined by the dual probe 
microdialysis experiments at two time points (mid-light and mid-dark).
The regulation of 5-HT release by excitatory amino acids was examined in the SCN at 
both the terminal and soma regions. The close proximity of the serotonergic and 
glutamatergic terminals in the SCN provides spatial evidence for interaction between 
the two systems. Indeed, 5-HT release in the SCN was regulated by the ionotropic 
glutamate receptor agonists kainate and NMDA and by the metabotropic glutamate 
receptor agonist 1S,3R-ACPD. AMPA receptor stimulation failed to affect 5-HT 
release in the SCN. The response to NMDA and ACPD showed diumal variation. 
Metabotropic receptor stimulation with ACPD at the highest dose enhanced 
significantly the measured 5-HT concentration at mid-light whilst having no effect at 
mid-dark. On the other hand, at the lowest dose tested, NMDA receptor stimulation at 
mid-dark reduced significantly 5-HT overflow in the SCN whilst having no effect at 
mid-light. This reduction in 5-HT overflow by NMDA appeared to involve the 
endogenous release of noradrenaline acting on presynaptic 012-adrenoreceptors, because 
addition of the ot2-adrenoreceptor antagonist idazoxan potentiated the release of 5-HT. 
At mid-dark, there was no reduction in 5-HT following NMDA receptor stimulation; 
this may be because of a diumal variation in either the ability of NMDA to release 
noradrenaline, or the function of the a 2-adrenoreceptor. At the highest dose tested, 
NMDA increased significantly the 5-HT overflow from the SCN at both time points 
tested.
The regulation of 5-HT release in the SCN by NMDA application to the soma region did 
not appear to exhibit a diumal variation under the given conditions and the dose tested. 
NMDA administration to the raphe nuclei significantly decreased SCN 5-HT overflow 
at both mid-light and mid-dark. The effect was likely to be the result of indirect 
stimulation of raphe intemeurones, and to be partly mediated by an increased 5-HT 
concentration in the soma region acting on the 5 -H T ia inhibitory autoreceptors. This 
modulation of the ascending raphe nuclei projection to the SCN by the excitatory amino 
acid agonist provides functional evidence for a retinal-raphe-SCN projection in the rat.
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7.2 DISCUSSION
Research into circadian rhythms has increased within the last few years and the results 
presented in this thesis have gone a little way to extending the information known about 
the function of the circadian pacemaker in mammals. A knowledge of the normally 
functioning circadian pacemaker aside from any intrinsic scientific interest can also 
inform studies of abnormalities in clock function such as jet-lag and depressive illness. 
In addition, the importance of timing during drug delivery in certain medical 
manipulations such as cancer chemotherapy, is now being recognised (for a review on 
clinical chronopharmacology see Lemmer, 1995). However, the differences in the 
intricate workings of the clock in two mammalian species, namely the rat and hamster, 
casts doubt upon the extrapolation of the results obtained in rodents to man.
One clinical condition that may have direct relevance to the results obtained in this 
thesis is that of depression. Over the past few years an increasing amount of evidence 
has indicated that depression, one of the most common mental illnesses in man, is 
associated with abnormalities in circadian rhythms (for a recent review see Rosenwasser 
and Wirz-Justice, 1997). Depressed patients may present with similar symptoms, but 
the causal mechanisms of each individual may be completely different. Difficulty in 
getting to sleep and early morning wakening are of the most common complaints in 
depressive illness. This latter abnormal timing is suggestive of a phase advance in the 
sleep wake cycle, and is one of the most robust findings that suggest that depression 
involves a disorder of time keeping. However, disruption of circadian parameters 
cannot simply be diagnosed as a phase advance in the sleep wake cycle, as these changes 
are not consistent in all humans or animal models of depression. It still remains obscure 
whether depressive illness leads to altered circadian rhythms, or whether a disruption in 
the normal time keeping function is responsible for an unstable state of mind.
The treatment of depressive illness has commonly been to enhance monoamine 
neurotransmitter levels in the brain (Blier and de Montigny, 1994; Leonard, 1995). The 
involvement of serotonin in depression and antidepressant therapies has been 
extensively studied (Meltzer, 1990; Briley and Moret, 1993; Willner, 1985) and has led 
to the development of selective serotonin reuptake inhibitors (SSRI) for the treatment of 
depression. Antidepressant therapies have a delay of approximately two weeks before
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the clinical benefits are observed. This is thought to be because of adaptive changes at 
serotonin receptors, but could also be the result of resynchronising the malfunctioning 
circadian pacemaker. Experiments on human subjects have shown that after a trans- 
Atlantic flight, the body clock (measured as blood pressure and heart rate rhythms) does 
not resynchronise to the new time zone even after eleven days after the time change 
(Nold et a l , 1996). This provides evidence that a long period of time is needed to 
restore synchronisation of the body clock to its environment.
The terminal 5 -H T ib receptor function has been shown to be affected in animal models 
of depression (Edwards et al., 1991), by acute stress (Bolanos-Jimenez et al., 1995) and 
following antidepressant therapies (Moret and Briley, 1988; 1990). In addition, the 5- 
HTia somatodendritic autoreceptor is also modified following chronic antidepressant 
treatment (O’Connor and Kruk, 1994). In general, long term serotonin reuptake 
blockade desensitizes the terminal 5 -H T ib autoreceptor, and sensitizes the 5 -H T ia 
autoreceptor thus enhancing synaptic availability of serotonin.
The 5 -H T ib autoreceptor function has been shown in this thesis to vary over 24 hours. 
Surely, therefore, the timing of drug delivery for antidepressant therapy is crucially 
important. If the drug is administered when the 5 -H T ib receptor is least active i.e. 
naturally down regulated, then how can the antidepressant therapy down regulate the 
receptor further? The antidepressant drug must therefore be administered when the 
autoreceptor is responsive to agonist stimulation, so that the benefits of receptor down 
regulation can be reaped. It can be argued that with respect to the 5 -H T iA autoreceptor, 
time of day is not an important consideration during antidepressant treatments as this 
receptor did not exhibit a diurnal variation.
Recently, functional antagonists at the NMDA receptor complex have also been shown 
to exhibit antidepressant actions in an animal model of depression (Trullas and 
Skolnick, 1990). The effect of the NMDA antagonists on the function of the NMDA 
receptor mimics that of chronic but not acute treatment with a range of antidepressant 
therapies including tricyclics and SSRIs (Nowak et al., 1993, 1996, 1998; Paul et al., 
1993). The NMDA receptors can be regulated by glycine and polyamines and 
substances such as Mg2+ and MK801 can sit in the ion channel and block receptor 
activation. Chronic antidepressant treatment decreased the ability of glycine to displace
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radioligand binding in mice cortical membranes (Paul et a l , 1993; Nowak et a l,  1993, 
1996, 1998) in addition to other effects on NMDA receptor function (see Nowak et a l, 
1993). This effect was a slowly developed adaptive phenomenon, which would 
correlate with clinical improvement following antidepressant therapies, and was 
persistent after the cessation of treatment (Paul et a l, 1993). Additionally this effect 
appeared to be specific to the neocortex, since the response was absent in the 
hippocampus (Nowak et a l, 1993, 1996). Interestingly, in the frontal cortex of suicide 
victims the high affinity glycine displaceable ligand binding to glutamate receptors is 
decreased significantly compared to age matched controls (Nowak et a l, 1995). The 
consensus of opinion is that the NMDA ion channel might serve as a final common 
pathway of antidepressant action and indicates glutamatergic pathway involvement in 
the pathophysiology of depression. However, the relationship between NMDA receptor 
activity to depression is likely to be a very complex phenomenon (see Discussion 
Nowak etal., 1995).
In animal models of depression, abnormalities in the function of the NMDA receptor 
have not been looked at in the hypothalamus, or more specifically, in the SCN. 
Likewise, the effect of antidepressant therapies on the NDMA receptor has not been 
studied in the SCN. Although the effect on the NMDA receptor after antidepressant 
drugs appeared specific to the neocortex, until a full examination of the brain is done, 
one cannot exclude the possibility that changes occur in the SCN after such treatments. 
On the otherhand, the effect of anti depressant therapies on the 5 -H T ib autoreceptor have 
been studied in the rat hypothalamus (Moret and Briley, 1 9 9 0 ) and SCN (O’Connor and 
Kruk, 1994). A down regulation of the 5 -H T jb autoreceptor results and would indicate 
a decreased sensitivity to endogenous 5-HT or to agonist stimulation.
As regards to the NMDA receptor involvement in the SCN during antidepressant 
therapies, one can only speculate. It does seem a viable possibility that either during a 
depressive episode, or after antidepressant treatment that there are alterations in the 
NMDA receptor complex. As Nowak et a l (1995) have already suggested, the 
likelihood of the involvement of the NDMA receptor in antidepressant therapies is 
complex. However, because of the reciprocal control of the serotonergic and 
glutamatergic systems in the SCN, it is possible that a dysfunction in either the 
serotonergic or glutamatergic system may lead to a dysfunction in both transmitter
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systems leading to the depressive episode. If NMDA receptor antagonists are the way 
ahead for antidepressant therapies and one considers the circadian parameters, then once 
again time of day must be taken into account during administration of the drugs. 
Administration during the light phase would be expected to decrease 5-HT 
concentration in the SCN, whereas during the dark period there would be no effect on 
SCN 5-HT concentration, as demonstrated in this thesis. Brain 5-HT levels are already 
reduced in depression, and if the antidepressant therapy, in the form of an NMDA 
receptor antagonist, was to decrease the 5-HT concentration further, then surely the 
depressive symptoms would be made worse. It must be borne in mind, however, that 
the results of this thesis demonstrate the function of the clock under normal conditions, 
and in the case of depression, disruptions in the transmitter balance may contradict the 
theories put forward here for the time of day administration. Therefore, many more 
experiments must be performed in animal models of depression as regards to the diumal 
variation in 5 -H T ib receptor function and the effect NMDA receptor agonists and 
antagonists would have on 5-HT concentration in the SCN. Suggestions for future work 
are discussed in the next section.
7.3 FUTURE WORK
The work presented in this thesis has opened up many avenues. Firstly, regarding the 
data from Chapter 3 on the function of both the 5 -H T ib hetero- and auto-receptors, it 
would be of great interest to examine the function of the heteroceptor across the 
light:dark cycle at more time points in order to establish whether there is a variation in 
its function. In addition, it must be clarified whether the response to the agonist 
RU24969 is via stimulation of the 5 -H T ib or the 5 -H T iA receptor.
The remarkable variability in the function of the terminal 5 -H T jb autoreceptor must 
have an underlying cause. Possibilities for this variation in function have already been 
outlined in the discussion section of Chapter 3, and it would be worthwhile investigating 
these suggestions, particularly the involvement of the novel four amino acid peptide 5- 
HT moduline which is postulated to act as an endogenous antagonist at 5 -H T ib 
receptors, and the involvement of the second messenger cascade that leads to the 
response.
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The variation in 5 -H T ib autoreceptor function is a diumal variation. Of considerable 
interest to the chronobiologist is whether the receptor exhibits a circadian variation, that 
is whether it is influenced by the internal pacemaker. This can be tested in animals 
maintained under constant environmental conditions such as continuous darkness. 
Under these conditions, the function of the receptor can be tested again by 
microdialysis. The disadvantage of performing microdialysis experiments in animals 
allowed to free run in constant darkness is the need to monitor locomotor activity. 
Animals present with individual activity rhythms that are slightly out of synchronization 
with their litter mates. Therefore, each individual used in microdialysis experiments for 
drug infusion at a set zeitgeber time must have locomotor rhythms monitored constantly. 
The onset of locomotor activity in animals allowed to free run is designated ZT 12.
The advent of a commercially available antibody that can detect the 5-HTiB receptor 
protein immunocytochemically in slices of rat brain would create a number of 
experiments localizing the receptor within the nucleus. As stated in Chapter 4, the 
initial aims of the immunocytochemical procedure were to utilise the 5-HTib antibody 
to a) examine the density of the receptor across the light:dark cycle, and to b) carry out 
double-labeling studies with antibodies to glutamate and serotonin to calculate the 
relative degree of hetero- and auto-receptors in the nucleus. The results of these 
experiments would still be of great interest.
As discussed in the preceding section (7.2), the results obtained in this thesis are 
interesting regarding antidepressant therapies. Animal models of depression are often 
used to test antidepressant therapies on aspects of behaviour and neurochemical levels in 
the brain. An animal model of depression could be set up and the experiments of this 
thesis repeated to identify differences in receptor function under normal conditions and 
during a depressive episode.
The question of whether there is a retinal-raphe-hypothalamic tract has been addressed 
briefly in this thesis with an attempt to give credence to a functional pathway. The 
problem here is that there is a dispute over whether the serotonergic projection to the 
SCN originates in the MRN or the DRN (outlined in the discussion section of Chapter 
6). Lesion studies and comprehensive tract tracing techniques might be employed to 
verify this problem in the Wistar rat, which would subsequently make the initial
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question easier to answer. A four millimeter probe membrane had to be utilised in these 
studies to span the whole dorsal-medial extent of the raphe nuclei. More specifically 
one could implant probes with smaller membrane surfaces (e.g. 1-2 mm) into specific 
raphe nuclei and determine if the ability of drugs (8-OH-DPAT or NMDA) to affect 
SCN 5-HT release specific to the MRN or DRN. Indeed there may be a number of 
drugs that might affect SCN 5-HT release when infused into the raphe, and a broad 
range of drugs can be tested in this system. Continuing along the theme of excitatory 
amino acid involvement in the regulation of 5-HT release, one could test the same 
excitatory amino acid agonists as used in Chapter 5. The regulation of 5-HT release in 
the SCN by somatodendritic 5-HTiA autoreceptors was shown in this study not to 
exhibit a diumal variation. Only two time points were investigated in this study and it 
might be worthwhile examining the 5-HTiA autoreceptor at additional time points across 
the light: dark cycle.
One way of confirming a projection to the raphe nucleus from the retina would be to 
implant dialysis probes into the individual raphe nuclei and determine whether retinal 
stimulation increases retinal transmitter release. The prime candidate transmitter of this 
pathway is probably glutamate, and with an HPLC set up for the detection of glutamate 
in the laboratory, this might be a logical step forward. The animals could either be 
maintained on a 12:12 light dark cycle or one of continuous darkness. During the 
(subjective) dark phase retinal illumination will excite the retinal neurones and release 
transmitter at their terminals. If there were a retinal projection to the SCN and it 
released glutamate at the terminals then it would be detectable by microdialysis and 
HPLC-ED, provided the circulating aCSF contained a selective glutamate reuptake 
inhibitor.
If retinal stimulation of the raphe nuclei occurs, and if this pathway is functional in, for 
example modulation of light-induced phase shifting of the circadian clock, as is 
postulated, then light might induce the expression of immediate early genes in these 
nuclei. Light will induce the expression of immediate early genes, particularly the most 
studied c-fos gene and its protein product Fos, in the SCN (e.g. Rea, 1989) and in the 
intergeniculate leaflet (Park et a l , 1993). A longer period of illumination is required to 
stimulate Fos-like immunoreactivity in the IGL than in the SCN (Park et a l, 1993), and 
it might be that the raphe nuclei respond in a similar manner to the IGL. Different
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lengths of illumination during the dark phase, and different zeitgeber times must be 
tested for the ability to induce Fos protein in the raphe. This would establish a role of 
the retinal-raphe pathway in the regulation of circadian rhythms.
Some preliminary experiments have been carried out that were not reported in the bulk 
of this thesis, but might pave the way for some exciting experiments. Firstly, 
immuocytochemical staining for the enzyme neuronal nitric oxide synthase (nNOS) was 
carried out in rat brain sections collected at six time points across the light dark cycle. 
The methodology for the collection of brains and subsequent processing of brains was 
similar to that reported in Chapter 4 for the detection of the 5 -H T ib receptor protein, but 
with the inclusion of the detergent agent Triton-X 100 present in all PBS wash stages. 
The primary antibody used (1:10,000; 48 hours) was donated by G. Leng from the 
university of Edinburgh and was raised in sheep.. The secondary antibody was thus 
donkey anti-sheep HRP (1:500; 24 hours, Sigma) normal donkey serum was used as a 
blocking agent. As outlined in the Introduction (Chapter 1), nitric oxide has a putative 
role in the regulation of circadian entrainment and is thought to be released upon 
stimulation of the RHT. One study has demonstrated NOS activity to exhibit increases 
in activity from mid-light to mid-dark (Ayers et a l, 1996) and it was therefore my aim 
to detect nNOS in the SCN of animals collected at six time points across the 12:12 
light:dark cycle. Three animals at each time point were sacrificed and processed for 
nNOS staining.
Figure 7.1 shows representative sections of the mid-SCN region at each time point. A 
startling finding was that the SCN did not appear to contain any nNOS. A positive 
control section of the supraoptic nucleus verified the functional capacity of the antibody 
under the given conditions (figure 7.2). Neuronal NOS staining was seen on the medial 
and dorsal borders of the nuclei, and in the subparaventricular area closely associated 
with the third ventricle and no day-night difference in the number of NOS-containing 
neurones were detected in the six time points across the light:dark cycle. Previous 
reports have also used immunocytochemical detection methods to detect nNOS within 
the nucleus and have failed to detect significant amounts within the nuclei (Decker and 
Reuss, 1994; Amir et al., 1995; Reuss et a l, 1995; Lupi et a l, 1996). Whilst the areas in 
which nNOS containing neurones were found are not the major retinorecipient area of 
the hypothalamus, they do receive afferents from the retinae (Johnson et a l, 1988a). It is
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possible therefore, that stimulation of the NOS-containing cells in this region release 
NO which diffuses into the SCN to exert its effect. Alternatively, the release of NO 
could be secondary to stimulation of the SCN neurones by retinal afferents. Watts and 
Swanson (1987) performed an extensive tract tracing study detailing the efferents of the 
SCN, and identified that the densest projection ends just dorsal to the SCN in a comma- 
shaped region named the subparaventricular zone; this area contains NO-producing 
cells. Indeed, the authors have suggested that circadian patterns of neuronal activity 
generated in the SCN are relayed to effector circuitry in two stages with cells being 
innervated by the subparaventricular plexus, subsequently supplying greater input to the 
target nuclei. It is possible, therefore, that NOS plays a significant role in the effector 
circuitry of the nuclei.
Unfortunately, a report by Amir (1992) casts doubt upon this hypothesis. Increases in 
heart rate, stimulated by a brief light pulse in urethane anaesthetised rats, were blocked 
by antagonists of NMDA receptors and competitive blockers of NO production only 
when infused directly into the SCN and not when infusions were made in a region 2 mm 
dorsal to the SCN. This suggests a retinal pathway utilising NO only within the SCN 
itself, and not dorsal to the nuclei where, in the present study, NOS staining cells were 
most prominent.
Wang and Morris (1996) who successfully detected NOS-containing neurones in the 
SCN by immunocytochemical methods, used an antibody directed against whole 
recombinant rat neuronal nitric oxide synthase, and in parallel stained for NADPH- 
diaphorase, an enzyme whose colocalisation with NOS-containing neurones was 
considered a suitable marker for neuronal NOS (Dawson et al, 1991). Although they 
detected NOS-immunoreactive fibres in the SCN they failed to detect NADPH- 
diaphorase activity, suggesting that their antibody for NOS recognised a yet unidentified 
from of neuronal nitric oxide synthase. This might explain why the present study and 
others have been unable to detect NOS-containing neurones within the SCN, in the 
presence of accumulating evidence for a role of nitric oxide in the signal transduction 
pathway in the suprachiasmatic nucleus.
Studies branching from these preliminary data are extensive. First, there must be more 
than one type of neuronal NOS in the central nervous system as is evident from the
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apparent lack of nNOS within the SCN despite the plethora of evidence for a role for 
nitric oxide in circadian rhythms. The study by Wang and Morris (1996) support this 
view. Molecular biology techniques must therefore be undertaken to identify the NOS 
molecule that is present in the SCN of rodents, and indeed why this protein is perhaps 
unique to the circadian pacemaker. A NOS molecule present in the SCN, but not 
present elsewhere in the central nervous system might be a feature of pacemaker cells, 
and thus upon identification of the molecule specific inhibitors or stimulatory agents 
might be able to modulate specifically the circadian pacemaker, and alleviate symptoms 
unique to disruptions of the circadian pacemaker, such as jet lag.
Specific HPLC methodology able to detect nitrates, one of the breakdown products of 
nitric oxide, commonly used to identify nitric oxide usage, is available commercially 
(Presearch Ltd.) and may enable the detection of nitrate in microdialysis samples. The 
detection of nitrite in dialysate samples would therefore be possible across the light:dark 
cycle and possible diumal variations in this nitric oxide breakdown product identified.
A second set of preliminary experiments involved microdialysis of animals during the 
dark period. Animals were implanted with probes into the SCN region as described 
previously and maintained on a reverse lighting schedule. Initially a short 15 min light 
pulse was administered at ZT 15 and ZT 21 in separate individuals. At these zeitgeber 
times a short light pulse delivered to the animals has the ability to induce phase shifts in 
behavioural rhythms and to induce c-fos expression in the SCN (Rea, 1989). In three 
animals, a light pulse delivered at ZT 15 induced a 3-4 fold increase in 5-HT as 
measured in the microdialysate sample (figure 7.3). The increase in magnitude of the 
response was similar in all animals although the timing of the increase after light 
exposure did vary. This experiment was repeated on a further six animals with only one 
third of the animals responding in a similar manner. In addition, a further three animals 
received a light pulse delivered an hour earlier at ZT 14 without effect. At ZT 21 the 
first two animals exposed to a light pulse exhibited a four fold increase in 5-HT 
concentration in the dialysate samples (figure 7.4). This was repeated on a further five 
animals with only two out of the five responding in a similar manner. Two more 
animals received a light pulse at ZT 20 and two others a light pulse at ZT 22. None of 
these animals responded to the light pulse with an altered dialysate 5-HT level.
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To my knowledge this effect of light on 5-HT release is novel. Unfortunately the 
inconsistency of the response in separate animals casts a shadow on the validity of the 
data. Forty four percent of the animals exposed to a light pulse at ZT 15 and 43 % of 
the animals at ZT 21 failed to respond with an effect on dialysate 5-HT concentration.
The effect of a light pulse on 5-HT release may be a very specific time-dependent 
occurrence with a very narrow window during which light can affect 5-HT release. As 
is seen in the few animals presented with a light pulse at ZT 14, 20 and 22, there was no 
effect on 5-HT release in any of these animals tested. Each individual used in these 
experiments although entrained to the same 12:12 light dark cycle, may have subtle 
variations in circadian parameters to his litter mates and the time window in each 
individual may vary slightly. The maximal phase delay or phase advance shown by any 
one individual to a light pulse delivered at the early or late (subjective) night, 
respectively, is also a very time specific event and the time specificity may reflect the 
ability of light to affect 5-HT release. Although as a general rule 5-HT applied to 
animals (hamster or mouse) inhibits light-induced Fos induction (Chapter 1 
section 1.2.2) the effect of 5-HT on light-induced Fos production in the rat is different. 
In the rat application of an antagonist at the 5-HTiA receptor blocks Fos induction 
(Recio et al, 1996) and qupazine applied systemically to rats can induce c-fos in the VL- 
SCN similar to that produced by light during the dark phase (Moyer et al., 1997). In this 
latter study, the author suggests that, in the rat, serotonin might mediate the effects of 
light on SCN Fos induction. The results from this brief experiment supports this theory.
From this point where can one take these experiments? Firstly one must repeat the 
experiments, perhaps using a longer duration light pulse and determine the true window 
in which light can affect 5-HT release. Verification that the light pulse is indeed 
capable of phase shifting circadian parameters can be done in the same animals by 
processing the brains for Fos-immunoreactivity after the presentation of a light pulse. A 
very interesting and logical progression from here will be whether administration of 5- 
HT and then more specifically 5-HT receptor agonists via the microdialysis probe can 
indeed induce Fos protein expression in the SCN similar to that seen after a light pulse, 
which would give functional purpose to an increase in 5-HT release after the 
presentation of a light pulse.
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This effect of light on 5-HT release is a very short acting response. From the 
experiments performed to elucidate a role of excitatory amino acid receptor regulation 
of 5-HT release in the SCN (Chapter 5), agonist stimulation usually produced a long 
lasting and sustained response on 5-HT concentration. However, agonists were applied 
for a much longer period than the duration of the light pulse and it is therefore possible 
that excitatory amino acid receptor stimulation results in the effect on SCN 5-HT 
concentration. A good candidate for this effect must be the diffusable molecule nitric 
oxide. If the response of 5-HT to light were a consistent response, nitric oxide synthase 
inhibitors such as L-NAME could be administered either systemically or via the probe 
before the presentation of the light pulse to see whether the increase in 5-HT 
concentration could be inhibited. Conversely, nitric oxide donors could be administered 
via the probe to determine their effects of 5-HT release. A suitable model for 
determination of the substance responsible for the rise in 5-HT concentration would be 
if the light pulse could be administered on two consecutive days to have a reproducible 
effect of 5-HT release. The animal could therefore act as its own control, and on day 2 
various inhibitors or agonists could be applied to identify the mediator of the response.
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Figure 7.1. Reprasentative brain sections at the level of the hypothalamic 
suprachiasmatic nuclei at (a) ZT 3, (b) ZT 6, (c) ZT 9, (d) ZT 15, (e) ZT 18 and (f) ZT 
21. Neuronal nitric oxide synthase (nNOS) neurones are visible as those containing a 
dark brown precipitate. Note the absence of nNOS within the suprachiasmatic nuclei, 
which are almond-shaped nuclei either side if the third ventricle (III) and above the optic 
chiasm (oc), but its presence in the subparaventricular zone (spv), on the borders of the 
nuclei and on the borders of the third ventricle. Magnification x 87.5.
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Figure 7.2. Representative brain section at the level of the supraoptic nucleus (SON) at 
ZT 6. Note the high density of brown precipitate indicative of neuronal nitric oxide 
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Figure 7.3. The effect of a short (15 min) light pulse, indicated by the black arrow, on 
extracellular 5-HT concentration from the SCN region. The light pulse was presented at 
ZT 15 and the figure represents data from three separate animals. Values are actual 5- 
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Figure 7.4. The effect of a short (15 min) light pulse, indicated by the black arrow, on 
extracellular 5-HT concentration from the SCN region. The light pulse was presented at 
ZT 21 and the figure represents data from two separate animals. Values are actual 5-HT 
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The following solutions were supplied with the Dynabeads® mRNA DIRECT kit 
(DYNAL®, Norway):
Lysis/binding buffer: 100 mM Tris-HCl, pH 8.0, 500 nM LiCl, 10 mM EDTA, pH 
8.0, 1 % LiDS, 5 mM dithiothreitol
Washing buffer with LiDS: 10 mM Tris-HCl, ph 8.0, 0.15 M LiCl, 1 mM EDTA, 0.1 
% LiDS
Washing buffer: 10 mMTris-HCl, pH 8.0, 0.15 M LiCl, 1 mM EDTA 
Elution solution: 10 mM Tris-HCl, pH8.0
IMMUNOCYTOCHEMISTRY
Gelatin coated slides: Into 100 ml distilled water add 1 g gelatin (Sigma). Heat and 
stir. Once the solution has cleared add 100 mg chromic potassium sulphate (Sigma). 
Allow to cool. Coat slides generously and allow to aire dry.
Phosphate buffered saline (PBS): Available in tablet form from Sigma. One tablet is 
dissolved into 200 ml distilled water to yield a 0.01 M sodium and potassium phosphate 
buffer, pH 7.4 containing 0.0027 M potassium chloride and 0.137 M sodium chloride.
4 % paraformaldehyde: 40 g per litre of PBS. Heat the PBS to 70°C in a fume hood. 
Add the paraformaldehyde (sigma) and wait for it to dissolve. Allow to cool, filter and 
pH to 7.4-7.6.
ABC comple/HRP: 45 jil reagent A and 45 jil reagent B are added to 5 ml PBS and 
vortexed. The solution is left at 4°C for 30 min prior to use.
DAB peroxidase substrate tablet set: Each SIGMA FAST DAB tablet set contains 0.7 
mg/ml DAB, 1.6 mg/ml urea hydrogen peroxide in 0.06 M Tris buffer when dissolved in 
1 nl distilled water.
199
WESTERN BLOTTING
Constituent 10% Running gel* 5% Stacking gel*
MilliQ water 4.35 ml 6.0 ml
1M Tris-HCl pH 6.8 - 1.25 ml
1M Tris-HCL pH 8.8 5.6 ml -
Acrylamide 5.0 ml 1.67 ml
10% SDS (w/v) 0.25 ml 0.15 ml
10% APS 50 pi 50 pi
TEMED 20 pi 20 pi
*Volumes sufficient for 4 gels
SDS-PAGE running buffer: 25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS, pH 
8.3.
5x SDS sample buffer: 5% SDS, 50% glycerol, 200 mM Tris-HCL pH 6.8,
bromophenol blue.
Semi-dry transfer buffer: 39 mM glycine, 48 mM Tris base, 0.0375% SDS, 20% (v/v) 
methanol.
Tris buffered saline (TBS): 20 mM Tris-HCL pH 7.5, 150 mM NaCl.
200
